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Abstract  
 
 
Particle engineering was used to modify particle morphology and the 
physicochemical/mechanical properties of carriers and active pharmaceutical ingredients. In this 
study, spray drying and crystallization were used as the main techniques for particle engineering; 
carriers included lactose, D-mannitol, and xylitol. L-leucine was used as an additive to modify the 
morphology of particles and salbutamol sulphate was used as an active pharmaceutical ingredient 
throughout the researched work. Engineered carriers were used, in some combination, in dry 
powder inhaler (DPI) formulations to determine whether or not there was an enhancement in the 
aerosolization performance of the engineered formulations. The prepared engineered carriers 
were analyzed using laser diffraction (particle size), differential scanning calorimetry (thermal 
behavior), scanning electron microscopy (morphology), powder X-ray diffraction (crystallinity), 
Fourier transform infrared spectroscopy (interaction at molecular level), powder flow 
characteristics (i.e. Carr’s Index and angle of repose), high pressure liquid chromatography 
(HPLC), UV-vis spectroscopy, and in vitro aerosolization performance (deposition). It was 
determined that the efficacy, via Fine Particle Fraction (FPF), of the engineered spray dried 
lactose-leucine DPI formulation was improved from 25.51 ± 1.23% to 47.11 ± 9.94%. The 
performance of the engineered spray dried mannitol-leucine DPI formulation was also improved 
to 52.96 + 5.21%. The engineered spray dried mannitol-lactose-leucine DPI formulation had an 
aerosolization performance of 61.42 + 4.21%. The engineered xylitol crystals, however, had an 
aerosolization performance of 42.94 + 15.21% whereas the mannitol-lactose crystals had an 
aerosolization performance of 68.69 + 4.65%. Finally, the mannitol-salbutamol sulphate crystals 
had a fine particle fraction (FPF) of 62.53 + 6.84%. A physical mixture comparative study showed 
that it was better to engineer the carriers rather than use the commercially available carriers 
currently in the market. In addition, the results also showed that L-leucine acts as a lubricating 
agent when incorporated into the DPI formulations. Lastly, all of the engineered carriers showed 
some degree of agglomeration, which made coarse particles suitable for DPI formulations. 
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Chapter 1 
Introduction 
 
1.1 Introduction1  
 
The pulmonary tract is used in a systematic fashion to tackle chronic obstructive pulmonary 
disease (COPD), asthma, bronchitis, airway disease, and cystic fibrosis (CF) through the 
administration of therapeutic agents.2 In addition, it is a noninvasive, rapid, and effective 
approach for the delivery of the therapeutic agent, both locally and systematically.3 It comes to 
no surprise as the respiratory tract offers a great potential for systematic delivery because the 
lungs have a large surface area for absorption with an  
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 Figure 1.1. The Respiratory Tract. Source: Ali Nokhodchi Lecture Note; Pulmonary 
Drug Delivery, 2018. 
abundant vasculature. There are approximately 300 million alveoli in each lung offering 
a surface area of about 100m2 for an effective gas exchange.4 It also contains small 
amounts of drug-metabolizing enzymes compared to the liver and gastrointestinal tract 
(GIT) providing conditions that favor drug absorption.5 Figure 1.1 presents a respiratory 
tree highlighting the different sections of the reparatory tract. 
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The respiratory tract, however, does pose a challenge; the effectiveness of the inhalation 
therapy depends upon the site of deposition of the active pharmaceutical ingredient 
(API). Deposition of inhaled drugs is a complicated process that relies on lung anatomy 
and physiology, the physicochemical properties of the API, the nature and 
characteristics of the formulation, and the type of delivery system used for 
administration.6 Only particles of a specific size (1-5µm) and shape will be able to deposit 
in the aveolar region, which is the main site of absorption.5, 7 Achieving this is usually 
done with a carrier; the chosen carrier needs to be safe, cost-effective, and pass strict 
pharmacopeia guidelines. It also needs to be selected in such a manner that it adheres 
to chemical properties that will not interfere with the drug delivery process and that 
complement the API.8–14 
 
Predicting the drug deposition of the drug in the respiratory tract is crucial in optimizing 
drug delivery and to evaluate its efficacy.15 Pharmaceutical aerosol particles can range 
from 10-2 to 102 µm and are categorized based on their size into coarse particles (≥ 5 
µm), fine particles (0.1 to 5 µm), and ultra-fine particles (≤ 0.1 µm).9 There are 
mathematical models available that illustrate the deposition and distribution of inhaled 
aerosols based on airway dimensions, flow dynamics, breathing pattern of the patient, 
and the shape of the particles involved.16 Particle deposition can occur via impaction, 
sedimentation, interception, or diffusion and Figure 1.217 presents the different types of 
particle deposition. 
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Figure 1.217. Particle Deposition. Mechanisms of deposition of inhaled particles in the 
respiratory tract.  
 
Impaction is considered a flow-dependent mechanism that is dependent on the 
aerodynamic diameter of the particle and is important for large particles (≥ 5 µm). 
Furthermore, large particles don’t follow the trajectory of the airway due to inertia and are 
subsequently swallowed by the patient.18-20 The deposition probability by impaction [P(I)] 
in cylindrical airways is calculated via Equation 1.121 and Equation 1.2 
20 
 
 
(Eq. 1.1)             
(Eq. 1.2)                               
 
where "	is the branching angle, p is the density of the particle, µ is the viscosity of fluid, 
v is the velocity of the particle, D is the diameter of the airway, and d is the particle 
diameter.  
 
Sedimentation occurs in the lower bronchial airway and the alveolar region, where airflow 
is slower, with particles in the range of 0.5 to 5 µm. If the aerosol particle size is between 
3 to 5 µm, then deposition occurs in the tracheal-bronchial region.22 Sedimentation of 
particles is governed by the gravitational force acting on the particles being more 
dominant than the dragging force imposed by the airflow; the rate of sedimentation 
increases with an increase in particle size and a decrease in flow rate.19, 22 The deposition 
probability by sedimentation [P(S)] in cylindrical airways is calculated with Equation 1.321 
 
(Eq. 1.3)                              
 
where g is the acceleration due to gravity, ⍬ is the angle relative to gravity, L is the tube 
length, p is the density of the particle, C is the Cunningham slip angle correction factor, d 
is the radius of the particle, R is the radius of the airway, and µ is viscosity of the fluid.  
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Particles deposited via interception do not diverge from the air stream and are elongated 
in their shape which causes them to be deposited as soon as they contact the airway 
wall. The aerodynamic diameter of these particles are smaller relative to their size causing 
them to be deposited in the lower airways.22,  23 
 
Diffusion is the key mechanism for particles that are less than 0.5 µm due to Brownian 
motion, which increases with decreasing particle size and air flow rate. Particles move 
from an area of high concentration to an area of lower concentration across the 
streamline and deposit upon contact with the airway wall; this is governed by geometric 
rather than aerodynamic size of the particles.21, 22, 24 The deposition probability by 
diffusion [p(D)] in cylindrical airways is calculated via Equation 1.421 
 
(Eq.1.4).                                 
 
where R is the airy diameter, k is the Boltzmann constant, T is the absolute 
temperature, n is the gas viscosity, and d is the particle diameter. 
 
The efficacy of inhaled therapy using a dry powder is dependent on at least four variables: 
the physicochemical properties of the formulation components, the design of the device, 
the mechanism of powder dispersion, and the patient inhalation maneuver.14, 25 The 
principal forces involved in dry powder dispersion from a dry powder inhaler (DPI) are 
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frictional, drag, lift, and inertial forces.8 Therefore, the blending technique used and the 
selection of the carrier properties such as size, shape, humidity, crystalline state, and 
surface roughness will influence the final aerosolization performance of the drug 
formulation.14 
 
DPIs are generally grouped into three categories based on the dose metering system: 
single-unit dose, multi-unit dose, and multi-dose reservoir. The single dose inhaler is the 
most widely utilized type of DPI which requires the patient to load the devise with a hard 
capsule containing micronized powder formulation prior to inhalation.26 The multi-dose 
devices are available with pre-metered doses stored in individually sealed protective 
packaging. The multi-dose reservoir contain the bulk powder formulation in a multi-dose 
reservoir where individual doses are metered under gravity and dispensed by a built-in 
mechanism.26 , 27 
 
Moreover, DPIs may be classified as passive or active devices. Passive devices rely 
solely on the energy generated by patient inspiratory flow rates to fluidize and disperse 
the powder. Active DPI devices possess an internal power source dispersion unit to 
aerosolize the powder using compressed air.28  
 
These principles have been implemented with those of particle engineering in such a 
way as to allow for novel formulations to be constructed and tested.  
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1.2 Particle Engineering 
§ 1.2.1 Spray Drying 
 
Methodologies for particle engineering have evolved from a traditional approach into 
taking on a more contemporary one, through the introduction of the spray drying 
technique, whose manifestation began about 140 years ago.29 More precisely, spray 
drying is an analytical technique in which dry powder is produced via the evaporation of 
an atomized liquid when it is mixed with a drying hot gas medium.30 Converting an 
aqueous solution into a solidified form in a matter of milliseconds, through the exchange 
of heat (ΔH), has allowed this technique to take on unique advantages while also granting 
it a wide spectrum of usage; both in industry and in research.30 Capable of producing an 
amorphous product, where the solid state of the active pharmaceutical ingredient (API) 
undergoes a phase equilibria change from the crystalline, or rather solid phase, to the 
amorphous phase, whose transition state underlies with that of the liquid and solid 
phases, can be be understood via Equation 1.5, which follows the Gas Laws30 
 
(Eq. 1.5).                            
 
where ΔG represents the Gibbs free energy difference between the two phase equilibria 
under standard conditions, R being the gas constant, T being the temperature at which 
the measurement was taken, in Kelvin, σAmorphous/σSolid as the solubility ratio of both phase 
equilibria, and where the moisture content and relative humidity follow US FDA guideline. 
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Spray drying, itself, is an energy intensive, continuous, and scalable drying process 
allowing for various specialized applications to be seen; from microcapsules to controlled 
release particles, composite micro-particles, and nanoparticles and liposomes.31-33 
Critical physical parameters that lie at the core of the process and feed variable induced 
changes are vapor pressure, evaporation rate, drying time, droplet size/distribution, 
crystallization rate, film formation rate, heat/mass transfer, and outlet temperature.34   
 
Inventive and innovative methods have been developed which include the ability to 
prepare solid amorphous dispersions, excipients in manufacturing, pulmonary and bio-
therapeutic particle engineering, encapsulation, and in drying a crystalline active API.30 
Moreover, the contemporary introduction of spray drying has allowed the, once poorly 
soluble API, to be more bioavailable such that there is an increase in the stability of the 
API in its amorphous state, an increase to the effective solubility to the API relative to the 
crystalline form, and in its ability to inherit crystallization of drug in vivo upon dosing and 
dissolution;35, 36  just to name a few. 
 
Aside from spray drying, however, other techniques are available that could be used like 
that of co-grinding, freeze drying, hot melt extrusion (HME), supercritical methods (SCM), 
or electrohydrodynamic based methods. In pharmaceutics, however, spray drying is a 
very well utilized unit of operation employed for drying operations to particle engineering 
of bulk active pharmaceutical ingredients, excipient and pulmonary formulations, 
granulations, etc.30, 37 Solid dispersions are kinetically stabilized systems and the chosen 
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method of manufacturing has a significant impact not only on the external morphology of 
the particle, but also on the intricate intra- and inter-molecular arrangement of the 
formulation. According to Chiou and Rielman, whom define solid dispersions, they consist 
of a dispersion of one or more active ingredients in an inert carrier matrix at solid state 
prepared by melting (fusion), solvent, or melting solvent method.38 Amorphous solid 
dispersions, soluble complexes, encapsulated systems, solid self-emulsifying systems, 
and nano-dispersion of poorly soluble drugs prepared by spray drying have become the 
primary solubilization strategy.39 Due to differences in the degree of disorder of the 
starting material, energy input, process time, drug-carrier mixing, and behavior of the 
formulation components in response to the process induced stress, the chosen technique 
is carefully selected as the solid state of the drug, its miscibility, molecular mobility, and 
stability are accounted for.40 Sugimoto et. al provides a comparison between the spray 
dried and co-grinding technique showing that the spray dried technique exhibited 
amorphous content while the co-grinding technique did not; highlighting an advantage to 
the use of the spray drying technique.41 Dontireddy and Crean  compared the spray drying 
technique with that of freeze drying showing the differences in amorphization between 
the two techniques; spray drying provided spherical particles via rapid evaporation 
whereas freeze drying provided irregular flake-like particles via rapid freezing.42  
 
Furthermore, when comparing spray drying to that of HME, it was found that spray drying 
had the advantage of being able to be used for thermo-labile and high melting API while 
also only requiring small amounts of API during the drug development process.34 Guns 
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et. al, however, states that HME provided higher kinetic miscibility between miconazole 
and Killicoat IR when compared to spray drying;43 opposite results were obtained by 
Mahmah et. al where a faster release rate was obtained from the spray dried formulation 
than with the HME formulation.44 Conventional HME does require an additional 
downstream process of extrudate milling that can contribute to the destabilization of the 
product. Apart from differences in solid state characteristics, the formulations are also 
expected to differ in their powder density, surface area, morphology, and flow 
properties.45 
 
Nevertheless, traditional methodologies implement an iterative design of experiments46 
or a statistical treatment47 when process parameters are in the developmental stages 
which are time intensive and require larger quantities of API. Reasoning to its reference 
as a contemporary approach were derived from the notion of spray drying taking on a 
spectrum of fundamental models that range from steady-state and equilibrium 
approaches to that of rate-based and computational fluid dynamics models.48 
 
Figure 1.3 presents a visual depiction of the spray drying process as an operational unit 
found within the laboratory; it’s small scale design allows for the careful manipulation of 
physicochemical properties like that of particle size, morphology, and microstructure. 
Dependent on key process parameters, particles may attribute a hollow sphere 
morphology with a low bulk density (<0.2g/cm3) or may have a shriveled raisin 
morphology having a high bulk density (0.2-0.4g/cm3).49 While other morphologies are 
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possible, however, large-sized spherical particles have been shown to give better flow 
properties and compressibility. 
 
Nevertheless, the industrial model follows the same principle as that of Figure 1.3 with 
the major difference being it’s intended purpose for larger scale production. Shifting from 
the lab scale to the production scale models requires adjustments like changing the feed 
system, atomization type, location, or conditions, drying gas dispensing system, chamber 
dimensions, exhaust gas duct, or change from single pass mode to multiple pass mode. 
Shifts have the capacity to alter the droplet trajectory, evaporation rate, increase the 
drying type, solvent mass in the drying air, and alter the wall depositions profiles, therefore 
it is imperative to understand the impact the parameters have on the overall system.50 It 
also becomes important to consider the downstream processing of the product and its 
development given the numerous avenues where key properties may be affected such 
as residual solvent, particle size, bulk density, flowability, compressibility, compatibility, 
disintegration, and overall stability.34 
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Figure 1.3.  Spray Drying Process Configuration. 
 
Furthermore, the spray drying process employs a series of offline experiments, an 
understanding of fundamental models, and a pre-disposed initial process definition that 
warrant a quick and efficient process. Concurrent processing of a hot gas medium, usually 
nitrogen, provides an inert process environment with the previously prepared organic 
solvent allowing spray dried solution to be atomized into droplets by the selected spray 
nozzle. The selected nozzles could be pneumatic, two-fluid, ultrasonic, rotary, and 
pressure nozzles.50, 51 Preparation of the solvent prior to its introduction is also of 
importance as the addition of a solute increases the thermal efficiency of the spray dried 
solution given that less solvent has to be evaporated.51 Physical properties of a solvent 
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such as its vapor pressure, boiling point, and freezing point are also affected upon 
addition of a solute.52 Solvents are either aqueous, alcohols (methanol, ethanol, or 
isopropanol), or other organic solvents such as dichloromethane (DCM), acetone, methyl 
ethyl ketone, dioxane, tetrahydrofuran (THF), ethyl acetate, chloroform, and acetonitrile; 
amongst these, DCM is the most utilized despite its toxicity potential.39 Choice of the 
mixture components and their ratio are critical to the process as a whole, as some 
combinations may result in a change in the particle’s morphology, which reduces the 
release of the API.53 Al-Obaidi et. al provides results from an investigation that explored 
the effect of changes in solvent ratios and their impact to the overall product.54 
 
Aiding to the drying process is the cyclone; efficient in separating dispersed particles from 
the continuous gas phase based on density differences between the two phases. As the 
solid particles become subjected to the accelerating flow, there is a lag in the velocity 
within a rotating vortex that allows for the separation of dense particles in relation to the 
low density medium. Commonly used cyclones include the reverse flow type where 
particle air dispersions are introduced tangentially into the top part of the cyclone. At the 
bottom of the cyclone the gas stream reverses leaving the cyclone through the vortex 
finder. As the acceleration of the gas flow increases, the chance for smaller particles to 
be separated also increases.39 
 
Droplet formation and solvent evaporation occur concurrently. This allows newly formed 
droplets to come into contact with the hot gas and then the encapsulated solvent 
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evaporates leaving behind a dried particle. The dried particle is collected in the collection 
chamber as shown in Figure 1.3.55 As solvent evaporation amerces, a solute mass 
concentration at the surface is observed where the concentration gradient between the 
droplet surface and core drives solute movement inward from the surface.56 During this 
movement, the droplet surface thickens the crust resisting mass transfer and any heat 
transfer to the droplet at this stage increases the particle temperature thereby facilitating 
further drying.57 Higher solvent evaporation rate implies increased transfer of thermal 
energy per unit time to solute molecules present in the droplet.58 Evaporative drying can 
be monitored or described using psychometric charts (Mollier diagrams) as they provide 
dry and wet bulb temperature, relative and absolute humidity, and enthalpy of the drying 
gas and relates them to one another.39 
 
Selection of the drying gas is crucial as the atomization gas type influences the droplet 
size, number density, and velocity that ultimately affect the characteristics of the final 
product.59, 60 Gases such as N2, Argon, and CO2 have completely varying profiles, when 
it comes to physical properties such as density and specific heat that are critical for the 
atomization process. For example, to obtain smaller droplets with high droplet velocities, 
lighter gases should be employed.34 Mass flow rate, specific heat, and temperature 
differential of the drying gas determine the energy lost in the evaporation process where 
CO2 provides better heat and mass transfer than that of air or N2.61, 218 Closed loop 
systems, while using N2 or CO2, have been studied and resulted in a lower yield of 40% 
of lactose powder as compared to 70% when air was used as the drying medium due to 
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lower absolute humidity in the system that used air as the drying medium.62 In the same 
study, it was shown that the degree of lactose crystallization was found to be highest 
when N2 was used when compared to CO2 thereby proving that the drying gas also has 
an effect on particle morphology. Conditioning of the drying gas, with respect to the 
humidity and temperature, are recommended given that this leads to the gas exerting its 
heat and mass transfer properties effectively.39  
 
Thermodynamic force for the solvent evaporation is the difference in the potential energy 
between the drying droplet and carrier gas; therefore the rate is given by Equation 1.663 
 
(Eq. 1.6)                         
 
where ρsatpure refers to the vapor pressure of pure water and ρw, air to the partial pressure 
of water in the gas phase. Nonetheless, droplet formation follows the principle of when 
the weight of ejected liquid overcomes the surface tension force, a newly formed droplet 
is observed. Such principle follows Equation 1.764  
 
(Eq. 1.7)                                                     
            
where r is the external radius of the opening, γ is the surface tension of the liquid, a2 is 
the capillary constant of the liquid which equals to 2γ/ρg, ρ is the density of the liquid, 
32 
 
and g is gavity. Thereby stable performance of the nozzle becomes keen as it ensures 
the success of particle production65 while also paying particular attention to the 
trajectories of droplets inside the drying chamber as this will avoid inter particle and 
particle-wall collisions.66 Under appropriate assumptions, the critical factors of the 
multivariable system can be identified as taking on the Stokes-Einstein equation, which 
is Equation 1.867 
(Eq. 1.8)                                              
        
where D is the diffusion coefficient, KB is the Boltzmann constant [1.38 x 10-23 m2 kg s-2 
K-1], T is the absolute temperature, η is the viscosity of the solution, and r is the globular 
radius. Moreover, water activity from within the droplet relates to the ratio of partial 
pressure and that of relative humidity (%RH), via Equation 1.9. 
 
(Eq. 1.9)                                      
 
Diffusion of the drug, polymer, and the solvent becomes an important attribute from the 
perspective of component distribution from within the particle and for homogeneity; 
surface enrichment of a particle is given by Equation 1.1030, 68 
 
(Eq. 1.10)                                    
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where Ei is the surface concentration of component i in relation to its average 
concentration in the droplet, cS,i being the surface concentration, cm, i is the average 
concentration of component i, and β is the profile function. Looking closer at the Peclet 
number [Pei], Equation 1.11, 
 
(Eq. 1.11)                                          
 
which relates to K , the evaporation rate, and the diffusion coefficient of component i in 
the liquid phase [Di]. When Pei < 1, the solute equalizes quickly leading to a uniform 
component distribution and formulation, whereas when Pei > 1, leads to a quick 
evaporation and a heterogeneous formulation.69 
 
Particle formation becomes dependent on the multivariable platform, like that of droplet 
formation, where the outcome of the overall system can be seen in Figure 1.4. Micro-
particles collected from the collection chamber take on one of three forms: (A) Monocore, 
(B) Polycore, or (C) Matrix. Porous microparticles have been shown to have unique 
advantages over non-porous ones, as they have less inter-particulate attractive forces 
with better flow characteristics and exhibit smaller aerodynamic diameters than their 
geometric diameters, which is known to facilitate greater deposition in the lower 
respiratory tract.70, 71 Dependent on the strength of the atomization, thickness of the outer 
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shell of the newly formed droplet, and internal pressure build up the particle can either 
explode, inflate, or crack.72 
 
 
 
 
 
 
Figure 1.4. Spray Dried Particle Differentiation 
 
 
Furthermore, large pilot-scale and production-scale spray dryers vary in that the operator 
may choose to operate the spray drier in an open-loop our closed-loop fashion. 
Differences between  the two is such that in the closed-loop option, the drying gas is 
recycled and passed through a condenser, reheated, and introduced back into the system 
while maintaining a constant pressure and inert environment.  
 
Two key control volumes are used in defining the physically of a spray drying unit: the 
macroscopic control volume and the droplet-environment control volume. Macroscopic 
control volume refers to the entire drying chamber and defines the overall thermodynamic 
based upon easily measured and monitored spray drying process parameters whereas 
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droplet-environment control volume comprises individual droplet formation, interaction 
with the hot gas and environment, and solvent evaporation.73 
 
Mass-balance and energy-balance calculations can be conducted using the inputs and 
outputs derived from the macroscopic control volume 51, 74 used to predict a continuum of 
outlet conditions across a range of inlet parameter values that characterize the spray 
drying operating space and defines a process design space. Droplet kinetics is defined in 
the droplet-environment control volume which focuses on two key factors already 
mentioned: droplet formation via the atomization process and solvent evaporation via the 
atomization plume.  
 
Choosing which mode of operation to go with is dependent on key thermodynamic 
process parameters and outlet conditions that relate with one another through 
fundamental relationships. 15 Such parameters include Msoln, drying gas flow rate (Mgas), 
Tin, Tout, and the relative saturation of the solvent (%RSout), which are related through the 
energy required to vaporize the solvent; as expressed in Equation 1.12  
 
(Eq. 1.12)                         
 
where ΔHvap is the heat of vaparization and xsolids is the mass fraction of solids in solution. 
Energy lost by the drying gas, however, takes on Equation 1.13 
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(Eq. 1.13)                          
where cp is the heat capacity of the drying gas. Furthermore, solving for %RSout gives 
rise to Equation 1.14 
(Eq. 1.14)  
   
where MWsolvent and MWgas refers to the molecular weight of the respective species, 
Pchamber is the absolute pressure of the spray drying chamber, and P * Tout is the 
equilibrium vapor pressure of the spray solvent evaluated at Tout.  
 
Nevertheless, it becomes important to mention that conventional methodologies use 
statistical design of experiment (DOE) analysis to understand the relationship of key 
process parameters75, 76 and the effect those parameters have on the quality of the 
product.77-84 Design space is the multidimensional combination and interaction of 
formulation variables and process parameters resulting in products with assured quality; 
therefore, the design space is crucial in post-approval manufacturing.85 Drawbacks in 
such approach include it lacking to take into account the fundamental physics of the 
process and is limited in its translational capabilities; where the aforementioned process 
takes into account all five process parameters.73 Quality by design is defined by the 
United State Food and Drug Administration (US FDA) as a systematic approach to 
development that begins with objectives and emphasizes product and process 
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understanding and process control, which are based on sound science and quality risk 
management.86 
 
Efforts by FDA’s process analytical technology (PAT) initiative, which coincides with those 
of the International Conference and Harmonization (ICH), are to assure high product 
quality through timely measurements of critical quality and performance attributes of raw 
materials, in-process materials, and final products.87 The said initiative supports the 
quality by design (QbD) model in that a methodology is drafted such that the desired final 
product not only meets all the predefined specifications, while achieving desired quality 
attributes but is also more cost-effective.88 
 
Needless to say, the effect that the aforementioned process parameters take on the 
physicochemical properties of the resulting spray dried formulation, while altering them 
from one another, and can be studied using the factorial design. Such design evaluates 
the response to surface models of the parameters while taking into account powder 
properties like particle size, fine particle fraction, yield, and outlet air temperature and are 
related to one another via Equation 1.1589 
 
(Eq. 1.15).   
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where y is the response, b0 - b1234 are equation coefficients, and x1 - x4 are factors (F, N, 
A, and T, respectively). Equation coefficients were calculated using coded values where 
the various terms are able to be compared regardless of their real magnitude; a positive 
parameter coefficient indicates that the response value increased with increasing variable 
and the opposite for that of the negative coefficient.  
 
Table 1.1371 presents the findings of Korycka et. al who used the aforementioned design 
on D-mannitol (mannitol) powders from 17-19 °C. 
 
Table 1.1. Factorial Design for Mannitol Powders 
Parameter Tout (°C) Y (%) VMD (µm) Span FPF (%) 
Average 85 88.0 5.16 1.34 49.0 
Standard 
Deviation  
1.2 0.1 0.27 0.14 4.8 
%CV 1.4 0.1 5.23 10.45 9.8 
Measure of 
absolute error 
2.2 0.1 0.27 0.14 2.8 
 
 
Table 1.290 91 culminates the factorial design while illustrating the effect that critical 
process parameters have on the final product when they are altered. It is known that 
process parameter alterations vary the crystallinity of the spray dried material thereby 
affecting porosity, flowability, sorption characteristics, solubility, dissolution rate, and 
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bioavailability.92 For instance, the rate at which the feed is injected influences the droplet 
size, its distribution, droplet velocity, and the particle’s surface topography while also 
having an influence on the heat of fusion.93-95 Temperature and moisture gradients 
generate inside the droplet due to higher temperatures influencing the particle formation 
process while also creating moisture gradients inside the droplet.96 Moisture uptake is 
related via the relative humidity of the environment as well as, both, the chemical (i.e. 
hydrophilicity and hydrophobicity) and physical (i.e. powder specific surface area and 
particle anomeric composition) properties.97 
 
Table 1.2. Process Parameters. Effect critical process parameters have on final product. 
Parameter  Effect on final product 
High Aspirator Rate  Increase in outlet gas temperature 
 Decrease in residual moisture in final product  
 Higher product uniformity 
High Viscosity or High Solid 
Content 
Increase in outlet gas temperature 
 Increase in particle size 
 Increase in yield 
 Decreased moisture content in final product  
High Humidity  Increase in wall deposition 
 Increased moisture in final product 
High Feed Rate Decrease in outlet temperature 
 Increase in particle size and droplet size 
 Increased moisture in final product 
High Gas Flow Decrease in outlet temperature 
 Decrease in particle size and droplet size 
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Parameter  Effect on final product 
High Inlet Temperature Increase in outlet gas temperature 
 Increased yield and a decrease in sticky nature 
Use of Organic Solvent Decrease in particle size due to a decrease in surface 
tension 
 
 
Moreover, selection of the correct nozzle correlates with that of the desired properties of 
the final product including its particle size distribution given that the droplet size, and by 
virtue particle size, is a function of the atomizer’s geometry, spray solution attributes (i.e. 
viscosity and surface tension), and atomization parameters (i.e. nozzle pressure).98 With 
that said, droplet size and soluble solids content directly correlate to the final size of the 
dried particle via Equation 1.16 
 
(Eq. 1.16).                    
 
where Dparticel is the diameter of the dried particle, Ddroplet is the diameter of the droplet, 
ρparticle is the density of the dried particle, and ρdroplet is the density of the spray dried 
solution. 
  
Two possible pathways arise from which nozzles are selected: continuous mode and 
droplet-on-demand. Operation with the continuous mode, as the name implies, introduces 
a continuous flowing liquid jet into the drying chamber whereas the droplet-on-demand 
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forms discrete droplets from a short duration of liquid jets. In practice, selection of one of 
the two modes becomes dependent on the required amount of droplets and the value of 
the liquid to be atomized.65 From that, selection is further divided into electro-
hydrodynamic generators (EHDG), mechano-hydrodynamic generators (MHDF), and 
thermo-hydrodynamic generators (THDG). Electro-hydrodynamic generators operate by 
using an external electric field to disturb the liquid jet into droplets causing there to be a 
surface charge in the liquid at the tip of the nozzle where the ejected liquid is transformed 
into a conical shape, called a Taylor cone, due to the induced electric stress.99 Mechano-
hydrodynamic generators, however, apply mechanical energy to the exiting liquid thereby 
disintegrating the liquid body into droplets; the applied mechanical energy may be in the 
form of shear force or vibrational forces via a piezoelectric transducer.100 Thermo-
hydrodynamic generators, however, employ thermal energy to the liquid causing it to heat 
the liquid thereby causing there to be an increase in pressure; leading to droplet 
formation.101 
 
Common atomizers used in the pharmaceutical industry include two-fluid nozzles 
(pneumatic atomization), pressure nozzles (hydraulic atomization), rotary atomizers 
(rotating wheel atomization) and ultrasonic atomizer.102-104 Mizoe et. al has introduced a 
methodology that uses a four-fluid atomizer system where its intent is to overcome the 
problem faced when needing a common solvent between two different API; here, two 
liquid and two gas passages are used such that it allows for the two different APIs to be 
dissolved in different solvents.105 In comparison, Chen et. al developed an amorphous 
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product by using a four-fluid atomizer and passing the API and solvent from four distinct 
routes giving an enhanced particle distribution in the lungs while increasing its 
absorption.106  
 
Rotary atomizers are governed by centrifugal forces and the droplet size is inversely 
proportional to the disk or wheel speed. Pressure nozzles, on the other hand, generate 
fine droplets by pressurizing a liquid feed from the pump into the nozzle orifice where the 
droplet size is inversely proportional to the pressure applied and directly proportional to 
the feed rate. Ultrasonic nozzles generate droplets based on piezoelectric driven 
actuators vibrating a thin perforated stainless steel membrane in a small spray cap; the 
membrane features an array of micron-sized holes that generates millions of droplets and 
a small droplet size distribution.39 
 
Following the formation of the droplet and its subsequent introduction into the chamber, 
other important properties come into play that have a major impact on the outcome of the 
formulation; one of which being the glass transition temperature (Tg). Understanding its 
importance can provide insight into wall deposition, which is a key processing problem, 
as the deposited particles indirectly affect the quality of the product through the 
degradation of the deposited particles onto the wall of the drying chamber.107 It has been 
shown that large drying chambers reduce wall depositions given that the walls are out of 
range from the particle trajectory.108, 109 Chamber geometry plays an integral role as it 
directly alters the airflow patterns thereby altering the particle behavior and particle flow 
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pattern110; pure conical, lantern, hour-glass,111 and parabolic geometries112 have been 
studied along with a horizontal configuration113. 
 
Particle deposition occurs due to the particle’s sticky nature as they dry, occurring above 
the glass transition temperature of the substance being spray dried; therefore, the outlet 
temperature should never be above the product’s glass transition temperature.114-116 The 
aforementioned sticky nature of the particles emerges due to the spray drying process as 
this produces amorphous powders that are thermoplastic due to their heating or their 
exposure to high humidity which results in water sorption and thermal plasticization of the 
particle’s surface.117 Stickiness is a significant issue with spray dried amorphous products 
resulting in low yields and overcoming this issue can be done by using high glass 
transition temperature additives.104, 118, 119 Higher drying temperatures correlate to an 
increase in the product's glass transition temperature and crystalline temperature while 
also decreasing molecular mobility aiding in the spray drying selection process.120 With 
this in mind, glass transition temperatures are a significant indicator of internal thermal 
stability which is why it is often regarded as a reference temperature for any given 
material. 
 
At temperatures above the glass transition temperature, the amorphous structure 
becomes rubber-like due to the polymer molecules becoming softer and more flexible 
allowing the polymer particles to have a greater molecular mobility. At temperatures below 
the glass transition temperature, the molecules are in a glassy state where the polymer 
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molecules have no segmental motion but vibrate slightly.121 Nevertheless, the introduction 
of additives to a formulation has been shown to increase the glass transition temperature 
of the droplet given that additives segregate to the surface of the droplets during spray 
drying.56, 69, 123 Therefore, polymers with higher glass transition temperatures are 
preferred given that they increase the product’s shelf-life while improving their physical 
stability.124, 125 
 
Moreover, understanding the formulation’s nucleation and saturation points may aid in 
the drawbacks that may be presented with the stickiness nature of the spray dried 
formulation and with attempting to preserve API and making it more cost effective. As 
Parimaladevi and Srinivasan presented in their work that deals with the uniformity of 
crystal size distribution in a solution, it was determined that when the supersaturation of 
the solution fell within the range of 4.51 to 5.67 (i.e. the concentration is 55-63g/100mL) 
nucleation of elongated needle-like crystals was observed.126 Taking this information into 
account, it, then, becomes applicable to the spray dried formulation given that when spray 
dried, a thin-like layer develops on the drying chamber walls, thus preventing any particles 
from further adhering to the chamber and obtaining a higher yield along the way. It shows 
that maintaining higher concentrations than the thermodynamically required amount in 
vivo/in vitro has provided a platform for higher absorption rates to be seen thereby 
highlighting the supersaturation maintenance potential of the formulation.127  Kaialy et. al  
has also presented results that affirm the success of needle-like crystals in the delivery 
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of salbutamol sulphate via the respiratory tract when compared to other, more uniform, 
spherical crystals.128  
  
Nevertheless, when a compound is in its amorphous form, it is known to have a higher 
Gibbs free energy, therefore a glassy material recrystallizes spontaneously into a more 
stable crystalline form with a lower Gibbs free energy.129 Moreover, the amorphous to 
crystalline transition state is a thermodynamically driven phenomenon due to the 
crystalline state being in a lower energy state than that of the amorphous state.34 This 
phenomenon is described by the William-Landel-Ferry equation where the crystallization 
rate of powder (r) is defined by the fraction of time for crystallization (θcr) at any 
temperature (T) for the time for crystallization (θg) at Tg.130, 131 Equation 1.17 summarizes 
the William-Landel-Ferry equation 
 
(Eq. 1,17).                   
 
where it is shown that ΔT directly contributes to the rate of powder crystallization.  
 
Given the occurrence of phase transitions in the spray drying process, it becomes 
important to understand the role that humidity plays in the overall schematics as the 
processed formulation may or may not undergo nucleation. Due to the amorphous state 
having a higher Gibbs free energy, thus resulting in having a higher solubility and a faster 
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dissolution in aqueous media,132 the Flory-Huggins theory aids in estimating the amount 
of water being absorbed by the formulation which is then coupled with the kinetics of 
nucleation and crystallization to provide more of an understanding of the chemical 
processes taking place.  
 
Another theory that becomes applicable is the Johnson-Mehl-Alvrami theory, which 
provides crystallization rate constants through its description of the solid-state reactions 
that take place and can be summarized by Equation 1.18. 
 
(Eq.1.18)                           
 
where  α is the fraction crystallized, Y(θ) represents the growth rate of all m dimensions 
of growth. g is a geometric constant, and I(τ) is the nucleation rate.133-137 Equation 1.18 
then, provides an avenue that helps understand the mechanism of nucleation that takes 
place during the spray drying process as the formulation begins to cool and changes its 
phase from liquid to solid. Continuous nucleation refers to the process where nuclei 
continue to form and grow throughout the transformation process. A fixed number of 
nucleation refers to when the growth proceeds from a fixed number of preexisting 
nucleation sites. Site-saturated nucleation is a hybrid of the above two cases where all 
nuclei are present at the beginning of the isothermal process and additional nuclei do not 
form during the transformation.138 
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Concentrating on the macro-level of the formulation’s physical composition, carrier 
selection proves to be significant given the known impact it has on the downstream 
processibility of the overall product. Characteristics such as chemical composition, 
molecular weight, molecular structure, solution/melt viscosity, kinetic and thermodynamic 
solubility in any given solvent, solubility parameters, melting point, glass transition 
temperature, and hydrogen donor/acceptor counts are but a few of the properties to 
consider when carrier selection is thought of.39 Determinant on composition, dispersions 
may be categorized into four generations with known specifications for each of them; first 
generation carriers utilize urea and sugars.139 Second generational carriers utilize 
amorphous polymers that are either synthetic in nature or starches and sugar glass. 
Popular synthetic carriers include, but are not limited to, poly(vinylpyrrolidone) (PVP), 
polyethylene glycol (PEG), crospovidone (PVP-CL), poly(1- vinylpyrrolidone-co-vinyl 
acetate) (PVP-VA), or polymethacrylates. Cellulose derivatives such as hydroxypropyl 
methylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose 
phthalate (HPMCP), or hydroxylpropyl methylcellulose acetate succinate (HPMC-AS) 
have also been utilized.34  
 
Third generation carriers utilize surfactants like poly(ethylene glycol)-block-
poly(propylene glycol)-block-poly(ethylene glycol) (poloxamer), glyceryl dibehenate 
(Compritol 888 ATO), lauroyl polyoxyl-32 glycerides (Gelucire), inulin lauryl carbamate 
(Inutec SP1) or polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
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copolymer (Soluplus). Meanwhile, fourth generation carriers, commonly used for 
controlled release purposes, are comprised of ethyl cellulose, hydroxypropyl cellulose, 
Eudragit RL, Eudragit RS, poly(ethylene oxide) (PEO), or poly(acrylic acid) (carbopol).34 
 
§ 1.2.2 Crystallization 
 
Crystallization is the separation of an ordered crystalline phase from a metastable 
solution.140 It is generally defined as an operation in which external means are used to 
adjust the solubility of an un-reactive solute to produce a supersaturation.141-143 The three 
major steps in the process of crystallization are the supersaturation of the solution, 
nucleation of the solution, and crystal growth of the target particles. 
 
Nucleation may occur to be primary or secondary in nature; primary nucleation is 
independent of seed or crystal present in the solution whereas secondary nucleation 
occurs as a result of a crystal present in the solution. When the nucleation is primary, it 
may occur as homogeneous or heterogeneous. Homogeneous nucleation is considered 
spontaneous, dependent on the degree of supersaturation, and occurs due to the 
clustering of solutes whereas heterogeneous nucleation occurs due to the presence of 
an external substance.144 
 
In essence, the main strategy in macromolecular crystallization is to gradually bring a 
target to solubilized in an appropriate aqueous solution to a region of supersaturation until 
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a crystal nucleates and grows. Crystals form under conditions that fall between those 
producing clear drops (conditions where macromolecular-solvent interactions are 
stronger than interactions between macromolecules) and those producing a 
precipitate.145 
 
Macromolecular crystallization in itself is a phase transition; to study the coexistence of 
the crystal and the solution forms of a macromolecule, one needs to determine the set of 
conditions at which the chemical potentials of the two phases are equal. These capitulate 
conditions under which different phases are thermodynamically stable.146-149 A phase, in 
other words, is simply a macroscopically homogeneous state of matter that does not 
account for any assumptions about its microscopic nature. 116 
 
That is to say, phase diagrams depict the state of matter under the variation of certain 
conditions; they help visualize different dependencies such as simple pressure-volume 
(P/V) isotherms or pressure-composition (P/x) diagrams. The phase diagrams that are 
commonly encountered in macromolecular crystallization, however, are temperature-
composition (T/x) and composition-composition (x/x) phase diagrams. While these phase 
diagrams all serve different purposes and contain different information, they all relate to 
each other as they are all thermodynamic phase diagrams.116 
 
In temperature-composition (T/x) phase diagrams, mixtures of the components are 
prepared and equilibrated at a given temperature and constant pressure and the nature 
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and relative amounts of phases are established point-by-point via experimental labor; 
from the sum of the data points, the phase fields and composition lines in the phase 
diagram are established. 116 In  composition-composition (x/x) phase diagrams, however, 
the primary components of the system are (1) water, (2) protein, and (3) a third pseudo-
component that contains constituents like that of buffer which is commonly known as the 
reagent. The downfall is that it is unknown where the solubility lines are, where the phase 
fields for stable crystals are located, or what other phases may or may not exist. 116 The 
area between the solubility line and the critical point is where crystallization is most likely 
to occur and has been coined as the nucleation zone or crystallization gap.150, 151 
 
§§ 1.2.2.1 Anti-solvent Crystallization 
 
Anti-solvent crystallization is a technique that is favored due to it offering an extended 
range of solvent polarity compared to single solvents.152 This, then, allows for the 
possibility to control crystal properties like that of purity152, crystal size153, 154, 
morphology155, crystal size distribution154, agglomeration156, 157, and polymorphism158-160. 
With anti-solvent crystallization, it is possible to produce a supersaturation fairly simply 
with low energy consumption which is why it is generally conducted in either batch or 
semi-batch mode for industrial production.157, 161, 162 
 
Supersaturation of the solution can be altered by simply adding an anti-solvent into the 
already supersaturated solution. Recent publications on the anti-solvent process using 
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various approaches are increasingly appearing in the literature.163-166 Techniques, like 
that of Zarkadas and Sirkar, use a porous hollow fibre membrane to maintain and 
control particle size distribution while those from Chen et. al use a modified technique to 
continuously coat drug particles with a nano-sized polymer for controlled drug 
delivery.167-169 
 
One of the main disadvantages with anti-solvent crystallization is the tendency for the 
solute to agglomerate uncontrollably.170 The cause of this is that the product solution 
becomes surrounded by the anti-solvent which is separated into an interface of solution 
and anti-solvent. When the two fluids are in contact with each other, the low solubility of 
the anti-solvent creates a localized high supersaturation with very high supersaturation 
ratios in the contact area. Before molecular mixing can occur, the localized high 
supersaturation forces the solute out of the solution without allowing sufficient time for 
ordering of molecules to enable crystal growth.171 
 
1.3 Strategic Application  
 
§ 1.3.1 Manufacturing Compliance  
 
Large-scale production and manufacturing of products used for purposes of inhalation 
are governed by the US FDA and the European Pharmaceutical Review in the United 
States and Europe, respectively. Their regulatory compliance is mandatory and failure 
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to comply will lead to product refusal. These governing bodies establish the standard 
operating procedures (SOP) for any given product while also ensuring that current good 
manufacturing procedures (cGMP) are followed by manufacturers.  
 
§§ 1.3.1.1 United States Food and Drug Administration (US FDA)  
 
According to the US FDA, a metered dose inhaler (MDI) consists of a drug formulation 
and a container closure system. A MDI drug formulation, then, contains the drug 
substance(s), either dissolved or suspended, in a propellant, mixture of propellants, or 
mixture of solvents, propellants, and/or other excipients. Concurrently, a MDI container 
closure system consists of the device constituent part (i.e. the canister, the actuator, the 
metering valve, etc.) and any additional features (i.e. integrated spacer, integrated dose 
counter, etc.) as well as protective secondary packaging (i.e. an overlap).172  
 
A DPI, on the other hand, differs considerably from those for MDIs and contains a drug 
formulation (the drug constituent part) as well as a container closure system. For 
purposes of DPIs, however, a drug formulation contains the drug substance and 
excipients including a drug carrier (i.e. D-mannitol, lactose, etc.). A DPI container closure 
system, then, contains the devices constituent part and any protective secondary 
packaging. Current designs of DPI products include pre-metered and device-metered 
DPIs; either of which can be driven by a patient’s own inhalation (passive) or with power-
assistance of some type (active) for production of drug particles intended for inhalation.172  
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Performance of MDI and DPI products depends on many key aspects of the drug 
formulation, container closure system, manufacturing, and patient handling. Product and 
process understanding is therefore critical to: (1) the development and manufacture of 
these products, (2) the maintenance of product quality and performance through the 
expiration date under patient use conditions, and (3) the maintenance of product quality 
and performance over the product lifecycle, including continual improvement.172 
 
This is why MDIs and DPIs are considered combination products by the US FDA. A 
combination product is defined as a product that is composed of two or more of the three 
types of medical products (i.e. drug, devise, and biological product) that are physically, 
chemically, or otherwise combined into a single entity, co-packaged together, or, under 
certain circumstances, distributed separately to be used together as a cross-labeled 
combination product.173 As such, they are subject to current good manufacturing practice 
(cGMP) requirements for drug and devises. For single-entity and co-packaged 
combination products, design control requirements apply to the development of the 
combination product as a whole. For cross-labeled combination products, design control 
requirements apply only to the devise constituent part but should ensure the safety and 
effectiveness of the device when used with the other constituent part(s) of the 
combination product.174 
 
Thereby, design controls apply to any combination product that includes a device 
54 
 
constituent part that is subject to them.175 This ensures that there are no negative 
interactions between the constituent parts while also ensuring that the product is safe, 
effective, and performs as expected. Guidance for industry on pharmaceutical 
development addresses product design and development procedures, which reflect 
quality by design principles. While quality by design and design controls share the same 
characteristics and goals, the device quality system regulation includes specific 
requirements for design development that manufacturers must satisfy.176 
 
§§ 1.3.1.2 European Pharmacopoeia Commission 
 
The European Pharmacopoeia Commission is the decision-making body for the 
European Pharmacopeia and is responsible for the elaboration and maintenance of its 
contents. More specifically, (1) it evaluates proposals for inclusion, revision, or 
suppression of monographs and general chapter, (2) allocates agreed work to a group of 
experts or working party, (3) reviews the overall progress that is made on the work being 
revised on a yearly basis, and (4) approves the terms of reference of groups of experts 
and working parties while defining the criteria that is to be applied for the selection of 
experts and ad hoc specialists which it appoints.177 
 
Together with the European Pharmaceutical Aerosol Group (EPAG) and the European 
Medicines Agency (EMEA), there exists a legal and scientific basis for quality control of 
medicines during their development, production, and marketing. The purpose of the 
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European Pharmacopeia is to promote public health through the recognized standards 
that promote the quality of medicines and its component; its existence allows for the free 
movement of medicinal products within Europe and abroad. This movement allows for 
the globalization and expansion of international trade to continue to develop global quality 
standards for medicines.178 
 
§1.3.2 Food Industry 
 
Particle engineering via spray drying has been implemented in the food industry in a 
manner that allows for its innovation to continue to advance. A manner that it is used is 
in the conversion of fruit juices into a powder form to increase a product’s shelf-life while 
also making it easier to handle.179, 180 The ease by which moisture is removed from the 
food specimens by rapid evaporation is what makes the use of spray drying more 
favorable.181 In addition, the interest of the food industry in natural flavor- and color-
enriched additives has driven the demand of fruit juices powders to increase. Fruits and 
vegetables which have been spray dried include, but are not limited to banana, orange, 
bayberry, mango, apricot, blackcurrant, raspberry, ginger, guava, lime, pineapple, 
tomato, and watermelon. 
 
Furthermore, the use of drying aids within the food industry is also something that is seen 
because they form an outer layer on the drops and alter the surface stickiness of the 
particles due to the transformation into a glassy state.182, 183 The changes in surface 
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stickiness reduce the particle-particle cohesion resulting in less agglomeration with lower 
water-holding capacity of the powders.184 
 
Karatas was able to develop an experimental spray dryer with a chamber wall scraper for 
tomato juice; a method that is useful for relatively less thermoplastic sugars like lactose 
and sucrose.185 Karatas and Esin investigated the fundamental aspects involved in the 
drying of tomato concentrate droplets fully exposed to air of constant humidity and 
velocity.186  
 
Masters modelled a pilot plant spray dryer with a cooling air jacket which reduced the 
particle stickiness on the wall while Masters introduced chambers with air brooms, which 
rotate slowly close to the wall, that can also cool the wall surface to prevent stickiness of 
powders; the air broom arm contains a row of nozzles that direct compressed air on to 
the wall surface.187, 188 Furthermore, Mani et. al used an air broom system for spray drying 
of banana and mango juice.180 
 
Introduction of atmospheric cool air at the lower part of the drying chamber is something 
that has also been seen as it results in the formation of solid particle surfaces which can 
also reduce the stickiness of the powder particles.189 However, only a limited amount of 
air can be introduced because the cooling process raises the relative humidity which then 
increases the surface moisture of the particles.190 
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Tonon et. al  spray dried acai pulp and studied the influence of inlet air temperature, feed 
flow rate, and maltodextrin concentration on process yield, powder moisture content, 
powder hygroscopicity, and anthocyanin retention, during micro-encapsulation.191 Tonon 
et. al studied the effect of temperature, water activity, and type of carrier agent on the 
anthocyanin stability and antioxidant activity of spray dried acai juice.192 Khalil and Sial 
studied the parameters for the production of instant mango juice powder.193 Goula et. al  
modeled the sorption isotherms using selected equations by spray drying tomato pulp 
and defining the glass transition temperature, water activity and water content 
relationships.194 
 
Chang and Nickerson micro encapsulated omega 3-6-9 via spray drying to be able to 
increase their concentration in food and prevent their oxidation.195 Papillo et. al, on the 
other hand, spray dried polyphenolic extract from Italian black rice and used it as an 
alternative ingredient in baked goods; they also found that the rise was a valuable source 
of polyphenols to produce functional foods.196  
 
§1.3.3 Pharmaceutical 
 
Within the pharmaceutical industry, there are numerous innovative ways spray drying is 
used, which continue to develop the technique further. Below are some of the most recent 
publications that involve the use of spray drying. 
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Rampacci et. al uses spray drying in a manner that provides clues on the in vitro 
performance of azithromycin/rifampicin combinations in co-spray dried microparticles 
against Rhodococcus equi, an emerging human pathogen found responsible for worrying 
zoonosis.197 Ito et. al, however, uses spray drying to prepare dry naked plasmid DNA 
(pDNA) powders which are then used to determine their effect on gene expression in the 
lugs of mice.198 Katsarov et. al, on the other hand, used spray drying to produce muco-
adhesive glutaraldehyde cross-linked chitosan micro-particles loaded with doxylamine 
succinate and pyridoxine hydrochloride for nasal drug delivery systems with sustained 
release. They found that the cross-linked particles exhibited sustained drug release at pH 
6.8 over a period of 5 h with an initial burst-effect in the first 30 min.199 Spray drying is 
also used by Ceschan et. al to formulate micro-particles carrying indomethacin (IN) for 
potential local (specific and non-specific bronchial inflammatory asthma responses) and 
systemic treatments (joint inflammation, rheumatoid arthritis and osteoarthritis pain) by 
optimizing micro-particle properties and characterizing their lung deposition, drug release, 
and evaluating cytotoxicity and also pharmacological effects in vitro.200  
 
Looking at the component of atomization in spray drying more specifically, researchers 
have been focussing on innovative atomization systems which use different forms of 
energy than the conventional nozzles; normally based on kinetic energy, pressure energy, 
centrifugal force, or piezoelectrospraying for droplet formation.34 Electrohydrodynamic 
spraying, also known as electrospraying, is a technique where the liquid feed is atomized 
via the application of electrical energy.201 , 202 
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Variations in the operating conditions, which help determine the shape of the liquid 
meniscus, its motion, and subsequent breakup, and introduction into the drying chamber, 
become tailored in such a way as to allow different jet formations and breakup patterns, 
or electrospraying modes, to be observed; some of which include dripping, micro-
dripping, spindle, multi-spindle, cone-jet, oscillating-jet, precession, or multi-jet type.203 , 
204 Such differences make electrospraying an attractive technique since it can produce 
particle sizes in the nanometer range.  
 
Its sophisticated set-up along with it producing low yields does provide a few drawbacks 
for the technique where more development is needed to allow it to be scalable to cGMP 
production levels.205, 206 However, the technique has been utilized to fabricate core-shell 
structures that improved the solubility of the API showing promise for the technique.207 
 
Pulse combustion drying, on the other hand, does show process intensification where the 
atomization of the feed takes place due to sound waves that are produced by a 
combustor.208, 209 Producing intermittent high temperature shock waves with a frequency 
of 50-100Hz makes this technique unique and promising.210 Its hot-high pressure gases 
and concurrent shockwaves result in a back-to-back combustion of fuel-air mixture in the 
pulse combustion chamber where drying takes place via shockwaves, ultrasonic waves 
(>155dB), gas flow, and gas temperature (>200°C) in the drying chamber. Pulse 
combustion dryers have the ability to improve the drying rate by 1.2 to 3 times, reduce air 
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consumption, and air emissions, but fall short with the amount of noise that is 
produced.211, 212 Wang et. al produced nitrendipine-Aerosil-Tween 80 amorphous solid 
dispersion particles that exhibited no agglomeration, were smaller in size and had a 
narrow size distribution.213 
 
With respect to crystallization, however, there are researchers like that of Mazlan et. al 
who has been able to elucidate the crystal structure and characterization of GDSL 
esterase J15, which is a member of Family II of the lipolytic enzyme.214 Ou et. al, on the 
other hand, used crystallization in developing a new method for the analysis of 
carbohydrates in matrix-assisted laser desorption/ionization (MALDI) MS.215 Afrose et. al  
used a controlled crystallization technique to develop ibuprofen (IBP) micro-particles to 
be used in improved dissolution studies. Their Raman data revealed that the excipients 
with a large number of hydroxyl groups distributed around the IBP particle in the crystal 
enhanced the dissolution of the drug due to the increase in the drug-solvent interactions 
through hydrogen bonding.216 Zhang et. al was able to use crystallization in the structural 
and functional characterization of a HIV-1 cell fusion inhibitor known as T20. Their crystal 
structure revealed the critical intra- and inter-helical interactions underlying the 
mechanism of action of T20 and its resistance to mutations.217   
 
While these are a few of the most recent publications dealing with the application of spray 
drying and crystallization, there are hundreds more.  
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1.4 Aims and Objectives 
 
The aim of this overall study is to engineer a carrier for salbutamol sulphate that will have 
optimal properties for a more effective aerosolization performance. The objectives are: 
(1) to be able to use these findings as a referencing tool for the development of aerosols, 
(2) to determine whether the use of excipients made a difference to the carrier’s 
aerosolization performance, (3) to determine optimized spray drying conditions for 
carriers to be used in DPI formulations, (4) to determine whether or not particle 
morphology and physicochemical properties played a role in the efficacy of aerosolized 
carriers, (5) to implement a set of practices that would be useful if any engineered 
formulation was to be commercialized, and (6) to find an innovative mechanism of 
agglomeration that resulted from the altering of physicochemical properties.  
 
Thus, making this research important as it contributes to the current understanding of 
aerosolized particles by providing further conclusions. This research also proposes 
principles and practices that aid in the development of the current field.  
 
Moreover, this chapter has presented the necessary background information that is 
needed for one to understand the intricacy of using inhalation as a means for drug 
delivery; it has also introduced techniques that are used in engineering a suitable 
formulation. Those techniques were then followed by extensively highlighting their most 
current application and use, both in industry and in research, while focusing on the theory 
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behind them. United States and European regulatory compliance agencies were also 
introduced as a way of illustrating the importance and magnitude that come with 
engineering aerosol formulations for therapeutic purposes.  
 
Chapter 3 explored the effect that L-leucine has on the aerosolization performance of 
spray dried lactose while Chapter 4 looked at the effect that L-leucine has on spray dried 
mannitol and its use as an alternative carrier for DPI formulations. Chapter 5 invetigates 
the effect that spray dried mannitol and lactose, in different ratios, has on its aerosolization 
performance while Chapter 6 investigates the use fo xylitol crystals in DPI formulations 
as well as its potential use as an alternative carrier in said formulations. Chapter 7 looks 
at mannitol and lactose crystals and Chapter 8 looks at mannitol and salbutamol crystals 
to determine their aerosolization efficacy. Chapter 9, then, looks at the effect L-leucine 
has on the aerosolization performance of physical mixtures while comparing them to the 
engineered carriers from Chapters 3-8. Finally, Chapter 10 provides a summary of all the 
findings while proposing future investigations.   
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Chapter 2 
 
         Materials and Methodological Approach 
 
2.1 Introduction 
 
In this chapter, a fundamental platform has been established through the creation of 
methodologies, which governed the original academic research presented in the chapters 
that follow. Here, one will find a more descriptive outline of the operating procedures that 
were used in the creation of the engineered carriers and drugs that were used throughout 
this overall study. It is important to note, however, that the standard operating procedures 
outlined within this chapter follow the regulatory guidelines set forth by the regulatory 
agencies from, both, the United States and the European Union. 
  
2.2 Materials 
  
 
D-Mannitol [Pearlitol®], Xylitol [(2S,4R)-pentane-1,2,3,4,5-pentol], and α-lactose 
monohydrate were supplied by Roquette (Lestrem, France), SS from L.B. (Bohle, 
Germany), and L-leucine by Acros Organics (Geel, Belgium), a Fisher Scientific company. 
Acros Organics also supplied the monobasic potassium phosphate and the 
Trifluoroacetic acid (TFA) used for the preparation of the mobile phase for high-pressure 
liquid chromatography (HPLC). Methanol, Ethanol, Acetone and Hydrochloric Acid were 
purchased from VWR International Ltd. (Leighton Buzzard, United Kingdom) and were 
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HPLC-grade.  
 
2.3 Spray Drying  
 
Spray drying was conducted using the Mini Spray Dryer B-290 from Buchi (Flawil, 
Switzerland) equipped with a dehumidifier (Dehumidifier B-296), an inert loop (Inert Loop 
B-295), and an outlet filter at room temperature (20°C). Parameters associated with the 
procedure were as follows: inlet temperature of 220°C, aspirator set to 100% 
(~35mm3/h), pump rate set to 5% (~2 mL/min), nozzle diameter of 5µm, and a flow rate 
of 22% designed for a closed environment with the use of nitrogen (N2) gas; several 
rigorous optimization procedures were implemented to achieve the selected parameters 
and overall protocol, however. 
 
In chapter three, each 100 mL of the solution for spray drying contained different 
concentrations of  L-leucine (0.1, 0.5, 1, 5, and 10 g) and 60 g of lactose. Meaning that 
the percentage of L-leucine in each solution was 0.1, 0.5, 1, 5, and 10% w/v, respectively. 
Both leucine and lactose were dissolved in deionized (DI) water while heating the solution 
to 75°C with a stirring speed of 120 rpm; the final solutions were spray dried under the 
conditions mentioned above.  
 
In chapter four, each 100 mL of spray dried solution contained different concentrations 
of L-Leucine (0.0, 0.06, 0.3, 0.6, 3.0, and 6.0g) and D-Mannitol (60.0, 59.94, 59.7, 59.4, 
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57.0, and 54.0g; respectively). Meaning that the percentage of L-Leucine in each solution 
was 0.0, 0.06, 0.3, 0.6, 3.0, and 6.0% w/v, respectively. Both L-leucine and D-mannitol 
were dissolved in deionized water and were heated to 75°C with a stirring speed of 120 
rpm at room temperature (20°C); the final solutions were then spray dried under the 
conditions mentioned above. 
 
In chapter five, the carriers for each of the formulations were prepared by weighing a 
constant amount of  L-leucine (5 g) to that of D-mannitol (1.35, 0, 47.5, 23.75, and 71.25g; 
respectively) and lactose (0, 1.35, 47.5, 71.25 and 23.75g; respectively) yielding the 
following carriers: Mannitol, Lactose, 1:1 (Mannitol:Lactose), 1:3 (Mannitol:Lactose), and 
3:1 (Mannitol:Lactose) all with 5% L-leucine (w/v). Carriers were dissolved in de-ionized 
(DI) water while heating the solution to 75°C while stirring at 120 rpm at room 
temperature (20°C); the final solutions were spray dried under the conditions mentioned 
above and consisted of them being w/w. Importantly, however, when preparing the D-
mannitol, lactose, and leucine solution for the carriers, it was important to add the lactose 
before the addition of D-mannitol and leucine to ensure a homogeneous mixture. 
 
2.4 Crystallization Methodology 
 
In chapter six, xylitol crystals were made with increasing concentrations of L-leucine (0, 
1, 5, and 10%; w/v) by weighing xylitol (60, 59.6, 57, and 54g, respectively) and L-leucine 
(0, 0.4, 3, and 6g, respectively) and combining them in a mixture. Doing this involved 
weighing the material and then placing them in a beaker where the volume was adjusted 
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to 100 mL with deionized (DI) water. Solutions were heated to 75°C under constant 
stirring (120 rpm) at room temperature (20°C) and then acetone was added at a constant 
rate of of 5 mL/min. The solutions were allowed to cool to room temperature to facilitate 
crystal formation. Crystals were then filtered under vacuum, placed in a dry oven to 
remove any residual moisture, and saved in glass vials for future use. 
 
In chapter seven, crystals were engineered to obtain a final stoichiometric ratio of the 
following carriers: [1:1 mannitol:lactose], [1:2 mannitol:lactose], [2:1 mannitol:lactose], 
[1:3 mannitol:lactose], and [3:1 mannitol:lactose] by weighing 25, 12.5, 25, 8.33, and 25g 
of D-Mannitol, respectively, and 25, 25, 12,5, 25, and 8.33g of lactose, respectively. After 
which, 200 mL of DI water was added to the blended material (w/v) where heating was 
conducted to obtain a final temperature of 75°C accompanied by a stirring speed of 120 
rpm at room temperature (20°C). Succeeding this, the solution was added to 500 mL of 
acetone at a constant rate of 1.5 mL/min to facilitate nucleation and, thus, crystal 
formation. Cooling was monitored at a close decreasing rate of 5°C/min after which the 
crystal formation process was allowed to ferment for 24 hrs upon nucleation. Upon 
completion of the incubation period, the engineered co-crystals were filtered under 
vacuum using 0.22 μm filters and allowed to dry completely overnight in a dry oven where 
the temperature was set to 50°C. The dried samples were kept in glass vials for future 
use. 
 
In chapter eight, carriers were engineered to obtain the following crystals: 1:1 
(salbutamol sulphate:mannitol), 1:2 (salbutamol sulphate:mannitol), 1:4 (salbutamol 
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sulphate:mannitol), 2:1 (salbutamol sulphate:mannitol), and 4:1 (salbutamol 
sulphate:mannitol). This was done by weighing salbutamol sulphate (10, 10, 6, 20, 20 g; 
respectively) and D-mannitol (10, 20, 24, 10, and 5 g; respectively) and mixing them with 
a Turbula blender (Type T2F,Junkermattstrasse, Switzerland) for 15 minutes at 72 rpm. 
After mixing, they were added to 100 mL of DI water and heated to 75°C at 200 rpm at 
room temperature (20°C). The heated solutions were then added to 500 mL of acetone 
at a rate of 1.5 mL/min and left overnight to facilitate crystallization. After crystallization 
had occurred the engineered co-crystals were filtered under vacuum using 0.22 μm 
filters and allowed to dry completely overnight in a dry oven where the temperature was 
set to 50°C.  
 
2.5 Sieving  
 
Mechanincal sieving is a pharmaceutical process where particles are passed through a 
series of sieves with progressively smaller mesh sizes; particles are then weighed and 
classified into size-fractions based on which mesh they fall on.219 In the process, coarse 
particles are removed from smaller particles.220 In general, however,  sieving produces 
lower levels of charge than other industrial processes such as micronization and 
pneumatic conveying.221 In drug-carrier DPI formulations, the carrier is sieved into a 
range of 63-90 μm or to 70-100 μm; in this case, it was 63-90 μm to comply with US 
FDA guidelines and the USA Pharmacopeia.222-226 In this study, particles that fell within 
the 63-90 μm range were collected using a Retsch AS 200 Digit Analytical Sieve Shaker 
(Hoan, Germany) where the collection pan was placed at the bottom, followed by the 63 
μm sieving pan, and finishing with the 90 μm sieving pan. The powders were placed on 
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top of the 90 μm sieving pan where sieving was performed for 30 minutes with an 
amplitude of 100 for each of the carriers. Particles which fell within the range of 63-90 
μm were collected, sealed, and stored in glass vials in an air-conditioned laboratory with 
a set temperature of 20°C and a relative humidity (RH) of 50% for future use within this 
study. 
 
2.6 Particle Size Distribution Analysis  
 
Particle Size Distribution Analysis was conducted using a laser diffraction particle size 
analyzer (Sympatec Ltd.,Waterford House, United Kingdom) equipped with a HELOS 
sensor and Windox software. Analysis of the formulations was completed using both the 
Rodos dry system and Cuvette wet system; the Cuvette system required the use of 
absolute ethanol and a stirring speed of 1200 rpm while the Rodos system required a 
pressure of 3.0 bar, feed rate of 60%, and trigger conditions that used optical 
concentration of greater than or equal to 0.2%. Detecting the particles was done using 
the R3 and R5 lenses, which have a particle size detection range of 0.5-175μm and 0.5-
875μm, respectively.  
 
The span of size distribution was calculated using Equation 2.1227 
 
(Eq. 2.1) 
  
 
%&'( = (+,-% − +0-%) +2-%3  
69 
 
 
where  D90%, D50%, and D10% refer to the particle size (in μm) of 90, 50, and 10% of the 
cumulative particle size distribution, respectively. The aerodynamic diameter was 
calculated using Equation 2.210, 11 
  
(Eq. 2.2)                                       
 
where daer refers to the aerodynamic diameter, dg to the geometric diameter, P to the 
density of the particle, P0 to the unit density, and χ to the shape factor. 
 
2.7 Preparation of Dry Powder Inhalation (DPI) formulations 
 
 
Using the stored 63-90 μm sieved carriers, salbutamol sulphate (SS) was introduced 
such that a final ratio (Carrier: SS) of 67.5:1 was obtained. This, then, corresponded to a 
theoretical dosage of 482 + 1.5 μg of SS per single unit from 1.35 g of each carrier and 
20 mg of SS. Mixing was carried out with the use of a Turbula blender (Type T2 
,(Junkermattstrasse, Switzerland) where each of the formulations was subjected to 30 
minutes of blending at a speed of 72 rpm to ensure a homogeneous formulation. 
 
In chapter eight where salbutamol sulphate:mannitol (co-crystallised formulation)  was 
implemented, the concentration of salbutamol sulphate was first determined. Once the 
salbutamol sulphate concentration was known, a final ratio of 67.5:1 was obtained for 
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each carrier. The carriers used were 1:1 (salbutamol sulphate:mannitol), 1:2 (salbutamol 
sulphate:mannitol), 1:4 (salbutamol sulphate:mannitol), 2:1 (salbutamol 
sulphate:mannitol), and 4:1 (salbutamol sulphate:mannitol). This meant that each carrier 
was weighed (30.80, 69.46, 128.43, 34.01, and 23.82 mg; respectively) and added to D-
mannitol (1.289, 1.250, 1.191, 1.286, and 1.296 g;respectively) to achieve the 67.5:1 
(Carrier:SS) ratio.  
 
Each capsule (gelatin, size 3) was filled with ~33 mg of each formulation and a minimum 
of 10 capsules were used for one deposition test. The test was repeated three times for 
each formulation to obtain the mean and standard deviation. In total, 30 capsules were 
used in the deposition test for each formulation.  Once capsule filling was completed, 
they were stored for 24 hours to decrease the electrostatic charge prior to them being 
used in the in vitro aerosolization study. 
 
 
2.8 Differential Scanning Calorimetry (DSC) Analysis 
 
Perkin Elmer’s (Shelton, Connecticut, United States of America) Differential Scanning 
Calorimetry (DSC) 4000 equipped with a Standard Single-Furnace was used to perform 
thermodynamic analysis; viewing and analyzing the data was completed with the 
accompanied Pyris Series software. Endothermic events were displayed using the 
configurations shown in Figure 2.1 where an endothermic curve would point up and an 
exothermic curve would point down. 
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Nevertheless, calculating the enthalpy for each thermal event was done by using the 
area under each curve, given that the peak area of each thermal event is proportional to 
its experienced enthalpy.228 A temperature range of 25-300 °C, 25-120 °C, 25-400 °C, or 
25-150 °C was used with a heating scanning rate of 10 °C/min or 5°C/min for all of the 
samples; the scanning rate was decreased to 5°C/minute as such rate is known to 
provide a more thorough thermal analysis.128, 228 The adopted methodology consisted of 
the following: (1) holding the starting temperature for one minute, followed by (2) using 
one of the scanning temperatures above, and (3) holding the end temperature for a 
minute.  
Figure 2.1 Differential Scanning Calorimetry Curve 
 
 
(Exothermic) 
(Endothermic) 
ΔH 
ΔT (in °C) 
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Determining thermal events for each carrier was completed through the analysis of the 
arising peak areas (enthalpy change) as it is known that such areas are proportional to 
thermal effects experienced by the sample. Equation 2.3228 was used by the software 
to determine the peak area: 
 
(Eq. 2.3)                       
 
where A represents peak area, ∆H for the enthalpy associated with the sample, m as the 
mass of the sample, and K as the calibration constant known to be independent of 
temperature. 
 
In addition, calculating the heat capacity (Cp) was completed by using Equation 2.4  
 
(Eq. 2.4)                                       
 
where d is the displacement, m is the mass, and Cp is the heat capacity; it is important 
to understand, however, that the rate of heat flow into the sample is proportionate to its 
heat capacity. 228  
 
2.9 Powder X-Ray Diffraction (PXRD) 
 
To investigate any changes in the solid state of the crystallized or spray dried samples 
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X-ray diffraction (PXRD) was used. Determination of particle crystallinity/amorphousness 
was completed by implementing Siemens’ Diffraktometer D5000 (Munich, Germany), 
where ~200 mg of each carrier was placed on a stainless steel holder such that a levelled 
surface was obtained when observed in comparison to the pan and diffractometer. The 
holder was then placed on the Diffraktometer in a manner where analysis was possible. 
At which point, the sample was exposed to X-rays (Cu Κ⍺ - 1.54056Å) with a voltage of 
40 kV and a current of 30 mA while being scanned from 5-50° on the 2θ plane at a 
scanning rate of 0.1 increments per second. 
 
 2.10 Fourier Transform Infrared (FT-IR) Spectroscopy 
 
Vibrational frequencies are determined through the interactions between 
electromagnetic radiation and that of matter; making it possible to observe vibrations of 
different symmetry.229 Therefore, vibrational spectroscopies provide definitive 
fingerprints of molecules through the molecule’s absorption of infrared (IR) or mid-IR 
radiation through inelastic scattering of radiation, which produces shifts from the 
excitation laser wavelength.230 These vibrational differences provide insight into the 
polymorphic composition of the carriers and any changes in the molecular level that are 
subjected to testing. Polymorphism, nonetheless, is the ability of a particle(s) to exhibit 
a different stereochemistry from another, thereby making them isomers; about one-third 
of all drugs display polymorphism.231 Evaluation, on the basis of polymorphism and the 
presence or absence of functional groups was accomplished with Perkin Elmer's 
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Spectrum One FT-IR Spectrometer (Shelton, Connecticut, United States of America) 
equipped with a Universal ATR Sampling Accessory; the Spectrum software was used 
is unison. Preceding to analysis, methanol was used to clean the instrument, after which 
a few milligrams (~ 2-5 mg)  of each of the carriers was used with a pressure of 100 bar. 
Each of the samples was scanned three times over a range of 4000-500 cm-1 to obtain 
spectra with appropriate resolution. 
 
2.11 Scanning Electron Microscope (SEM)  
 
Electron micrographs were obtained using a JMS-820 Scanning Microscope (Freising, 
Germany) with a voltage of 4 kV to evaluate the morphology, size, shape, and presence 
or absence of agglomerates in the samples.232, 233 Before subjecting each formulation to 
electrons, they were thinly placed on double-sided carbon tape followed by them being 
sputter coated using Agar Scientific’s S150 Sputter Coater (Essex, United Kingdom) with 
gold (Au), under vacuum in an Argon-rich environment; to view each of the 
carriers/formulations, different magnifications were employed. 
 
Adjusting the brightness of the collected images was done using Equation 2.5: 
 
(Eq. 2.5)                                            
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where β refers to the brightness, βc to the current density at the cathode surface, e to 
the electron charge [1.59 X 10-19 C ], V to the accelerating voltage, k to Boltzmann’s 
content [8.6 X 10-5 eVK ], and T to the absolute temperature in Kelvin. 
 
 
2.12 Powder Flow Characterization 
 
 
§ 2.12.1 Carr’s Index (CI) 
 
Carr’s index (CI) was measured for some carriers as an indication of powder flowability 
using an Erweka (Heusenstamm, Germany). Each powdered carrier was filled into a 10 
mL graduated cylinder and weighed. After recording the volume (bulk volume) the 
cylinder was tapped 100 times under standard conditions [room temperature at 20°C 
and relative humidity (RH) at 50%] and the new volume (tap volume) was recorded. Using 
mass, bulk and tapped volume, the bulk and tapped density was calculated 
(mass/volume). Carr’s Index (CI), was calculated using Equation 2.6.  
 
(Eq. 2.6)                                  
 
where CI is the Carr’s index, Dt is the tap density, and Db is the bulk density.  
 
§ 2.11.2 Angle of Repose (δ) 
76 
 
 
Angle of repose (δ) was measured using the methodology outlined in the European 
Pharmacopoeia234 where the angle of repose was the constant solid angle (relative to the 
horizontal base) assumed naturally by a cone-shaped pile of powder. Such angle was 
calculated using Equation 2.8: 
(Eq. 2.8)                                          
  
where h is the height of the powdered cone and D is the diameter of the base of the 
formed powdered pile. The angle of repose of less than 30° indicates excellent flow 
characteristics whereas values beyond 45° indicate poor powder flowability.  
 
2.13 In vitro Deposition Study 
§ 2.12.1 Multi-Stage Liquid Impinger (MSLI) 
 
A Multi-Stage Liquid Impinger (MSLI), equipped with a USP induction port (Copley 
Scientific in Nottingham, United Kingdom), was used alongside the Critical Flow 
Controller (Copley TPK) and a High Capacity Pump (Copley HCP5) that allow for a 4kPa 
pressure drop to be observed. Because the MSLI has the capacity to filter particles, it 
allowed for cutoff diameters to be taken into account in each of the individual stages. 
Calculating the cutoff diameter for each individual stage was determined using Equation 
2.9:  
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(Eq.2.9)                                                          
 
where D50,Q refers to the cutoff diameter at the flow rate of Q, and N refers to the values 
obtained for each individual stage of the MSLI when the flow rate is 60 L/min. As a result, 
when such flow rate is used, the cutoff diameters for each of the individual stages 
become 13.00, 6.80, 3.10, and 1.70 μm, respectively. Furthermore, at the flow rate of 
100 L/min, the cutoff diameters change and become 10.07, 5.27, 2.40, and 1.32 μm, 
respectively.  
 
Moreover, the Equation 2.10 was employed to determine the test flow duration, in 
seconds, used within each deposition to adhere with the United States Pharmacopeia 
(USP) specific standard test methods for Aerosols, Nasal Sprays, Metered-dose inhalers 
(MDIs), and Dry Powder Inhalers.222, 223 
(Eq.2.10)                                           
 
where Qout is the volume of air passing through the airflow meter. Testing the air flow 
through the device was done with a calibrated Test Flow Meter DFM3 (Nottingham, 
United Kingdom) ensuring a 4kPa pressure drop across the whole device; the Test Flow 
Meter DFM3 also conforms with USP 33 and Ph. Eur. 6.0.235, 236 
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Each in vitro deposition study used 10 capsules (size 3) per run where every capsule was 
filled with ~33 mg of the Carrier:SS being investigated which corresponded to a 
theoretical API dose of 482 + 1.5 μg of salbutamol sulphate per capsule. All of the 
formulations were done a total of three times, equivalent to 30 capsules (each filled with 
~33mg) per formulation.  
 
In addition, specific parameters were employed for the analysis of the aerosolization of 
said capsules including the recovery dose (RD), emitted dose (ED), percent recovery, 
percent emission, impaction loss, mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD), fine particle fraction (FPF), fine particle dose (FPD), 
drug loss (DL), dispersibility (DS), and effective inhalation index (EI). 
 
Moreover, RD is defined as the amount of drug (in μg) recovered from the inhaler, 
induction port (IP), mouthpiece (M), and Stages 1-5 (S1-5), ED as the amount of drug (in 
μg) recovered from IP and S1-5, percent recovery as the ratio of RD to the theoretical 
dose (482 + 1.5 μg), percent emission as the ratio of ED to RD, impaction loss as the 
mass fraction of drug in IP and S1 to RD (IP + S1: RD), MMAD as the mass median 
aerodynamic diameter, GSD as the geometric standard deviation, FPF as the ratio 
between FPD to RD (FPD:RD), FPD as the sum of drug (in μg) from S3-5, DL as the ratio 
of the amount of salbutamol sulphate recovered from capsules, mouthpiece, and inhaler 
to RD [(capsules + (I + M)): RD], and DS as the ratio of FPD to ED (FPD:ED).  
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Furthermore, to determine the effective inhalation index (EI) of each of the formulations, 
Equation 2.11 was implemented where EI refers to the effective inhalation index, EM to 
the percent emission, and FPF to the Fine Particle Fraction.227, 237 
(Eq.2.11)                                   
 
All the in vitro deposition studies were conducted in an air-conditioned laboratory where 
the temperature was 20°C and the relative humidity (RH) was 50%.  
 
2.14 Homogeneity Assessment 
 
Assessing the uniformity of salbutamol sulphate (SS) in each of the formulations that was 
prepared and compare it to the theoretical dose of 482 + 1.5μg found in each capsule 
[which was expressed in terms of coefficient of variation (%CV)]. To this end, ten different 
samples were taken from each of the formulations in an ordered fashion; eight out of the 
ten simulating a circle, while the ninth and tenth sample were taken directly from the 
middle. Carefully weighing the ten samples from each formulation, which yielded a mass 
range of 10-12mg, they were introduced to 100 mL of deionized (DI) water in volumetric 
flasks for preparation for high-pressure liquid chromatography (HPLC). 
 
In chapter four through eight, UV-vis spectroscopy was used rather than HPLC. For 
those formulations, 3 or 5 samples were taken from each, which yielded a mass range 
of 50 mg, and were then introduced to 50 mL of deionized (DI) water in volumetric flasks; 
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the wavelength associated to the assay was set at 225nm. Results are based on 
obtaining the average of the three or five samples alongside the standard deviation for 
each distinct formulation. 
 
2.15 High-Pressure Liquid Chromatography (HPLC) 
§ 2.15.1 Qualitative and Quantitative Analysis of 4-[2-(tert-butylamino)-1- 
hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid  
 
In chapters three, four, and five, qualitative and quantitative analysis of salbutamol 
sulphate was completed by using a mobile phase containing 95% (v/v) of 25 mM 
potassium phosphate (monobasic) pH 3.0 and 5% (v/v) of methanol. The flow rate of the 
mobile phase through the HPLC column was 1.5 mL/min with a total run time of 25 
minutes per injection set at a wavelength of 225 nm yielding a retention time of 12min. 
To adjust the pH to 3.0, a 1 M HCl solution was used while stirring at 180rpm, after which 
the mobile phase was filtered and degassed using a Fisher Scientific (Leicestershire, 
England) 0.22-μm filter before its use.  
 
In chapters six, seven, and eight, however, a mobile phase containing 80% 0.1% 
Trifluoroacetic acid (TFA) and 20% methanol was used at a flow rate of 1.5mL/min with 
a total run time of 10 minutes per injection and a wavelength of 225 nm, which yielded a 
retention time of 6 min. Samples in chapter nine used both methods. The methodology 
was adjusted due to the residual matter that accumulated in the crevices of the system. 
  
81 
 
Nonetheless, HPLC was executed via the Agilent 1100 series HPLC system (Santa Clara, 
California, USA) where a degasser (G1322A), binary pump (G1312A), variable wavelength 
detector (VWD G1314A), column thermostat (G1316A), and thermostatic autosampler 
(ALS G1329A) coupled with the Waters Spherisorb 5 μm ODS2 4.6 × 150 mm analytical 
column (Milford, Massachusetts, USA). Likewise, internal standards of varying 
salbutamol sulphate concentrations (0.00. 0.50, 2.50, and 5.00 μg/mL, respectively) were 
used to calibrate and normalize the results.  
 
§ 2.15.2 Qualitative and Quantitative Analysis of L-Leucine 
 
Qualitative and quantitative analysis of L-Leucine was completed by using a mobile 
phase containing 50% (v/v) of 0.1% Trifluoroacetic acid (TFA) in water and 50% (v/v) of 
methanol. The flow rate of the mobile phase through the HPLC column was 0.8 mL/min 
with a total run time of 15 minutes per injection set at a wavelength of 260 nm which 
yielded a retention time of 3 minutes. Standard solutions of varying L-Leucine 
concentrations (0.00, 0.50, 1.00, 5.00, and 10.00mg/mL, respectively) were used to 
calibrate and normalize the results. 
 
2.16 Statistical Analysis (ANOVA) 
 
One-way analysis of variance (ANOVA) was used to evaluate the results in this study 
where statistical probability (P) values less than 0.05 were considered a significant 
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difference. The test was followed by the Tukey’s Honestly Significant Difference (HSD) 
test. All data is expressed as the mean ± standard deviation. 
 
2.17 Air Jet Mill 
 
Air jet milling was conducted using an MC Jet Mill MC One from DEC Group with the 
following settings: Venturi set to 5 and the Ring set to 4.  
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Chapter 3 
 
 Agglomerated novel spray dried lactose-leucine tailored 
as a carrier to enhance the aerosolization performance of 
salbutamol sulphate from DPI formulations  
 
 
3.1 Introduction  
 
In this chapter, the focus was to engineer a spray dried carrier composed of lactose and leucine 
and investigate the effect that leucine has on the overall aerosolized dry powder inhaler (DPI) 
performance for salbutamol sulphate. To date, lactose is the most commonly documented 
carrier in the pharmaceutical industry due to it being highly stable, adhering to good flow 
properties, and being widely accepted as a safe excipient.14 Although other carriers such as 
mannitol128 and sorbitol238 have been suggested in DPI formulations, lactose is still the only 
excipient approved by the US FDA in DPI formulations of APIs. 
 
The use of leucine, however, has previously been shown to improve the aerosolization 
performance of several drugs from DPIs because it reduces the inter-particulate adhesive forces 
and API aerodynamic particle size due to its surfactant behavior.239-242 Coupling both lactose 
and leucine together in a spray dried solution allowed for the manufacture of an agglomerate 
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spray dried lactose-leucine system to be created which was aimed to enhance the performance 
of salbutamol sulphate in DPI formulations. 
 
3.2 Materials and Methodology  
§ 3.2.1- 3.2.12  
Refer to Chapter 2 sections 2.2, 2,3, 2.5-2.11, 2.14, and 2.15.  
 
3.3 Results and Discussion  
  
§ 3.3.1 Particle Size Analysis 
Figure 3.1 shows two cumulative particle size distribution (PSD) diagrams that illustrate each of 
the carrier’s PSD when using the (A) dry system and when using the (B) wet system. Because of 
the use of the Mini Spray Dryer B-290, it was expected to obtain particle sizes below the approved 
range of 63–90-μm (Figure 3.1A), given that the spray drying process produces particles below 
10μm.68  
 
Likewise, Figure 3.1B shows that the particle sizes of each of the carriers, when using the wet 
system, fell within the 63– 90 μm range. The known occurrence of agglomeration was exploited 
in such a manner that allowed for it to be used as a carrier within this study. Such focus offered 
the opportunity to investigate the agglomerates on the basis of parameters that are used in the 
characterization and analysis of single particles. The particle size measurement in the dry system 
was able to break the aggregates of spray dried particles (due to applying a pressure of 3 bar 
during the measurement) whereas in the wet system the spray dried particles stayed as 
aggregates, although the ultrasound was applied during the measurement.  
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Figure 3.1 Particle Size Distribution. Particle size distribution (PSD) diagrams of each carrier 
when using the (A) RODOS dry system and when using the (B) CUVETTE wet system; the 
carriers used were spray dried lactose monohydrate containing 0, 0.1, 0.5, 1, 5, and 10% L- 
leucine  
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Table 3.1 highlights each of the carrier’s distinct characteristics such as volume mean diameter 
(VMD) and span of the RODOS dry system and the CUVETTE wet system comparing each 
characteristic side by side. Table 3.1 shows that all of the carriers experienced a significant 
difference in their VMDs when comparing each system to one another. For the dry system, the 
VMD ranged from 8.39 ± 0.40 to 37.97 ± 0.08 μm whereas the range for the wet system was 
79.31 ± 2.19 to 87.95 ± 1.91 μm due to the presence of aggregated particles. The dry system  
experienced a particle diameter range of 1.56 ± 0.05 μm (D10%) to 75.46 ± 7.22 μm (D90%) 
whereas the particle diameter range for the wet system fell between 20.77 ± 11.02 μm (D10%) 
and 147.87 ± 170.11 μm (D90%). Due to the aggregation of particles, samples that were measured 
through the wet system showed smaller span values (narrower distribution) compared to that of 
the dry system, coinciding with the possibility of the dry system containing mixtures of aggregated 
and de-aggregated spray dried particles during the measurement (Table 3.1). 
 
Table 3.1 Particle Analysis. Particle analysis of spray-dried lactose monohydrate and spray-dried 
lactose monohydrate-leucine where the concentration of leucine was 0.1, 0.5, 1, 5, and 10% 
Formulation VMD (μm) Dry 
System 
VMD (μm) 
Wet System 
Span 
Dry System 
Span 
Wet System 
Spray Dried Lactose 37.97 ± 0.08 87.14 ± 0.35 2.12 ± 0.09 1.36 ± 0.01 
0.1% L-Leucine 23.95 ± 5.35 87.47 ± 4.94 3.61 ± 0.11 1.61 ± 0.14 
0.5% L-Leucine 11.50 ± 0.28 79.68 ± 1.78 2.67 ± 0.13 2.14 ± 0.10 
1% L-Leucine 8.39 ± 0.40 86.88 ± 0.84 2.57 ± 0.06 1.73 ± 0.03 
5% L-Leucine 13.58 ± 0.20 79.31 ± 2.19 2.62 ± 0.12 1.74 ± 0.08 
10% L-Leucine 17.47 ± 0.63 87.95 ± 1.91 3.10 ± 0.23 1.40 ± 0.02 
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showing the volume mean diameter (VMD) and span when using the RODOS dry system vs the 
CUVETTE wet system (mean + standard deviation) 
  
Such outcomes, then, allowed for the carriers to be implemented and further studied to determine 
their physicochemical properties and particle morphology given that they underwent spray drying, 
known to alter such characteristics, while also introducing L-leucine as an excipient. VMD 
(obtained via wet method) of the formulation after mixing for 30 min with salbutamol sulphate 
showed that the mixing process was unable to break down the agglomerates as the VMD was 
similar to the VMD of particles before mixing. For example, the VMD of formulations containing 
0.1 and 10% L-Leucine after 30 min of mixing with SS was 88.0 ± 9.62 and 71.97 ± 0.16 μm, 
respectively.  
 
Figure 3.2 highlights the electron micrographs of each of the carriers making it evident that all of 
the formulations, with respect to their carrier, experienced some agglomeration giving way to their 
larger particle size; thereby supporting the results presented in Figure 3.1 and Table 3.1. 
Moreover, the SEM micrographs also indicate each of the carrier’s morphology contains spherical 
particles with some agglomerates, particularly in the cases of 0.5% leucine (some of these 
agglomerated particles for each formulation are shown by red arrows). Such irregularity has 
previously been shown to be more effective in the delivery of salbutamol sulphate when compared 
to particles that are classified as being more spherical and regular in shape.243 The morphology 
of the spray dried lactose, with increasing concentrations of leucine, is supported by data 
published by Aquino et al. where they showed that more irregular and corrugated particles were 
obtained in the presence of high concentrations of leucine.244 Generally, corrugated particles 
disperse better than spherical ones as this kind of particle reduces contact areas and decreases 
inter-particulate cohesion.  
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Figure 3.2 Scanning Electron Microscopy. SEM images of (A) spray dried lactose monohydrate, 
spray dried lactose containing leucine where leucine concentrations were (B) 0.1%, (C) 0.5%, 
(D) 1%, (E) 5%, and (F) 10% L-leucine.  
 
(A) Spray Dried 
Lactose
(B) 0.1% L-Leucine 
(C) 0.5% L-Leucine (D) 1% L-Leucine 
(E) 5% L-Leucine (F) 10% L-Leucine 
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Therefore, it was expected that the formulation composition of the leucine carrier would result 
with an enhanced aerosolization performance when compared to the carrier without leucine, 
which, in essence, would deliver salbutamol sulphate more poorly.  
§ 3.3.2 Solid-state characterization of spray dried samples  
 
Figure 3.3 shows DSC traces of L-leucine, original lactose monohydrate, and spray dried lactose 
containing 0, 0.1, 0.5, 1, 5, and 10% L-leucine indicating where water evaporation, amorphous 
lactose recrystallization (Hc), α- lactose melting (Hα), and β-lactose melting (Hβ) took place. It is 
obvious from the figure that commercial lactose monohydrate shows an endothermic peak around 
149°C, which corresponds to the evaporation of water, followed by an exothermic peak around 
171°C, indicating the amorphous state in the sample; moreover, the endothermic peak around 
220°C corresponds to the melting of α-lactose whereas any peak around 238°C is an indication 
of the presence of β-lactose in the sample.224  
 
Pure L-leucine was also tested to determine whether or not any thermal events arose between 
the 25–300°C range, which would rule out whether such events were due to the presence of L-
leucine or not. No thermal events were seen within the range where lactose thermal events 
occurred and the endothermic peak around 300°C corresponds to the melting of L-leucine or its 
decomposition. Spray dried lactose showed three main thermal events with the first being an 
exothermic peak around 170°C, attributed to the recrystallization of amorphous lactose to both α-
lactose and β-lactose, which was then followed by the melting of α-lactose at around 220°C; 
furthermore, the third endothermic peak around 238°C was an indication of β-lactose in the 
sample. Moreover, spray dried lactose did not show any thermal traces for the water evaporation 
which was a similar pattern that was observed for spray dried lactose containing 0.1, 0.5, and 1% 
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leucine but with different intensities when compared to the spray dried carrier with no leucine. 
Spray dried formulations containing 5 and 10% L-leucine did not show any sharp or obvious peaks 
for water evaporation, the transition of amorphous lactose to crystalline lactose, and melting of 
lactose.  
 
Figure 3.3 Differential Scanning Calorimetry. DSC thermal peaks of L-leucine, commercial lactose 
monohydrate, spray-dried lactose monohydrate-leucine where the concentration of leucine were 
0, 0.1, 0.5, 1, 5, and 10% w/v (where an exothermic peak would point up and an endothermic 
peak would point down). 
 
On the basis of this information, all spray dried carriers were considered to be in their amorphous 
state as the data that was collected indicates given that a definite crystalline structure was not 
Ch
an
ge
 in
 E
nt
ha
lp
y 
Temperature (ºC) 
91 
 
present prior to their analysis which would have been depicted through the emergence of the 
amorphous lactose recrystallization enthalpy. Neither a recrystallization nor a melting peak was 
observed in the 5 and 10% L-leucine carrier which serves as an indicator of their higher stability 
against recrystallization. Such results follow similar patterns that have been presented elsewhere 
where amorphous drug carriers were formulated in such a way as to increase amorphous 
stability.245-248 To make sure spray dried lactose was in the amorphous state, a more reliable 
technique (PXRD) was used. 
 
Figure 3.4 contains the X-ray diffraction peaks for spray dried lactose monohydrate containing 0, 
0.1, 0.5, 1, 5, and 10% L-leucine which provides an insight into the polymorphic state of each of 
the carriers. A carrier’s morphology plays an integral role in the drug delivery process that dictates 
whether a formulation is deemed effective in the delivery of the API of interest.224  
 
Figure 3.4. X-Ray Diffraction. X-Ray diffraction patterns of spray dried lactose monohydrate, 
spray dried lactose monohydrate-leucine where the concentration of leucine was: 0.1%, 0.5%, 
1%, 5% and 10%. 
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Looking at Figure 3.4 more closely, it becomes evident that all of the carriers, from each of the 
formulations, were classified as being in their amorphous state given the absence of peaks (halo 
structure). In addition, all of the carriers showed two distinct peaks each (2θ = 12.2° and 18.6°) 
that were broad and distributed over a wide range of degrees on the 2θ plane, which also 
characterizes them as being of amorphous state. Likewise, given that all of the carriers exhibited 
irregular diffraction of electromagnetic radiation when compared to pure L-leucine (XRD not 
shown), it correspondingly catalogues them as amorphous as well.249 
 
To further assess the solid-state of each carrier within this study and identify any interaction 
between lactose and leucine at the molecular level, FT-IR spectroscopy was implemented with 
the understanding that amorphous lactose displays a distinct frequency at 1260 and at 900 cm-1, 
α-lactose monohydrate at 920 cm-1, and β-lactose at 950 cm-1.224 Figure 3.5 presents the results 
for the FT-IR spectra of L-leucine, spray-dried lactose monohydrate with its different 
concentrations of L-leucine (0, 0.1, 1, 5, and 10%), and further supports the fact that the carriers 
are in their amorphous state as the aforementioned peaks were present. In addition, Figure 3.5 
also reveals that, with the increasing concentration of L-leucine, each formulation underwent a 
phenomenon known as Fermi resonance where a shift in the vibrational energy causes the 
spectra to have a change in its intensity and resolution.250 251 
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Figure 3.5. FT-IR. FT-IR spectra of pure L-leucine, spray dried lactose monohydrate, spray dried 
lactose monohydrate-leucine where the concentration of leucine was: 0.1%, 0.5%, 1%, 5% and 
10% highlighting the areas that are eliminated or broadened as the concentration of L-leucine 
increases while also showing where the amorphous, α-lactose, and β-lactose peaks are to be 
found. 
 
Such variation within the spectra explains why the frequencies that are associated to key 
functional groups like aromatic C-H, alkanes, aldehydes, hydroxyl, carbonyl, ethers, and primary 
amines (which have frequencies at 2900, 3100–3400, 800–1400, and 3500 cm-1) become 
broadened or eliminated completely. 
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§ 3.3.3 In vitro analysis of DPI formulations  
§§ 3.3.3.1Salbutamol sulphate assessment 
 
Performance of the drug delivery profile of salbutamol sulphate, with respect to each of the 
formulations within this overall study, is defined in Figure 3.6 where the amount of salbutamol 
sulphate recovered from each individual section within the MSLI is looked with a narrower focus: 
capsules (C), inhaler (I), mouthpiece (M), induction port (IP), stage 1, stage 2, stage 3, stage 4, 
and filter (stage 5). All of the formulations experienced minimal salbutamol sulphate deposits in 
the capsules with 5 and 10% L-leucine having the least amount after their actuation due to the 
lubrication effect of leucine, which makes particles flow more easily from the capsule to the inhaler 
device (Cyclohaler). The lubrication effect of the spray dried leucine has been reported where 
increasing amounts of L-leucine show good lubricating properties.252 As particles manoeuvre 
through the respiratory tract, spray dried lactose monohydrate along with 0.1% L-leucine 
experienced the highest amounts of salbutamol sulphate (43.63 ± 23.48 and 49.89 ± 27.80μg, 
respectively) in the inhaler device when compared to the concentrations above 0.5% L-leucine 
which experienced the least amount at 13.79 ± 11.47μg; the lubrication effect of leucine can also 
be observed here, as described previously. Furthermore, all of the formulations showed about the 
same amount of salbutamol sulphate in the mouthpiece (Figure 3.6) but begin to differ at the IP 
as spray dried lactose monohydrate had the highest amount (65.24 ± 4.26μg) when compared to 
the other formulations, which had a range of 12.66 ± 5.66 to 29.02 ± 18.56μg. 
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Figure 3.6. Aerosolization Profile. Aerosolization performance of each of the formulations (spray 
dried lactose monohydrate, spray dried lactose monohydrate-leucine where the concentration of 
leucine was:  0.1%, 0.5%, 1%, 5% and 10% highlighting the amount of SS recovered (percent 
recovered). 
 
 
Moreover, 0.1% L-leucine had the highest salbutamol sulphate recovered from within stage 1 
(176.06 ± 50.94μg), but where it began to change was with stage 2 onward as 0.5% L-leucine 
experienced the highest salbutamol sulphate amounts in stage 2, stage 3, stage 4, and filter 
(81.89 ± 50.20, 145.58 ± 88.08, 87.45 ± 48.49, and 29.25 ± 20.16μg, respectively) indicative of it 
96 
 
being the most successful at delivering salbutamol sulphate to the targeted area that correlates 
to the alveoli, found in the lower respiratory tract. In other words, the formulations ranked in the 
following order 0.5% L-leucine > 0.1% L-leucine > 1% L-leucine > spray dried lactose monohydrate 
> 5% L-leucine > 10% L-leucine.  
 
Table 3.2 shows the aerosolization performance and deposition data for all formulations studied. 
All of the formulations differed remarkably (p < 0.05) from one another with respect to DL and 
percentage emission (Table 3.2) given that they all undertook a high number of actuations (n = 
10) per run, with each being filled with a consistent weight of around 33 ± 1 mg. The table shows 
that the performance of DPI formulations containing spray dried leucine is much better than when 
leucine was excluded from the formulation (the lowest drug loss belonged to spray dried lactose 
containing 0.5% L-leucine).  
 
Impaction loss (IL) within the formulations varied from 34.61 ± 12.38%, attributed to 0.5% L-
leucine, to 52.49 ± 2.81%, belonging to spray dried lactose monohydrate. Such variation between 
the formulations could be attributed to their aerodynamic diameter given that impaction is a flow-
dependent mechanism governed by particle size.18 
 
Effective inhalation index (EI) ranged from 10.87 ± 0.22 (spray dried lactose monohydrate) to 
11.98 ± 0.37 (0.5% L-leucine) aligning with other data suggesting that 0.5% L-leucine has a high-
drug aerosolization efficiency.  
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DS and FPD also showed a variation among the formulations with ranges of 29.31 ± 0.36 to 48.94 
± 10.78% and 262.28 ± 156.60 to 110.41 ± 4.77 μg, respectively. Such variation was attributed 
to the formulation’s particle size given that the phenomenon of inertial impaction becomes 
prevalent for large particles.18 
 
When it came to MMAD and GSD, however, all of the formulations gave similar results with MMAD 
being 3.12 ± 0.10 μm and GSD being 2.12 ± 0.03 μm. Because particles greater than or equal to 
10 μm are removed by the mucociliary escalator and subsequently swallowed in the upper 
respiratory tract, it was determined that SS had the ability to enter the respiratory tract without 
facing any problems.20, 21 
 
The results showed that spray dried lactose-leucine (containing 0.5% L-leucine) exhibited the 
highest FPF of 47.11 ± 9.94% suggesting that such formulation was the most efficient at delivering 
the most SS to the lower respiratory tract. This is because of the correlation that is seen between 
FPF and amount of SS delivered; that is to say, when FPF increases, the expected amount of SS 
that is delivered to the lower respiratory tract also increases.253 Such values, when compared to 
those obtained by Kaialy et. al254 (FPF of 44.85 ± 1.76%) and Kaialy and Nokhodchi255 (FPF of 
46.9 ± 3.6%), prove to be an increase in the efficacy of salbutamol sulphate’s aerosolization 
performance. This formulation also had the highest percentage emission of 96.41 ± 1.23%, when 
compared to the other formulations (Table 3.2), suggesting that SS was able to detach itself from 
the carrier easier when compared to the other formulations. This means that optimal 
physicochemical properties were attained such that a complementary system emerged between 
SS and the 0.5% L-leucine carrier. On the other hand, spray dried lactose monohydrate showed 
the lowest percentage emission (87.02 ± 3.79%) and consequently the lowest FPF (25.51 ± 
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1.23%). Such results infer that SS had a more difficult time detaching itself from the spray dried 
lactose monohydrate carrier during inhalation when compared to 0.5% L-leucine. 
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Table 3.2 Aerosolization Parameters. Recovered dose (RD), emitted dose (ED), percent recovery, percent emission, percent impact loss, mass 
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), drug loss (DL), 
dispersibility (DS), and effective inhalation index (EI) of salbutamol sulphate obtained from each of the different formulations (spray dried lactose 
monohydrate, spray dried lactose-leucine where the concentration of leucine was 0.1%, 0.5%, 1%, 5%  and 10% ) 
 
Formulation RD  
(μg) 
ED  
(μg) 
Recovery 
 (%) 
Emission (%) Impact Loss 
(%) 
MMAD 
(μm) 
GSD  
(μm) 
FPD 
(μg) 
FPF  
(%) 
DL  
(%) 
DS  
(%) 
EI 
SD Lactose 434.09 ± 40.27 376.79 ± 19.65 90.25 ± 8.37 87.02 ± 3.79 52.49 ± 2.81 3.13 ± 0.15 2.18 ± 0.07  110.41 ±  4.77 25.51 ±  1.23 14.31 ±  4.12 29.31 ±  0.36 10.87 ±   
0.22 
0.1% L-
Leucine 
455.47 ± 53.13 398.95 ± 29.95 94.69 ± 11.05 87.92 ± 4.89 43.46 ± 10.14 3.19 ± 0.09 2.09 ± 0.03  158.53 ±  39.73 34.99 ±  8.89 13.72 ±  5.34 39.62 ±  8.79 10.93 ±   
0.39 
0.5% L-
Leucine 
542.26 ± 297.51 520.92 ±281.30 112.74 + 61.85 96.41 ± 1.23 34.61 ± 12.38 3.26 ± 0.05  2.09 ± 0.01  262.28 ± 156.60 47.11 ±  9.94 4.14 ± 1.52  48.94 ± 10.78 11.98 ±   
0.37 
1% L-
Leucine 
363.63 ± 49.05 342.77 ± 51.17 75.60 ± 10.20 94.15 ± 1.54 37.60 ± 10.86 3.16 ± 0.13  2.10 ± 0.03  159.45 ±  14.31 44.33 ±  6.53 6.55 ±  1.53 47.12 ±  7.23 11.77 ±  
 0.26 
5% L-
Leucine 
297.32 ±175.08 272.87 ±179.66 61.81 ± 36.40 88.91 ± 7.43 35.95 ± 4.00 3.00 ± 0.18 2.13 ± 0.08 134.81 ±  91.41 43.08 ±  7.38 12.00 ±  8.18 48.26 ±  5.35 11.48 ±  
 0.63 
10% L-
Leucine 
366.52 ±166.33 338.81 ±149.50 76.20 ± 34.58 92.82 ± 2.34 38.74 ± 22.45 2.99 ± 0.23  2.12 ± 0.08 174.83 ± 121.38 44.50 ± 17.40 7.82 ±  2.26 48.27 ± 19.67 11.71 ±  
 0.66 
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§§ 3.3.3.2 Homogeneity assessment 
Assessing the homogeneity of each of the formulations was an essential phase of this study given 
that a uniform formulation will give rise to a more effective drug delivery profile with a consistent 
dose to the patient. Table 3.3 eludes the homogeneity profile of each of the formulations (spray 
dried lactose monohydrate, samples spray dried with 0.1, 0.5, 1, 5, and 10% L-leucine) under 
investigation showing the potency of each and also presents the percent content homogeneity, 
which is expressed as the percent coefficient of variation (%CV), of each of the aforementioned 
formulations. The drug content of all formulations was within 75–125%, and the smallest %CV of 
5.48% belonged to 0.5% L-leucine, which was the formulation that showed the best aerosolization 
performance. Such results indicate that 0.5% L-leucine had the best salbutamol sulphate content 
homogeneity among all of the formulations followed by 0.1% L-leucine with a %CV of 7.15%. In 
addition, the results showed that it is a bit difficult to obtain a very low CV% for DPI formulation 
containing salbutamol sulphate in the DPI formulation studied in the current research. This should 
be investigated more in the future ongoing research.  
Table 3.3. Content Homogeneity. Content homogeneity of Spray Dried Lactose Monohydrate, 
0.1% L-Leucine, 0.5% L-Leucine, 1% L-Leucine, 5% L-Leucine, and 10% L-Leucine expressed as 
the percentage coefficient of variation (%CV). 
Formulation Potency %CV 
Spray Dried Lactose 91.36 ± 9.40 10.29 
0.1% L-Leucine 83.62 ± 5.98 7.15 
0.5% L-Leucine 102.66 ± 5.62 5.48 
1% L-Leucine    94.72 ± 16.97 17.92 
5% L-Leucine    89.71 ± 11.87 13.23 
10% L-Leucine 89.98 ± 7.78 8.65 
*However, has not been taken into account for in vivo inhalation studies.  
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3.4 Conclusion 
 
The results presented in this chapter have proven that the addition of L-leucine into the spray dried 
solutions altered the physicochemical properties of lactose. This alteration allowed for a more 
effective aerosolization performance of salbutamol sulphate to be observed; there was a two-fold 
increase in the fine particle fraction (FPF) of the 0.5% L-leucine formulation. Furthermore, the 
addition of L-leucine also proved to improve the stability of amorphous spray dried lactose, as was 
evident in the DSC data. L-leucine also provided a lubrication effect for the formulations, which 
the in vitro deposition study showed. All these benefits provide a foundational platform from which 
to build on in the chapters that follow. Never the less, this chapter has also proven that a more 
effective formulation can be achieved than the one that is currently in use in the market.  
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Chapter 4 
The Crucial Role of Leucine Concentration on Spray Dried 
Mannitol-Leucine as a Single Carrier to Enhance the 
Aerosolization Performance of Albuterol Sulphate  
 
 
4.1 Introduction 
 
The main aim of this chapter is to explore D-mannitol (mannitol) as an alternative carrier to lactose 
for lactose intolerant patients. To this end, in this chapter, the focus was to engineer a spray dried 
carrier composed of D-mannitol and leucine and investigate the effect of leucine concentration on 
the overall aerosolized DPI performance for albuterol sulphate; DPIs are a common tool for use 
in patients facing COPD and asthma. It has previously been documented that pulmonary delivery 
of a therapeutic dose has tremendous advantages over any other form of administrative route.256 
In recent years, the respiratory tract has been used as a diagnostic tool for patients suffering from 
intermittent allergic asthma or allergic rhinitis through the use of D-mannitol as a means to increase 
the water content in the respiratory tract.257 It has also been postulated that D-mannitol could be 
an alternative carrier in DPI formulations to lactose,258 which is a carrier that is widely used in the 
pharmaceutical industry.14 
 
Efforts to use D-mannitol have shown to have an altering effect on the viscoelastic properties 
associated to the phlegm, which is located in the airway, while also increasing the water content 
by creating an osmotic gradient, which facilitates an efflux of water into the airway lumen.259-265 In 
addition, D-mannitol is not classified as being a reducing sugar, given the absence of the aldehyde 
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functional group, and it is less hygroscopic than lactose. D-Mannitol also provides a sweet 
aftertaste which can be used as a benefit for the patient by confirming that an adequate dose has 
been delivered.266 ,  267 
 
In Chapter 3, it was determined that the addition of L-leucine improved the aerosolization 
performance of the 0.5% L-leucine carrier by altering its physicochemical properties causing an 
increase in the FPF to 47.11 ± 9.94%. In this chapter, an investigation was carried out to see if 
the same concentration will have the same effect on D-mannitol. In addition, this chapter explores 
the modified D-mannitol as an alternative to lactose to be used in dry powder inhalation 
formulations. Moreover, D-mannitol on the market usually shows poor aerosolization performance, 
therefore, the commercial D-mannitol has to be modified to enhance its performance in DPI 
formulations..   
 
4.2 Materials and Methodology  
§ 4.2.1- § 4.2.13 
Refer to Chapter 2 sections 2.2, 2,3, 2.5-2.11, and 2.13-2.16. 
 
4.3 Results and Discussion   
§ 4.3.1 Particle size analysis  
 
Figure 4.1 shows the cumulative size distribution obtained by two distinct systems: Rodos (dry 
system; Figure 4.1A) and Cuvette (wet system; Figure 4.1B). Based on the information from the 
figure, it was deduced that the carriers all underwent a degree of agglomeration. The pressure 
applied to the carriers in the dry system was able to de-agglomerate particles and reduce their 
size range. This explains why there was such a remarkable difference in the size of the particles 
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between the two systems. The difference was expected because the spray drying technique 
produces single particles between 1-10μm.268, 269  
 
The agglomeration, however, was explored further in a manner that helped in the understanding 
of the carrier’s adhesive and cohesive forces. It was these forces that helped in the 
characterization of whether or not a formulation was effective in its aerosolization performance. 
The emergence of agglomerates arising after spray drying is not something new as it has been 
found before (see Chapter 3) where lactose agglomerated into more coarse particles and were 
then implemented into the engineered DPI formulations being investigated.227 
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Figure 4.1. Particle Size Distribution. Particle Size Distribution (PSD) diagrams of each 
formulation’s carriers when using the (A) Rodos dry system and when using the (B) Cuvette wet 
system; Spray Dried Mannitol, 0.06% L-leucine:Mannitol, 0.3% L-leucine:Mannitol, 0.6% L-
leucine:Mannitol, 3% L-leucine:Mannitol, and 6% L-leucine:Mannitol. 
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Table 4.1 elucidates the volume mean diameter (VMD) along with the span of each of the distinct 
carriers comparing the Rodos and Cuvette systems side-by-side. All of the carriers experienced 
a significant difference in their VMDs (p < 0.05) with ranges from 23.98 ± 0.26μm (Spray Dried 
Mannitol) to 52.99 + 4.05μm (6%  L-Leucine)  when the dry system was used; in the case of using 
the wet system, these values increased (Table 4.1). In all the cases, the results showed that the 
VMDs for the spray dried samples were smaller when measured with the dry system than when 
the wet system was used. Furthermore, it was concluded that all of the carriers from each of the 
formulations underwent a degree of agglomeration, which supports the data already presented. 
The values for the dry system are smaller than the wet system because a pressure of 3 bar was 
used during the measurement, which allowed the aggregated particles to de-agglomerate, as 
previously stated. The wet system’s aggregated particle sizes, however, were close to the size of 
carriers used in DPI formulations. Moreover, it was concluded that the performance of the DPI 
system was not compromised due to the size of the particles.  
 
Table 4.1. Particle Analysis. Particle Analysis of Spray Dried Mannitol, 0.06% L-leucine, 0.3% L-
leucine, 0.6% L-leucine, 3% L-leucine, and 6% L-leucine showing the volume mean diameter 
(VMD) and span when using the Rodos dry system or the Cuvette wet system. 
Carrier VMD (μm)        Dry System   
VMD (μm)        
Wet System   
Span               
Dry System  
Span               
Wet System  
Spray Dried Mannitol 23.98 + 0.26 69.55 + 3.85 2.43 + 0.09 1.65 + 3.50 
0.06% L-Leucine 40.50 + 0.73 81.10 + 2.34 1.55 + 0.83 1.08 + 2.77 
0.3% L-Leucine 33.91 + 1.34 87.03 + 2.54 1.97 + 0.63 1.09 + 2.60 
0.6% L-Leucine 27.05 + 0.95 64.74 + 1.69 2.69 + 0.44 1.42 + 2.02 
3% L-Leucine 29.86 + 0.19 72.82 + 0.07 2.25 + 1.95 2.02 + 0.20 
6% L-Leucine 52.99 + 4.05 63.46 + 0.18 1.45 + 0.15 1.63 + 6.71 
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With respect to the Span, all of the carriers experienced similar values (p > 0.05) having ranges 
from 1.45 + 0.15 (belonging to 6% L-Leucine) to 2.69 + 0.44 (belonging to 0.6% L-Leucine) and 
1.08 + 2.77 (from 0.06% L-Leucine) to 2.02 + 0.20 (from 3% L-Leucine); for both the dry and wet 
systems, respectively. Moreover, the dry system experienced a particle diameter range of 5.98 + 
0.76 μm (D10%) to 66.76 + 1.66 μm (D90%) where the particle diameter range for the wet system 
fell between 28.77 + 0.62 μm (D10%) and 124.72+3.62 μm (D90%). 
 
Figure 4.2, nonetheless, presents the electron micrographs of each of the carriers in each 
formulation (0, 0.06, 0.3, 0.6, 3, and 6% L-Leucine; respectively). All of the carriers were 
characterized as spheroidal with confirmation of there being some degree of agglomeration, which 
correlates to the results already presented in Figure 4.1 and Table 4.1. 
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Figure 4.2. Scanning Electron Microscopy. SEM electron micrograms of (A) Spray Dried 
Mannitol, (B) 0.06% L-leucine, (C) 0.3% L-leucine, (D) 0.6% L-leucine, (E) 3% L-leucine, and (F) 
6% L-leucine. 
 
§ 4.3.2 Solid-state characterization of spray dried samples 
(A) SD Mannitol (B) 0.06% L-Leucine 
(C) 0.3% L-Leucine (D) 0.6% L-Leucine 
(E) 3% L-Leucine (F) 6% L-Leucine 
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Figure 4.3 presents the DSC traces of L-leucine, Spray Dried Mannitol, 0.06% L-leucine, 0.3 L-
leucine, 0.6% L-leucine, 3% L-leucine, and 6% L-leucine; the endothermic peak is associated to 
the melting of mannitol. Moreover, Table 4.2 summarizes the enthalpy and melting peak of each 
formulation. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Differential Scanning Calorimetry. DSC thermal peaks of L-Leucine, Spray Dried 
Mannitol, 0.06%  L-leucine, 0.3%  L-leucine, 0.6%  L-leucine, 3%  L-leucine, and 6%  L-leucine, 
where an exothermic peak would point up and an endothermic peak would point down. 
 
Table 4.2 authenticates the results presented in Figure 4.3, where it illustrates an endothermic 
event at 169.79 + 0.45°C which is known to be the melting of mannitol.237, 270	 An important 
observation to highlight, nonetheless, is the broadening of the endothermic peak as the leucine 
concentration increases. The increase in enthalpy can be associated to the ability for leucine to 
provide a stabilization effect for the carriers. This stabilization effect is supported by the fact that 
more energy is needed to melt the mannitol crystals as the concentration of leucine increases. 
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Additionally, pure leucine was tested to determine whether or not any thermal event would take 
place between the 25-300°C  range, and, as can be seen in Figure 4.3, it was well above 300°C. 
Furthermore, Table 4.3 shows the actual amount of leucine presents in each of the carriers via 
HPLC analysis. 
 
In a study conducted by Kaialy et. al, it was found that freeze-dried mannitol containing the three 
polymorphic forms (α-, β-, and Δ-) produced a larger endotherm peak than mannitol with two 
polymorphic forms (α- and β-).271 Conventionally, the melting enthalpy (ΔH) represents the degree 
of crystallinity of a substance. By mixing two substances, the purity is reduced and lower melting 
points appear in the DSC thermographs. Any shift in melting point is indicative of a strong solid-
solid interaction, which explains why the 6% Leucine carrier had the broadest thermal peak.272 273 
 
Table 4.2. DSC Thermal Traces. DSC thermal traces of Spray Dried Mannitol, 0.06%  L-leucine, 
0.3%  L-leucine, 0.6%  L-leucine, 3%  L-leucine, 6%  L-leucine, and L-leucine that indicate the 
enthalpy, in J/g, of mannitol melting (ΔH) along with the Temperature (°C) of where such melting 
took place. 
Carrier Temperature (°C) ∆H (J/g) 
Spray Dried Mannitol 170.01 + 0.16 198.38 + 8.97 
0.06% L-Leucine 170.07 + 0.77 175.52 + 55.68 
0.3%  L-Leucine 170.45 + 0.11 213.10 + 6.17 
0.6%  L-Leucine 169.49 + 0.06 182.87 + 19.44 
3%  L-Leucine 169.32 + 0.33 201.98 + 16.61 
6%  L-Leucine 169.41 + 0.15 213.79 + 3.21 
 L-Leucine — — 
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Table 4.3. L-Leucine Content. Actual amount of L-leucine found in each of the carriers (Spray 
Dried Mannitol, 0.06%  L-leucine, 0.3%  L-leucine, 0.6%  L-leucine, 3%  L-leucine, 6%  L-leucine). 
Formulation % L-Leucine 
Spray Dried Mannitol 0.00 ± 0.00  
0.06% L-Leucine 0.02 ± 0.02  
0.3% L-Leucine 0.82 ± 1.84  
0.6% L-Leucine 2.86 ± 1.22  
3% L-Leucine 7.24 ± 2.01  
6% L-Leucine 12.93 ± 1.19  
 
Figure 4.4 demonstrates the powder X-ray diffraction (PXRD) patterns obtained from each of the 
formulation’s carriers highlighting the presence and location of the distinctive polymorphic 
characterization. It is understood that mannitol possesses three distinctive polymorphs (α-, β-, 
and Δ-) that are characterized by where they present themselves on the diffraction patterns; with 
α-mannitol exhibiting peaks at 9.57° and 13.79°, β-mannitol at 10.56° and at 14.71°, and Δ-
mannitol with a peak at 9.74° and 22.2°.271, 274-276  
 
PXRD of commercial mannitol showed the main diagnostic peaks for β-mannitol at 10.56°, 14.71°, 
23.40°, 29.50° and 38.80°. This indicates that the commercial mannitol contains only β form of 
mannitol. Spray Dried Mannitol showed extra peaks at 2θ of 13.79° and around 17° which is an 
indication of α-mannitol; this shows that the spray dried mannitol contains both α- and β- mannitol. 
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It is obvious from PXRD of spray dried mannitol containing various concentrations of L-Leucine 
that these samples contained both α- and β-mannitol. Although all spray died samples showed 
the presence of α- and β-mannitol, the intensities of diagnostic peaks are not the same, which 
could be an indication of different ratios of these two polymorphic forms in the sample. The lack 
of any diagnostic peak at 9.74° and 22.2 indicates there is no Δ-mannitol in the samples. Table 
4.4 summarizes all the polymorphic forms of mannitol associated with each carrier. In conclusion, 
XRD results showed that all formulations are in a crystalline state regardless of the type of 
polymorphic form they contain.  
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.4. X-Ray Diffraction. Powder X-Ray diffraction patterns of Leucine, Spray Dried 
Mannitol (SDM), SDM- 0.06% L-leucine, SDM-0.3% L-leucine, SDM-0.6% L-leucine, SDM-3% L-
leucine, and SDM-6% L-leucine.  
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Table 4.4. Mannitol Polymorphs. Characterization of mannitol polymorphs found within each 
formulation’s carriers.  
Carrier α-mannitol β-mannitol Δ-mannitol 
Commercial Mannitol  — ✓ — 
Spray Dried Mannitol ✓ ✓ — 
0.06% L-Leucine ✓ ✓ — 
0.3% L-Leucine ✓ ✓ — 
0.6% L-Leucine ✓ ✓ — 
3% L-Leucine ✓ ✓ — 
6% L-Leucine ✓ ✓ — 
 
 
Solid-state characterization was further assessed with the implementation of FT-IR (Figure 4.5). 
It was understood that α-mannitol exhibits a peak at 1195cm-1, β-mannitol at 929cm-1, 959cm-1, 
and 1209cm-1, and Δ-mannitol at 967cm-1.258 Looking at Figure 4.5, it is clear that the commercial 
mannitol showed the main peaks for β-mannitol. Spray Dried Mannitol exhibited the peaks 
associated to the β-polymorph (α-mannitol was not detectable due to a very low concentration, it 
was more clear in the XRD figure) whereas all other spray dried samples containing leucine 
showed peaks associated to the α-mannitol and β-mannitol polymorphs. 
 
The apparent broadening and widening in the peaks within 2500-3700cm-1
 
is due to the presence 
of L-leucine in the samples. L-Leucine, being a branched-chain amino acid (BCAA), belongs to a 
group of proteins that are known for having an aliphatic side-chain and that are non-polar; the 
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aliphatic side-chain explains the results obtained in the spectra. In essence, the presence of L-
leucine allowed for there to be an increase in the vibrational stretching that is observed by the 
hydroxyl group.277 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. FT-IR. FT-IR spectra of commercial mannitol, Spray Dried Mannitol, spray dried 
mannitol containing 0.06% L-leucine, 0.3% L-leucine, 0.6% L-leucine, 3% L-leucine, 6% L-leucine, 
and L-leucine where ⇡ represents α-mannitol, ↑ represents β-mannitol, and ⇞ represents Δ-
mannitol.  
Commercial Mannitol 
SD Mannitol 
0.06% L-Leucine 
0.3% L-Leucine 
0.6% L-Leucine 
3% L-Leucine 
6% L-Leucine 
L-Leucine 
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§ 4.3.3 In vitro analysis of DPI formulations  
§§ Albuterol sulphate assessment 
 
Aerosolization performance of all of the formulations is summarized in Figure 4.6 where the 
amount of Albuterol sulphate deposited in each of the stages of the deposition is shown [capsules 
(C), inhaler (I), mouthpiece (M), induction port (IP), Stage 1, Stage 2, Stage 3, Stage 4, and Stage 
5]. All of the formulations experienced minimal Albuterol sulphate deposits (p > 0.05) in the 
capsules with 3% L-leucine having the highest amount (6.62 + 4.59μg) and 0.06% L-leucine having 
the lowest amount (2.98 + 0.42 μg). As particles maneuvered through the simulated respiratory 
tract (MSLI), 3% L-leucine experienced the highest amount of Albuterol sulphate (51.35 + 
49.66μg) in the inhaler when compared to 6% L-leucine, which experienced the least amount at 
13.26+6.34μg. Furthermore, all of the formulations showed similar amounts of Albuterol sulphate 
in the mouthpiece and induction port (see Figure 4.6), but began to differ at Stage 1 where 
aerodynamic particle size becomes more significant.  
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Figure 4.6. Aerosolization Profile. Aerosolization performance of each formulation (Spray Dried 
Mannitol, spray dried mannitol containing 0.06% L-leucine, 0.3% L-leucine, 0.6% L-leucine, 3% L-
leucine, and 6% L-leucine) highlighting the amount of Albuterol sulphate (AS) recovered (percent 
recovered).  
 
Moreover, Spray Dried Mannitol had the highest Albuterol sulphate recovered from within Stage 
1 (170.70 + 37.06μg), but 0.06% L-leucine and 0.3% L-leucine were not far behind with 157.75 + 
9.04μg and 148.30 + 32.12μg, respectively. This shows that as the concentration of L-leucine 
increases the amount of Albuterol sulphate deposits in Stage 1 decreases. This could be due to 
the lubrication effect that is seen when L-leucine is added as an excipient (Chapter 3). The results 
showed that 6% L-leucine experienced the highest Albuterol sulphate amounts from within Stage 
3, and Stage 4 (118.74 + 44.84μg, and 67.40 + 15.75μg; respectively) indicative of it being the 
most successful at delivering Albuterol sulphate to the lower part of the lungs. In other words, the 
formulations, with respect to MMAD, ranked in the following order: 6% L-leucine = 0.06% L-leucine 
> Spray Dried Mannitol > 0.6% L-leucine > 0.3% L-leucine > 3% L-leucine. 
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Likewise, looking at the RD, ED, and percentage recovery of each formulation, which is presented 
in Table 4.5, it was concluded that all of the formulations, with the exception of Spray Dried 
Mannitol, experienced similar values (p < 0.05). Such results are indicative of L-leucine’s powder 
dispersion effect,244, 278, 279 its ability to act as a lubricant (see Chapter 3), and its ability to aid in 
storage and stability280 as Spray Dried Mannitol showed significantly different results and 
contained no L-leucine. 
  
Additionally, all of the formulations differed remarkably from one another (p < 0.05) with respect 
to drug loss (DL), see Table 4.5, given that they all undertook a high number of actuations (n= 
10) per run with each being filled with a consistent weight of 33.13 + 0.46 mg. Nevertheless, 6%  
L-leucine experienced the least amount of drug loss with 9.64 + 1.01% indicative of optimized 
properties allowing for the best attachment and detachment of Albuterol sulphate when compared 
to all other formulations.  
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Table 4.5. Aerosolization Parameters. Recovered Dose (RD), Emitted Dose (ED), Percent Recovery, Percent Emission, Percent 
Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Dose (FPD), Fine 
Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) of Albuterol sulphate obtained from 
each of the different formulations (Spray Dried Mannitol, 0.06% L-leucine, 0.3% L-leucine, 0.6% L-leucine, 3% L-leucine, and 6% L-
leucine)  
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact Loss 
(%) 
MMAD 
(μm) 
GSD 
(μm) FPD FPF (%) DL (%) DS (%) EI 
Spray Dried Mannitol 431 + 143.68 
394.56 + 
147.19 
89.74 + 
29.87 
90.34 + 
5.20 
45.59 +  
6.29 
 
3.06 +  
0.10 
 
2.10 + 
0.08 
168.20 + 
85.39 
37.06 + 
8.66 
10.54 + 
5.35 
40.75 + 
7.55 
11.28 + 
0.62 
0.06% L-Leucine 376.84 + 41.04 
338.39 + 
41.00 
78.034 + 
8.53 
89.72 + 
1.16 
45.34 +  
2.08 
3.20 +  
0.05 
2.01 + 
0.03 142.08 + 24.68 
37.54 + 
2.46 
11.08 + 
1.25 
41.83 + 
2.19 
11.28 + 
0.16 
0.3% L-Leucine 356.54 + 7.83 
320.93 + 
15.09 
74.13 +  
1.63 
89.98 + 
2.43 
45.84 +  
9.97 
2.92 + 
 0.07 
2.09 + 
0.01 138.80 + 32.62 
38.86 + 
8.54 
11.29 + 
2.76 
43.19 + 
9.34 
11.35 + 
0.40 
0.6% L-Leucine 394.58 + 61.56 
355.06 + 
58.83 
82.03 + 
12.80 
89.88 + 
1.58 33.68 + 9.98 
3.01 + 
 0.11 
2.07 + 
0.06 194.60 + 61.90 
48.45 + 
9.44 
11.30 + 
1.67 
53.80 + 
9.69 
11.76 + 
0.47 
3% L-Leucine 386.66 + 97.37 
327.19 + 
109.64 
80.39 + 
20.24 
84.25 + 
13.76 30.01 + 4.96 
2.91 + 
 0.17 
2.11 + 
0.06 182.85 + 73.96 
47.19 + 
13.76 
17.42 + 
13.92 
55.15 + 
8.13 
11.42 + 
1.24 
6% L-Leucine 376.34 + 73.37 
354.95 + 
68.08 
78.24 + 
15.25 
94.35 + 
0.64 
28.74 + 
 9.13 
3.20 +  
0.21 
2.05 + 
0.05 201.78 + 58.77 
52.96 + 
5.21 9.64 + 1.01 
56.14 + 
5.61 
12.14 + 
0.21 
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It is interesting to note that when the concentration of L-leucine increased from 0 to 0.3% no 
significant changes were observed in impaction loss (IL), whereas beyond 0.3% a significant 
reduction was observed for the IL value so that samples containing 6% L-leucine showed the least 
IL (28.74 + 9.13%). Such variation between the formulations could be attributed to their 
aerodynamic diameter given that impaction is a flow-dependent mechanism governed by particle 
size.18 In addition, 6% L-leucine showed the smallest VMD of its coarse particulate matter (VMD 
of 63.46 + 0.18μm; results from Table 4.1) when compared to the other formulations; all of which 
had higher VMDs for their agglomerated coarse particles (see Table 4.1 and Figure 4.2).  
 
Effective inhalation index (EI) ranged from 11.28 + 0.16 (0.06% L-leucine) to 12.14 + 0.21 (6% L-
leucine) showing a linear relationship with FPF (r2
 
= 0.81), data not shown. This indicates that 
the presence of L-leucine is necessary to enhance the EI value.  
 
DS (dispersibility) and FPD also confirmed that samples with a higher concentration of L-leucine 
showed better dispersibility and high fine particle dose where both are an indication of a good 
aerosolization performance of Albuterol sulphate. There was a linear relationship (r2
 
= 0.89) 
between the carriers of the wet system’s VMDs and that of FPD (data not shown) which brings in 
the notion of inertial impaction and its prevalence, as previously discussed; such relationship also 
builds upon the variations observed between the formulations.  
 
When it came to MMAD and GSD, however, all of the formulations gave similar results with MMAD 
and GSD (p > 0.05). In addition, a linear correlation (r2= 0.69) between the L-leucine concentration 
and FPF was established (data not shown) suggesting that L-leucine played a significant role (p 
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< 0.05) in decreasing the particle’s density and size,279 while providing an anti-hygroscopic 
effect,280 as it has been shown for L-leucine to precipitate on the surface of drying droplets when 
spray drying.30, 278, 279, 281, 282  These precipitated L-leucine patches were accounted for when 
engineering the carriers as the end product shows; knowing this aids in the developmental 
process for physicochemical property selection and with the invention/creation of methodological 
processes.  
 
Furthermore, 6% L-leucine witnessed the highest FPF of 52.96 + 5.21% indicative of it being the 
most efficient at delivering the highest amount of Albuterol sulphate to the lower respiratory tract. 
In addition, this formulation also showed the best drug-carrier cohesive-adhesive balance ratio as 
this ratio is directly related to the FPF of any given API.283  Such results also support those of 
Labiris and Dolovich which experienced a similar outcome.284 Moreover, this formulation also had 
the highest percentage emission of 94.35 + 0.64%, when compared to the other formulations (see 
Table 4.5) inferring that it released the most Albuterol sulphate into the simulated system 
providing sufficient evidence to classify it as the best formulation.  
 
All in all, optimal properties were attained such that a complementary system emerged between 
Albuterol sulphate and the 6% L-leucine carrier and one that was effective when implemented. 
Arriving to this conclusion was done through numerous factors and checkpoints (i.e 
physicochemical properties, particle size, particle density, etc.) along the way that catalyzed a 
cascade of favorable conditions for the 6% L-leucine carrier-to-Albuterol sulphate system. On the 
other hand, Spray Dried Mannitol showed the lowest FPF (37.06 + 8.66%) inferring that Albuterol 
sulphate had a more difficult time detaching itself from the Spray Dried Mannitol carrier during the 
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inhalation process when compared to 6% L-leucine, which performed with the highest efficacy 
profile for aerosolization purposes.  
 
§§ 4.3.3.2 Homogeneity assessment 
 
Assessing the homogeneity of each formulation was an essential phase of this overall study 
given that a uniform formulation will give rise to a more effective drug delivery profile with a 
consistent dose to the patient; it also adheres to USP guidelines. Figure 4.7 eludes the 
homogeneity profile of each of the formulations (0, 0.06, 0.3, 0.6, 3, and 6% L-leucine) under 
investigation showing the potency of each while Table 4.6 presents the percentage content 
homogeneity, which is expressed as the percentage coefficient of variation (%CV), of each of 
the aforementioned formulations.  
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Figure 4.7. Potency. Percent potency of each formulation (Spray Dried Mannitol, spray dried 
mannitol containing 0.06% L-leucine, 0.3% L-leucine, 0.6% L-leucine, 3% L-leucine, and 6% L-
leucine) with respect to Albuterol sulphate.  
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Table 4.6. Content Homogeneity. Content homogeneity of Spray Dried Mannitol, 0.06% L-leucine, 
0.3% L-leucine, 0.6% L-leucine, 3% L-leucine, and 6% L-leucine expressed as the percent 
coefficient of variation (%CV)  
Formulation Assay % % CV 
Spray Dried Mannitol 91.95 ± 19.22  20.90 
0.06% L-Leucine 122.37 ± 4.75  3.88 
0.3% L-Leucine 105.18 ± 14.81  14.08 
0.6% L-Leucine 112.02 ± 13.38  11.94 
3% L-Leucine 110.07 ± 13.11  11.90 
6% L-Leucine 110.96 ± 14.84  13.38 
*However, has not been taken into account for in vivo inhalation studies.  
 
All of the formulations varied considerably from one another with regard to potency with a range 
of 122.37 + 4.75% (sample containing 0.06% L-leucine) to 91.95 + 19.22% (Spray Dried Mannitol 
without L-leucine). Regarding %CV, the smallest %CV of 3.88% belonged to 0.06% L-leucine 
and the highest %CV of 20.90 belonged to Spray Dried Mannitol without L-leucine (see Table 
4.6). Such results indicate that 0.06% L-leucine had the best Albuterol sulphate content 
homogeneity amongst all of the formulations. Table 4.6 also showed that the presence of L-
leucine improved the homogeneity of the samples compared to the sample without L-leucine. 
The table also shows that all formulations adhered to the acceptable range of 75-125% set by 
the USP and its European counterpart.  
 
4.4 Conclusion 
 
The results presented in this chapter have proven that mannitol solutions containing different 
concentrations of L-leucine were successfully spray dried.  In addition, it was also shown that the 
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presence of L-leucine changed the properties of the resultant spray dried particles. This modified 
mannitol showed an improvement in the aerosolization performance of Albuterol sulphate (FPF =  
52.96 + 5.21%), which was measured through the FPF. The results also confirmed that mannitol 
can serve as a suitable alternative carrier over lactose in DPI formulations and could be suitable 
for lactose intolerant patients suffering from asthma or COPD. In the future, it would be beneficial 
to explore the use of both spray dried lactose and mannitol, together, to determine their effect 
when used in DPI formulations. 
 
 
 
 
 
 
 
 
 
125 
 
Chapter 5 
 
Effect Different Mixtures of the Spray Dried Mannitol and 
Lactose with Leucine have on Dry Powder Inhaler 
Performance of Salbutamol Sulphate (Albuterol)  
 
5.1 Introduction 
 
In this chapter, the focus was to engineer a spray dried carrier composed of mannitol, lactose,  
and 5% L-leucine (w/w) and investigate the effect that different mannitol:lactose ratios have on the 
overall aerosolized dry powder inhaler (DPI) performance for salbutamol sulphate. β2-Andrenergic 
receptor agonists, like that of to salbutamol sulphate, acts on the β2-andrenergic receptor 
facilitating smooth muscle relaxation and dilation of bronchial passages.285 This enables patients 
suffering from asthma, a chronic inflammatory disease characterized by the obstruction of airflow 
due to bronchial airway constriction in response to a stimulus,286 the ability to breathe. Such 
process, however, is achieved via delivery of a successful therapeutic dosage of salbutamol 
sulphate to be deposited more peripherally; that is to say, in the middle and small airway.287, 288 
Therefore, aerosolization performance becomes a significant factor in the development and 
implementation of any given dry powder inhaler (DPI) formulation given that inter-particulate 
forces are directly influenced by particle density, morphology, surface roughness, particle-size 
distribution, presence of fine particle excipients, surface energy, carrier flow, and carrier 
material.289,  290 
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In Chapter 4, it was determined that the aerosolization performance of albuterol sulphate 
containing spray dried 6% L-leucine with mannitol was affected in such a way that the FPF was 
increased to 52.96% from 47.11% (Chapter 3). This increase suggested that mannitol can serve 
as an alternative carrier to lactose. In this investigation, the goal is to determine whether a spray 
dried formulation containing binary mixtures of mannitol:lactose with different ratios (with 5% L-
leucine; w/w) can improve the aerosolization performance further or not. 
 
5.2 Materials and Methodology  
§ 5.2.1- § 5.2.13 
Refer to Chapter 2 sections 2.2, 2,3, 2.5-2.11, and 2.14-2.16. 
 
5.3 Results and Discussion  
 § 5.3.1 Particle Size Analysis and Morphology  
 
Particle interactions are of great importance in DPI formulations where the dispersion of the active 
pharmaceutical ingredient particles from carrier particles is critical for lung deposition.220 It holds 
true that particles with a diameter between 5-10 μm deposit primarily in the extrathoracic airways 
and particles between 1-5 μm mostly deposit in the tracheo-bronchiol region; particles with a 
diameter below 1 μm deposit in the alveolar region.291, 292  
 
Nonetheless, particle analysis was carried out for each of the carriers within this study to 
determine whether their volume mean diameter (VMD) fell within the pre-requisite range of 63-90 
μm.222, 293 Figure 5.1 presents the particle size distribution (PSD) diagrams of the carriers 
illustrating their particle size and their cumulative distribution when using the (A) Rodos  dry 
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system (Figure 5.1A) and (B) Cuvette wet system (Figure 5.1B). As is clear by Figure 5.1B, the 
carrier’s VMDs are greater than those in Figure 5.1A due to particle agglomeration. Small particles 
carry a greater net charge-to-surface ratio (net-CSR) than larger particles as particle charge is 
inversely related to particle mean diameter.128, 294, 295 
 
Furthermore, the aggregated particles comply with pharmacopoeia guidelines as they all fall 
between 63-90 μm; Table 5.1 provides the true numerical VMD values along with the span for 
each of the carriers for both the dry and wet systems. When the carriers were subjected to the 
Rodos system, their VMDs ranged from 13.58 + 0.20 μm (Lactose) to 37.52 + 0.52μm (3:1 
[Mannitol:Lactose]), however, with the Cuvette system, this range became 69.59 + 0.99μm (1:3 
[Mannitol:Lactose]) to 86.38 + 1.62μm (3:1 [Mannitol:Lactose]). The span for the carriers was 
determined to be 1.62 + 0.05 (3:1 [Mannitol:Lactose]) to 2.62 + 0.12 (Lactose) and 1.15 + 0.02 
(1:1 [Mannitol:Lactose]) to 2.03 + 0.02 (1:3 [Mannitol:Lactose]) for the dry and wet systems, 
respectively. The dry system experienced a particle diameter range of  6.48 + 2.22 μm (D10%) to 
64.94 + 9.70 μm (D90%) whereas the wet system showed a range of 52.88 + 6.36 μm (D10%) to 
142.66 + 19.14 μm (D90%). 
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Figure 5.1. Particle Size Distribution. Particle Size Distribution (PSD) diagrams of carriers (Spray 
Dried Mannitol, Spray Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose]) when using the (A) Rodos dry system and when using the (B) Cuvette wet 
system. 
(A) 
(B) 
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Table 5.1. Particle Analysis. Particle size Analysis of Spray Dried Mannitol, Spray Dried Lactose, 
mixtures of mannitol:lactose (1:1, 1:3, and 3:1) showing the volume mean diameter (VMD) and 
span when using the Rodos dry system or the Cuvette wet system. 
Carrier VMD (μm)          Dry System   
VMD (μm)          
Wet System   
Span                    
Dry System  
Span                    
Wet System  
Spray Dried Mannitol 29.86 + 0.19 72.82 + 0.07 2.25 + 1.95 2.02 + 0.20 
Spray Dried Lactose 13.58 + 0.20 79.31 + 2.19 2.62 + 0.12 1.74 + 0.08 
1:1  [Mannitol:Lactose] 37.51 + 0.48 79.95 + 1.16 1.75 + 0.04 1.15 + 0.02 
1:3  [Mannitol:Lactose] 35.06 + 6.21 69.59 + 0.99 2.28 + 0.19 2.03 + 0.02 
3:1  [Mannitol:Lactose] 37.52 + 0.52 86.38 + 1.62 1.62 + 0.05 1.36 + 0.01 
 
 
 
Figure 5.2 presents the electron micrograms of all the carriers (SD Mannitol, SD Lactose,  different 
ratios of Mannitol:Lactose (1:1,1:3 and 3:1). Both the SD Mannitol and SD Lactose carriers were 
characterized as resembling the structure of a tomahawk while the other ratios of 
Mannitol:Lactose] (1:1, 1:3 and 3:1) were characterized as spherical. Based on the electron 
micrograms, nonetheless, it was deduced that some degree of agglomeration took place which 
coincides with the data presented in Figure 5.1 and Table 5.1. 
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Figure 5.2. Scanning Electron Microscopy. SEM electron micrograms of (A) Spray Dried 
Mannitol, (B) Spray Dried Lactose, (C) SD 1:1 [Mannitol:Lactose], (D) SD 1:3 [Mannitol:Lactose], 
and (E) SD 3:1 [Mannitol:Lactose] all with 5% L-leucine (w/w). 
 
(A) Spray Dried  Mannitol (B) Spray Dried  Lactose 
(C) 1:1 [Mannitol:Lactose] (D) 1:3 [Mannitol:Lactose] 
(E) 3:1 [Mannitol:Lactose] 
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§ 5.3.2 Solid-state characterization of spray dried samples 
 
Figure 5.3 presents the thermal traces associated to each of the carriers while highlighting the 
endotherm or exotherm found within each sample. To rule out the possibility of L-leucine having 
any thermal events within the 25-300°C range, a pure sample of L-leucine was analyzed; as can 
be seen from Figure 5.3, L-leucine had no thermal event within the aforementioned range. 
 
 
 
 
 
 
 
 
 
Figure 5.3. Differential Scanning Calorimetry. DSC thermal peaks of Spray Dried Mannitol, Spray 
Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose], where 
an exothermic peak points up and an endothermic peak points down. 
 
Spray Dried Mannitol with 5% L-leucine (w/w) presented an endothermic peak at 169.79 + 0.35 
°C, known to be attributed to the melting of mannitol,224, 270  with a resulting enthalpy of 208.66 + 
6.87J/g (Table 5.2). Spray Dried Lactose with 5% L-leucine (w/w), however, showed four 
endothermic peaks (138.88 + 1.06, 160.16 + 0.13,  208.48 + 0.30, and 227.45 + 1.82°C) and one 
exothermic peak (171.13+ 0.23°C). The first and second endothermic peaks (138.88 + 1.06°C 
and 160.16 + 0.13°C), which are associated to the evaporation of water,297 resulted with an 
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enthalpy of 84.15 + 9.29 and 33.04 + 10.72 J/g (Table 5.2) whereas the third endothermic peak 
(208.48 + 0.30°C), associated to the melting of α-lactose,297 gave an enthalpy of 53.96 + 5.98 J/g 
(Table 5.2). The last endothermic peak at 227.45 + 1.82°C associated to the melting of β-
lactose,297 resulted with an enthalpy of 29.87 + 4.65J/g (Table 5.2). The exothermic peak at 
171.13+ 0.23°C is due to the crystallization of  amorphous lactose297 which had an enthalpy of -
16.35 + 2.09J/g (Table 5.2). 
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Table 5.2. DSC Thermal Traces. DSC thermal traces of Spray Dried Mannitol, Spray Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 
[Mannitol:Lactose], and 3:1 [Mannitol:Lactose] (all with 5% L-leucine [w/w]) that indicate the enthalpy (ΔH), in J/g, of each thermal 
event along with the Temperature (°C) of where such thermal event took place. 
 
   Water Evaporation Mannitol Melting 
Amorphous 
Lactose α-lactose melting β-lactose melting 
Formulation 
Temper
ature 
(°C) 
∆H (J/g) 
Tempe
rature 
(°C) 
∆H 
(J/g) 
Temperat
ure (°C) 
∆H 
(J/g) 
Temper
ature 
(°C) 
∆H 
(J/g) 
Temperatu
re (°C) 
∆H 
(J/g) 
Temper
ature 
(°C) 
∆H (J/g) 
Spray Dried 
Mannitol — — — — 
168.79 + 
 0.35 
208.66+ 
6.87 — — — — — — 
Spray Dried 
Lactose 
138.88 + 
1.06 
84.15 +  
9.29 
160.07 +  
0.13 
33.04 + 
10.72 — — 
171.13 +  
0.23 
-16.3+ 
2.09 
208.48 +  
0.30 
53.9+ 
5.98 
227.45 + 
 1.82 29.87 + 4.65 
1:1 129.77 + 0.00 
49.07 +  
11.40 — — 
158.19 + 
 0.05 
166.39+ 
19.04 — — — — — — 
1:3 127.22 + 2.98 
36.88 +  
3.03 — — 
156.11 +  
0.16 
91.36 + 
9.80 — — 
201.34 + 
 0.08 
33.71 + 
23.48 
219.55 + 
 5.09 9.54 + 5.12 
3:1 126.33 + 0.25 
21.54 +  
0.53 — — 
163.94 +  
0.01 
178.22+ 
25.63 
138.46 + 
 0.05 
3.00 + 
0.12 — — — — 
L-Leucine — — — — — — — — — — — — 
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Furthermore, when looking at the carriers containing mixtures of Mannitol:Lactose with 5% L-
leucine (w/w) and their respective thermal events, it appears that they all experienced temperature 
shifts from those observed from the Spray Dried Mannitol and Spray Dried Lactose  both with 5% 
L-leucine (w/w) (see Figure 5.3 and Table 5.2). This shift is associated to the introduction of L-
leucine in the samples prior to undergoing spray drying. 
 
Nevertheless, the 1:1 [Mannitol:Lactose] carrier exhibited two endothermic peaks at 129.77 + 
0.00 and 158.19 + 0.05 °C) corresponding to the evaporation of water and the melting of mannitol 
with enthalpies of 49.07 + 11.40 J/g and 166.39 + 19.04 J/g, respectively. The 1:3 
[Mannitol:Lactose] carrier, however, experienced four endothermic peaks (127.22 + 2.98, 156.11 
+ 0.16, 201.34 + 0.08, and 219.55 + 5.09°C) where the enthalpies for the endothermic peaks 
were 36.88 + 3.03, 91.36 + 9.80, 33.71 + 23.48, and 9.54 + 5.12J/g (respectively) [see Table 5.2]. 
These thermal events indicate the occurrence of water evaporation (127.22 + 2.98°C), 
amorphous lactose recrystallization (175.23 + 7.87°C), the melting of mannitol (156.11 + 0.16°C), 
α-lactose melting (201.34 + 0.08°C), and β-lactose melting (219.55 + 5.09°C); see Figure 5.3 and 
Table 5.2. 
 
Moreover, the 3:1 [Mannitol:Lactose] carrier resulted in having three endothermic peaks (126.33 
+ 0.25, 138.46 + 0.05, and 163.94 + 0.01°C) where the enthalpy for the evaporation of water 
(126.33 + 0.25°C) was 21.54 + 0.53J/g, amorphous lactose recrystallization (138.46 + 0.05°C) 
was 3.00 + 0.12J/g, and the enthalpy for the melting of mannitol (163.94 + 0.01°C) was 178.22 + 
25.63J/g. Interestingly, the 1:1 [Mannitol:Lactose] and 3:1 [Mannitol:Lactose] carriers failed to 
show any traces of α-lactose or β-lactose melting suggesting their absence in the sample. 
Moreover the 3:1 [Mannitol:Lactose] carrier showed signs of its amorphicity through the presence 
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of the amorphous lactose recrystallization enthalpy, which was absent in the 1:1 
[Mannitol:Lactose] carrier. 
 
Figure 5.4 shows the powder X-Ray diffraction (PXRD) peaks associated to each carrier, aiding 
in the characterization of the carrier’s polymorphic form. Powder X-Ray Diffraction (XRPD) can 
identify if the sample is crystalline or amorphous. 
 
Mannitol’s polymorphic forms ( α-, β-, and Δ-) are known to exhibit distinguishable diffraction 
peaks with α-mannitol having such peaks at 9.57° and 13.79°, β-mannitol at 10.56° and 14.71°, 
and Δ-mannitol at 9.74° (see Chapter 3).296 With the results presented in the Figure, it was 
determined that spray dried mannitol, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose] were composed of the  α-  and β-polymorph as indicated in the Figure. Spray 
Dried Lactose, on the other hand, differed remarkably from all the other carriers due to its 
amorphous nature; the broadened and shallow peaks at 12.5° and 18.3° have been reported 
elsewhere as being attributed to lactose’s amorphicity (see Chapter 3). Moreover, such results 
support those presented in Figure 5.3 via a more reliable and accepted technique of solid-state 
characterization of newly developed formulations. 
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  α-mannitol 
 
β-mannitol 
 
Figure 5.4. X-Ray Diffraction. Powder X-Ray diffraction patterns of Spray Dried Mannitol, Spray 
Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]. 
 
 
Figure 5.5 presents the infrared spectrum of all the carriers, and that of L-leucine, indicating the 
solid-state characterization of each carrier within this overall study. It has been documented 
elsewhere that lactose possesses four peaks within the spectra that elucidates its polymorphic 
form; amorphous lactose presenting peaks at 1260cm-1 and 900cm-1, α-lactose at 920cm-1, and 
β-lactose at 950cm-1. Mannitol, on the other hand, is distinguishable via five peaks: α-mannitol at 
1195cm-1, β-mannitol at 929cm-1, 959cm-1, and 1209cm-1, and  -mannitol at 967cm-1.296 
SD Mannitol 
SD Lactose 
1:1 
[Mannitol:Lactose] 
1:3 
[Mannitol:Lactose] 
3:1 
[Mannitol:Lactose] 
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By looking at Figure 5.5, Spray Dried Mannitol is composed of the α- and β-polymorph, Spray 
Dried Lactose with amorphous content,  α-lactose and β-lactose, 1:1 [Mannitol:Lactose] with  α- 
and β-mannitol, 1:3 [Mannitol:Lactose] with amorphous lactose,  α-lactose, β-lactose,  α-mannitol, 
and β-mannitol, and 3:1 [Mannitol:Lactose] with amorphous lactose,  α-mannitol, and β-mannitol. 
Furthermore, these results, and those presented in Figure 5.3, complement one another and 
were, therefore, used in the solid-state characterization of the carriers. 
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Figure 5.5. FT-IR. FT-IR spectra of Spray Dried Mannitol, Spray Dried Lactose, 1:1 
[Mannitol:Lactose], 1:3 [Mannitol:Lactose], 3:1 [Mannitol:Lactose], and  L-leucine where ⇡ 
represents α-mannitol, ↑ represents β-mannitol, and ⇞ represents Δ-mannitol. 
 
 
 
1400 800 Wavenumber 
⍺-man  Β-man  
⍺-lac  Β-lac  
Amorphous 
%
T 
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§ 5.3.3 In vitro analysis of DPI formulations  
§§ 5.3.3.1 Salbutamol sulphate assessment 
 
Aerosolization performance of all of the formulations is summarized in Figure 5.6 where the 
amount of salbutamol sulphate deposited into each of the stages of the Multi-Stage Liquid 
Impinger (MSLI) is shown [capsules (C), inhaler (I), mouthpiece (M), induction port (IP), Stage 1, 
Stage 2, Stage 3, Stage 4, and Stage 5]. As can be seen in the figure, spray dried lactose 
obtained the lowest amount of salbutamol sulphate in the capsules with 1.90 ± 0.58 μg while the 
1:1 [Mannitol:Lactose] carrier obtained the highest with 9.52  ± 7.32 μg. When it came to the 
inhaler device, however, the 1:3 [Mannitol:Lactose] carrier exhibited the least with 8.82 ± 2.47 
μg whereas the 1:1 [Mannitol:Lactose] carrier exhibited the highest amount with 42.11 ± 41.74 
μg.  
 
When it came to the mouthpiece, spray dried mannitol obtained the least amount of salbutamol 
sulphate with 8.11 ± 0.91 μg while the 1:1 [Mannitol:Lactose] carrier obtained the highest 
amount with 12.21 ± 4.93 μg. In the induction port, the 1:3 [Mannitol:Lactose] carrier obtained 
the least mount of salbutamol sulphate with 7.84 ± 3.42 μg while spray dried lactose obtained 
the highest amount with 14.58 ± 6.15μg. The 1:3 [Mannitol:Lactose] carrier also had the least 
amount of salbutamol sulphate in Stage 1 with 73.30 ± 14.22 μg while the 3:1 
[Mannitol:Lactose] carrier had the most with 130.33 ± 23.93μg. In Stage 2-5, the 1:3 
[Mannitol:Lactose] carrier obtained the highest amount of salbutamol sulphate with 41.30 ± 
23.89, 128.10 ± 56.12, 79.01 ± 33.48, and 24.51 ± 15.16μg (respectively) categorizing it as the 
optimal carrier. As far as the lowest amounts are concerned, the 3:1 [Mannitol:Lactose] carrier 
obtained 19.68 ± 8.86μg for Stage 2, Spray Dried Lactose obtained 67.78 ± 48.36μg for Stage 
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3, the 3:1 [Mannitol:Lactose] carrier obtained 49.90 ± 12.55μg for Stage 4, and the 1:1 
[Mannitol:Lactose] carrier obtained 9.56 ± 2.35μg for Stage  5. 
  
  
  
    
   
    
   
  
 
Figure 5.6. Aerosolization Profile. Aerosolization performance of each formulation (Spray Dried 
Mannitol, Spray Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose]) highlighting the amount of salbutamol sulphate recovered (percent 
recovered). 
 
Table 5.3 presents the recovered dose (RD), emitted dose (ED), percent recovery, percent 
emission, percent impact loss, mass median aerodynamic diameter (MMAD), geometric standard 
deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), drug loss (DL), dispersibility 
(DS), and effective inhalation index (EI) for salbutamol sulphate obtained from each of the 
different formulations (Spray Dried Mannitol, Spray Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 
[Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) and correlates with the data already presented in 
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Figure 5.6. With that being said, Spray Dried Mannitol accounted for receiving the least amount 
of salbutamol sulphate for RD, ED, percent recovery, and percent emission with 213.23 + 
59.44μg, 147.97 + 53.44μg, 44.33 + 12.36%, and 73.03 + 28.66% (respectively); the 1:3 
[Mannitol:Lactose] carrier, however, received the highest amount of salbutamol sulphate for RD, 
ED, percent recovery, and percent emission with 371.01 + 144.43μg, 354.07 + 140.71μg, 77.13 
+ 30.03%, and 95.21 + 0.95% (respectively). 
 
The 1:3 [Mannitol:Lactose] carrier received the lowest impact loss with 23.29 + 5.83% whereas 
the highest was the 3:1 [Mannitol:Lactose] carrier with 44.65 + 11.75%. These results suggest 
that the 1:3 [Mannitol:Lactose] carrier obtained the best aerosolized performance amongst the 
carriers. With respect to MMAD, the 1:1 [Mannitol:Lactose] carrier obtained the largest diameter 
with 3.10 + 0.06μm, whereas Spray Dried Lactose obtained the lowest diameter with 3.00 + 
0.18μm. In addition, the 1:1 [Mannitol:Lactose] carrier also received the lowest GSD with 2.03 + 
0.04μm whereas the highest GSD came from Spray Dried Lactose with 2.13 + 0.08μm.  
 
With respect to FPD, the 1:3 [Mannitol:Lactose] carrier obtained the highest amount with 231.63 
+ 103.21 and the lowest amount was from Spray Dried Mannitol with 75.82 + 43.07. The 1:3 
[Mannitol:Lactose] carrier received the highest FPF with 61.42 + 4.21% whereas the lowest was 
from Spray Dried Mannitol with 38.10 + 21.84%. These results prove that the 1:3 
[Mannitol:Lactose] carrier was the best engineered carrier amongst all the carriers. The 1:3 
[Mannitol:Lactose] carrier also received the lowest drug loss with 5.93 + 1.04% whereas the 
highest drug loss was from Spray Dried Mannitol with 29.10 + 30.22%. The 1:3 [Mannitol:Lactose] 
carrier had the highest dispersibility with 64.49 + 3.77% and effective inhalation index with 12.51 
+ 0.21 whereas the lowest dispersibility came from the 3:1 [Mannitol:Lactose] carrier with 45.82 
+ 10.19% and the lowest effective inhalation index came from Spray Dried Mannitol with 10.32 + 
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2.63. All in all, taking all of the measurements as a whole and not individually, the 1:3 
[Mannitol:Lactose] carrier navigated itself as having the best aerosolization performance when 
compared to the other carriers. That being said, this carrier is the most effective at delivering 
salbutamol sulphate to the lower respiratory tract via a dry powder inhaler.  
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Table 5.3. Aerosolization Parameters. Recovered Dose (RD), Emitted Dose (ED), Percent Recovery, Percent Emission, Percent 
Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Dose (FPD), Fine 
Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) of salbutamol sulphate obtained from 
each of the different formulations (Spray Dried Mannitol, Spray Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose]). 
 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact Loss 
(%) 
MMAD 
(μm) 
GSD 
(μm) FPD FPF (%) DL (%) DS (%) EI 
Spray Dried Mannitol 213.23 + 59.44 
147.97 + 
53.44 
44.33 + 
12.36 
73.03 + 
28.66 
28.89 +  
3.20 
3.05 + 
 0.14 
2.05 + 
0.01 75.82 +  43.07 
38.10 + 
21.84 
29.10 + 
30.22 
48.53 + 
14.22 
10.32 + 
2.63 
Spray Dried Lactose 297.32 + 
175.08 
272.87 + 
179.66 
61.83 + 
36.40 
88.91 + 
7.43 
35.95 +  
4.00 
3.00 + 
 0.18 
2.13 + 
0.08 
134.81 + 
91.41 
43.08 + 
7.38 
12.00 + 
8.18 
48.26 + 
5.35 
11.48 + 
0.63 
1:1 348.55 + 68.13 
294.22 + 
87.42 
72.46 + 
14.16 
83.63 + 
14.25 
34.42 +  
7.71 
3.10 +  
0.06 
2.03 + 
0.04 153.89 + 83.95 
42.58 + 
18.43 
18.96 + 
14.88 
49.30 + 
15.65 
11.17 + 
1.51 
1:3 371.01 + 144.43 
354.07 + 
140.71 
77.13 + 
30.03 
95.21 + 
0.95 
23.29 +  
5.83 
3.02 +  
0.17 
2.08 + 
0.03 231.63 + 103.21 
61.42 + 
4.21 5.93 + 1.04 
64.49 + 
3.77 
12.51 + 
0.21 
3:1 316.06 + 38.22 
295.68 + 
34.92 
65.71 + 
7.95 
93.57 + 
0.49 
44.65 +  
11.75 
3.02 +  
0.06 
2.04 + 
0.03 
137.69 + 
47.09 
42.85 + 
9.36 8.91 + 1.57 
45.82 + 
10.19 
11.68 + 
0.38 
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§§ 5.3.3.2 Homogeneity assessment 
 
To assess the formulations for their homogeneity they underwent a uniformity assessment. Figure 
5.7 presents the homogeneity profiles for all of the formulations (Spray Dried Mannitol, Spray 
Dried Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) through 
percent potency; Table 5.4 shows the percent content homogeneity, which is expressed as the 
percent coefficient of variation (%CV). 
 
With respect to their potency, all of the formulations adhered to the required specification set by 
the US Food and Drug Administration by falling within the 75-125% range. When it came to %CV, 
3:1 [Mannitol:Lactose] obtained the smallest %CV with 0.76% whereas the largest %CV was 
obtained by the 1:3 [Mannitol:Lactose] carrier with 23.47%. These results indicate that the 3:1 
[Mannitol:Lactose] carrier had the best content homogeneity amongst all of the carriers and the 
1:3 [Mannitol:Lactose] carrier had the worst content homogeneity. The 1:3 [Mannitol:Lactose] 
carrier, which was the best engineered carrier, obtained a %CV of 23.47%. 
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Figure 5.7. Potency. Percent potency of each formulation (Spray Dried Mannitol, Spray Dried 
Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) with respect 
to salbutamol sulphate. 
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Table 5.6. Content Homogeneity. Content homogeneity of Spray Dried Mannitol, Spray Dried 
Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose] expressed 
as the percent coefficient of variation (%CV). 
Formulation % CV 
Spray Dried Mannitol 11.90 
Spray Dried Lactose 13.23 
1:1 (Mannitol:Lactose) 13.22 
1:3 (Mannitol:Lactose) 23.47 
3:1 (Mannitol:Lactose) 0.76 
*However, has not been taken into account for in vivo inhalation studies.  
 
 
5.4 Conclusion 
 
The results presented in this chapter have proven that different concentrations of mannitol:lactose 
solutions were successfully spray dried. They also show that the aerosolization performance of 
the 1:3 [Mannitol:Lactose] carrier was successfully achieved; this achievement was measured in 
the carrier’s FPF, which was 61.42 + 4.21%. The use of 5% L-leucine (w/w) modified the 
physicochemical properties of the spray dried particles along with their morphology. The results 
also showcase the lubrication effect that L-leucine provides to the carriers upon aerosolization. 
They also show that by combining mannitol and lactose in a spray dried solution, with 5% L-
leucine, an improved DPI formulation can be achieved; one more effective than the current 
marketed brand. 
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Chapter 6 
 
 
Effect of Leucine on Dry Powder Inhaler Performance of 
Salbutamol Sulphate containing Xylitol Crystals 
 
 
6.1 Introduction 
 
In this chapter, the focus was to engineer a crystal composed of xylitol and different 
concentrations of L-leucine and investigate the effect it has on the overall aerosolized DPI 
performance of salbutamol sulphate. In addition, the current chapter investigates whether xylitol 
could be a good alternative to lactose in DPI formulations containing salbutamol sulphate. 
(2S,4R)-pentane-1,2,3,4,5-pentol, commonly known as xylitol, is a five carbon sugar found in 
berries, mushrooms, cauliflower, lettuce, corn, and birch tree bark and it is most commonly used 
as a diabetic sweetner. Xylitol is not metabolized by cariogenic bacteria, which are cavity-causing 
bacteria found in the human mouth, allowing for its popular use as an ingredient in chewing gum. 
Studies have shown that xylitol chewing gum prevents acute otitis media (ear aches or infections) 
because the continuous act of chewing and swallowing assist with the disposal and removal of 
earwax while also clearing the middle ear.298 Having a low glycemic index and it being insulin 
independent has allowed xylitol to be used by non-insulin dependent diabetics as well as by the 
obese.299 
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Orally administered xylitol is known to prevent colds and facilitate calcium absorption, which  is 
known to give way to stronger bones; it’s cooling effect serves as an effective means of masking 
unpleasant flavors associated to medications.300 Furthermore, its use in tableting has been known 
to significantly improve a tablet’s mechanical strength and dissolution behavior.301 Its use as a 
carrier in DPI formulations, however, has never been studied, and is the focal point of this overall 
study. 
 
Among metered-dose inhalers (MDI), nebulizers, and DPIs, which are the three aerosol devices 
used to deliver therapeutic agents to the lungs, the DPI is the most promising due to them being 
propellant-free, portable, easy to use, cost-effective, and the formulations used with said device 
experience enhanced stability when stored.302 Crystals, as a whole, provide a unique opportunity 
by allowing one to modulate their physicochemical properties and limit polymorphs.303 Moreover, 
crystal engineering also improves solubility304-306, physical stability307, 308, mechanical properties309, 
310 such as flowability and compressibility, increases bioavailability311, improves pharmacokinetic 
properties312, and improves permeability301. Use of an additive (i.e. L-leucine) has already been 
reported to alter the micrometric properties (i.e. size and shape) of engineered crystals.301 
 
In addition, an attempt was made in this chapter to investigate whether or not L-leucine can 
enhance  the aerosolization behavior of salbutamol sulphate in DPI formulations used with a 
cyclohaler device. Furthermore, an attempt was made to explore whether or not xylitol can act as 
another carrier to replace lactose DPI formulations for lactose intolerant patients. 
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6.2 Materials and Methodology  
§ 6.2.1- § 6.2.13 
Refer to Chapter 2 sections 2.2, 2.4-2.11, and 2.13-2.16. 
 
6.3 Results and Discussion  
 § 6.3.1 Particle size analysis 
 
Figure 6.1 provides the particle size distribution (PSD) diagrams of the unseived engineered 
carriers from each formulation for both the RODOS and Cuvette systems. In Figure 6.1A, all of 
the carriers, with the exception of Xylitol with 0% L-leucine (LEU), experienced similar particle size 
distribution curves; therefore, it was determined that the presence of L-leucine affected the kinetics 
and nucleation behavior of xylitol. Xylitol with 0% LEU  experienced a fixed number of nucleations, 
thereby given larger crystals, whereas all the other carriers experienced a continuous nucleation 
process, henceforth the smaller crystals. Figure 6.1B, however, shows all of the carriers adhering 
to, and satisfying, the requirement of being between 63-90μm when used for inhalation. The 
results also show that the engineered carriers underwent some degree of agglomeration given 
the difference in particle size between the Rodos and Cuvette systems. 
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Figure 6.1. Particle Size Distribution. Particle Size Distribution (PSD) diagrams of the engineered 
carriers (Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU) 
when using the (A) Rodos dry system and when using the (B) Cuvette wet system. 
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Table 6.1 presents the volume mean diameter (VMD) alongside the span for each of the 
engineered carriers under Rodos and Cuvette conditions. All of the carriers experienced a 
difference in their VMDs with ranges from 19.68 + 2.66 μm from Xylitol with 1% LEU to 55.49 + 
4.06 μm from Xylitol with 0% LEU and 63.40 + 1.21 μm from Xylitol with 0% LEU to 86.75 + 12.92 
μm from Xylitol with 1% LEU for the dry and wet systems, respectively. 
  
With respect to the carrier’s span, the dry system experienced a range of 1.17 + 0.13 from Xylitol 
with 0% LEU to 6.37 + 0.56 from Xylitol with 10% LEU while the wet system experienced a range 
from 1.02 + 0.07 from Xylitol with 0% LEU to 1.81 + 0.12 from Xylitol with 5% LEU. Furthermore, 
the dry system experienced a particle diameter range of 6.44 + 9.60 μm (D10%) to 64.34 + 14.78 
μm (D90%) where the particle diameter range for the wet system fell between 23.75 + 8.53 μm 
(D10%) and 137.73 + 25.84 μm (D90%). 
  
 
Table 6.1. Particle Analysis. Particle Analysis of Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol 
with 5% LEU, and Xylitol with 10% LEU showing the volume mean diameter (VMD) and span 
when using the Rodos dry system and the Cuvette wet system. 
Carrier VMD (μm)        Dry System   
VMD (μm)        
Wet System   
Span               
Dry System  
Span               
Wet System  
Xylitol with 0% LEU 55.49 + 4.06 63.40 + 1.21 1.17 + 0.13 1.02 + 0.07 
Xylitol with 1% LEU 19.68 + 2.66 86.75 + 12.92 4.14 + 0.50 1.52 + 0.34 
Xylitol with 5% LEU 22.03 + 0.62 80.34 + 3.25 5.53 + 0.10 1.81 + 0.12 
Xylitol with 10% LEU 19.93 + 1.69 82.80 + 1.16 6.37 + 0.56 1.66 + 0.04 
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Figure 6.2 presents the electron micrograms of all the carriers where it was determined that both 
commercial Xylitol and Xylitol with 1% LEU presented needle-like shapes, Xylitol with 0% LEU 
showed a spherical shape, and Xylitol with 5% LEU along with Xylitol with 10% LEU showed a 
tomahawk shape. Based on these results and those reported by Kaialy et. al 313 where it was 
argued that a needle-like shape serves as a better carrier than that of a spherical one or tomahawk 
one; thus, it was determined that either Commercial Xylitol or Xylitol with 1% LEU would perform 
the best in the aerosolization study. 
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Figure 6.2. Scanning Electron Microscopy. SEM micrograms of (A) Commercial Xylitol, (B) Xylitol 
with 0% LEU, (C) Xylitol with 1% LEU, (D) Xylitol with 5% LEU, and (E) Xylitol with 10% LEU. 
 
§ 6.3.2 Solid-state characterization of engineered carriers 
 
Figure 6.3 presents the chromatographs of Commercial Xylitol and the engineered carriers (Xylitol 
with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU) indicating the 
location of any thermal event taking place; whereas Table 6.2 summarizes the enthalpy of the 
(A) Commercial  Xylitol (B) Xylitol with 0% LEU 
(C) Xylitol with 1% LEU (D) Xylitol with 5% LEU 
(E) Xylitol with 10% LEU 
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reaction (ΔHrxn) for each individual carrier’s thermal event with the corresponding temperature, in 
°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Differential Scanning Calorimetry. DSC thermal peaks of L-Leucine, Commercial 
Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU, 
where an exothermic peak points up and an endothermic peak points down. 
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Table 6.2. DSC Thermal Traces. DSC thermal traces of Commercial Xylitol, Xylitol with 0% LEU, 
Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU, and L-Leucine indicating the 
enthalpy, in J/g, of xylitol melting (ΔHrxn) along with the Temperature (°C) of where such melting 
took place. 
Carrier Temperature (°C) ∆Hrxn (J/g) 
Commercial Xylitol 95.87 + 0.14 194.09 + 2.67 
Xylitol with 0% LEU 95.36 + 0.40 146.37 + 3.92 
Xylitol with 1% LEU 95.78 + 0.66 196.44 + 8.97 
Xylitol with 5% LEU 95.74 + 0.03 116.34 + 5.03 
Xylitol with 10% LEU 95.01 + 0.26 96.25 + 6.75 
Pure Leucine — — 
 
 
Data presented in Table 6.2 authenticates the illustrated data presented in Figure 6.3 where it 
shows a xylitol exothermic event at 95.53 + 0.57°C, which is known to being associated to the 
melting of the orthorhombic stable form of xylitol.314 Due to the lack of any thermal events below 
100°C, it was determined that there were no detectable amounts of free water in the samples. 
Absence of said peaks can also be attributed to the presence of L-leucine as it is known to facilitate 
moisture protection while providing stability for the formulation. Furthermore, the lack of any 
thermal event at 61°C in all xylitol samples indicates the absence of the monoclinic hygroscopic 
metastable form of xylitol in the carriers.315 
 
L-Leucine’s introduction into the engineered formulations had an effect on the enthalpies of the 
reactions of all the samples by manifesting a reduction in the sample’s overall enthalpy as the 
concentration of L-leucine increases; this linear correlation (data not shown) is attributed to the 
inter- and intra-molecular interactions (i.e. Van dar Waals, hydrogen bonding, etc.) that have been 
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altered, in the micro level, from the original. Using the crystallization methodology of this study 
proved to have no significant impact on xylitol’s polymorphous form or its molecular structure 
given that FT-IR spectroscopy showed no significant changes from sample to sample (data not 
shown). 
 
Figure 6.4 depicts the powder X-ray diffraction (PXRD) patterns for Commercial Xylitol, L-leucine,  
and all of the engineered carriers (Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, 
and Xylitol with 10% LEU) providing insight into their crystallinity. Demonstrating sharp diffraction 
angles with no halo background or widening allowed for them to be classified as crystalline. 
Moreover, a linear correlation (r2 = 0.99) existed between the increase in L-leucine concentration 
and the sharpening of the peaks, as seen in the figure. It is also worth noting that the desired 
polymorph was obtained by all of the carriers which presented improved pharmaceutical 
performance. 
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Figure 6.4. X-Ray Diffraction. Powder X-Ray diffraction patterns of Pure Leucine, 
Commercial Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 
10% LEU. 
 
§ 6.3.3 In vitro analysis of DPI formulations 
  
§§ 6.3.3.1 Salbutamol sulphate assessment 
 
Aerosolization performance of all of the formulations is summarized in Figure 6.5 where the 
amount of salbutamol sulphate deposited into each of the stages of the Multi-Stage Liquid 
Impinger (MSLI) is shown [capsules (C), inhaler (I), mouthpiece (M), induction port (IP), Stage 1, 
Stage 2, Stage 3, Stage 4, and Stage 5 (filter)]. As can be seen in the figure, Commercial Xylitol 
obtained the lowest amount of salbutamol sulphate in the capsules with 1.16 + 0.32 μg while 
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Xylitol with 10% LEU obtained the highest amount with 6.09 + 4.98 μg. When it came to the inhaler 
device, however, Commercial Xylitol exhibited the highest amount with 14.26 + 4.26 μg and Xylitol 
with 10% LEU with the least amount with 5.27 + 2.49 μg. 
 
Additionally, Commercial Xylitol obtained the lowest amount of salbutamol sulphate in both the 
mouthpiece, with 3.87 + 2.18 μg, and induction port, with 4.89 + 2.74 μg; whereas Xylitol with 5% 
LEU received the highest amount, with 11.93 + 2.31 μg, in the mouthpiece and Xylitol with 10% 
LEU received the highest amount with 12.71 + 3.27 μg in the induction port. For Stages 1-5, Xylitol 
with 5% LEU accounted for obtaining the highest amount in all five stages: 141.73 + 5.97, 32.34 
+ 20.46, 88.37 + 62.34, 56.33 + 32.09, and 38.78 + 43.23 μg, respectively. For the lowest 
amounts, however, Xylitol with 0% LEU obtained 75.87 + 21.63 μg in Stage 1, Xylitol with 1% 
LEU obtained 19.06 + 4.71 μg for Stage 2, 23.28 + 15.21 μg for Stage 3, 16.02 + 8.12 μg for 
Stage 4, and Xylitol with 0% LEU obtained 6.11 + 4.95 μg for Stage 5. These preliminary results 
suggested that Xylitol with 5% LEU would prove to be the most effective at delivering the 
salbutamol sulphate into the alveoli rather than the Commercial Xylitol and Xylitol with 1% LEU, 
which were both previously categorized as needle-like in shape. 
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Figure 6.5. Aerosolization Profile. Aerosolization performance of Commercial Xylitol and each 
engineered formulation (Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol 
with 10% LEU) highlighting the amount of SS recovered (percent recovered) for each and 
comparing them side-by-side. 
 
 
Table 6.3 presents the recovered dose (RD), emitted dose (ED), percent recovery, percent 
emission, percent impact loss, mass median aerodynamic diameter (MMAD), geometric standard 
deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), drug loss (DL), dispersibility 
(DS), and effective inhalation index (EI) for salbutamol sulphate obtained from each of the 
different formulations (Commercial Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 
5% LEU, and Xylitol with 10% LEU) and correlates with the data already presented in Figure 6.5. 
Xylitol with 1% LEU accounted for receiving the least amount of salbutamol sulphate for RD, ED, 
and percent recovery with 173.67 + 44.85 μg, 160.49 + 38.62 μg, and 36.11 + 9.32%, 
respectively; Xylitol with 5% LEU, however, received the highest amount of salbutamol sulphate 
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for RD, ED, and percent recovery with 390.01 + 163.29 μg, 369.23 + 154.57 μg, and 81.08 + 
33.95%, respectively. 
 
Moreover, Xylitol with 5% LEU also received the highest percent emission with 94.67 + 0.01% 
whereas Xylitol with 0% LEU received the lowest with 91.91 + 3.46% suggesting that Xylitol with 
5% LEU was capable of injecting more of the engineered formulation into the system than any 
other formulations. 
 
Xylitol with 1% LEU received the highest impaction loss with 61.38 + 13.21% whereas 
Commercial Xylitol received the lowest amount with 43.72 + 12.20%. With respect to MMAD, 
Xylitol with 10% LEU obtained the largest diameter with 3.29 + 0.10 μm, which further supports 
its performance fallacy, whereas Commercial Xylitol received the lowest with 2.77 + 0.45μm 
indicating a positive correlation between the smaller particle diameter to that of its efficacy. In 
addition, Xylitol with 5% LEU obtained the largest GSD with 2.21 + 0.13μm and Xylitol with 10% 
LEU received the smallest with 2.05 + 0.01 μm. 
 
With respect to FPD, Xylitol with 5% LEU received the highest with 183.48 + 137.26 µg and the 
lowest was Xylitol with 1% LEU with 46.41 + 26.06 µg. Commercial Xylitol proved to obtain the 
highest FPF amongst all of the formulations with a FPF of 44.13 + 11.27%, whereas Xylitol with 
5% LEU came at a close second with 42.94 + 15.21%. A linear correlation (r2 = 0.97) between 
FPF and effective inhalation index was established correlating to the formulation’s effeciency. 
Xylitol with 5% LEU, however, was managed to obtain the lowest drug loss with 6.57 + 0.39%, 
but the highest with 10.28 + 1.95% was from Xylitol with 1% LEU; thereby placing Commercial 
Xylitol as the more effective formulation as a whole. Commercial Xylitol did receive the highest 
dispersibility with 47.90 + 11.69%, but the lowest went to Xylitol with 1% LEU with 27.88 + 11.96%. 
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Lastly, Xylitol with 5% LEU received the highest effective inhalation index with 11.72 + 0.65 
whereas Xylitol with 1% LEU obtained the lowest with 10.88 + 0.50. 
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Table 6.3. Aerosolization Parameters. Recovered Dose (RD), Emitted Dose (ED), Percent Recovery, Percent Emission, Percent 
Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Dose (FPD), Fine 
Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) of salbutamol sulphate obtained from 
each of the different formulations (Commercial Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 
10% LEU). 
 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss 
(%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) 
DL 
(%) DS (%) EI 
Commercial Xylitol 239.29  + 111.70 
221.16  + 
106.22 
49.75 + 
23.22 
92.01 + 
1.75 
43.72 + 
12.20 
2.77 + 
0.45 
2.18 + 
0.31 
113.57 + 
82.45 
44.13 + 
11.27 
8.56 + 
2.11 
47.90 + 
11.69 
11.66 
+ 0.53 
Xylitol with 0% LEU 216.19 + 
170.69 
197.97 + 
154.33 
44.95 + 
35.49 
91.91 + 
3.46 
50.01 + 
19.40 
3.10 + 
0.10 
2.09 + 
0.06 
92.87 + 
109.59 
34.25 + 
16.98 
10.12 + 
3.94 
37.27 + 
18.73 
11.21 
+ 0.78 
Xylitol with 1% LEU 173.67 + 
44.85 
160.49 + 
38.62 
36.11 + 
9.32 
92.75 + 
2.08 
61.38 + 
13.21 
2.92 + 
0.24 
2.19 + 
0.10 
46.41 +  
26.06 
25.84 + 
11.05 
10.28 + 
1.95 
27.88 + 
11.96 
10.88 
+ 0.50 
Xylitol with 5% LEU 390.01 + 
163.29 
369.23 + 
154.57 
81.08 + 
33.95 
94.67 + 
0.01 
43.87 + 
16.61 
2.83 + 
0.26 
2.21 + 
0.13 
183.48 + 
137.26 
42.94 + 
15.21 
6.57 + 
0.39 
45.36 + 
16.07 
11.72 
+ 0.65 
Xylitol with 10% LEU 264.91 + 76.86 
249.25 + 
69.90 
55.07 + 
15.98 
94.25 + 
0.88 
49.13 + 
13.56 
3.29 + 
0.10 
2.05 + 
0.01 
93.27 + 
 33.93 
35.61 + 
12.58 
7.88 + 
2.12 
37.75 + 
13.10 
11.39 
+ 0.57 
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All in all, taking all of the measurements as a whole and not individually, Xylitol with 5% Leu was 
the formulation with the best aerosolization performance given its FPD over that of Commercial 
Xylitol which had the best FPF. That is to say, Xylitol with 5% Leu delivered more salbutamol to 
the lower stages of the MSLI compared to Commercial Xylitol making Xylitol with 5% Leu the 
better formulation. 
  
 
§§ 6.3.3.2 Homogeneity Assessment 
 
All of the formulations underwent a homogeneity assessment to determine their uniformity which 
allows each formulation to be referenced with the specification guidelines set by the 
pharmaceutical governing bodies. Figure 6.6 presents the homogeneity profiles for all of the 
formulations (Commercial Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, 
and Xylitol with 10% LEU) through percent potency; Table 6.4 shows the percent content 
homogeneity, which is expressed as the percent coefficient of variation (%CV). 
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Figure 6.6. Potency. Percent potency of each formulation (Commercial Xylitol, Xylitol with 0% 
LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU) with respect to 
salbutamol sulphate. 
 
With respect to percent potency, all of the formulations adhered to the required specification set 
by the US Food and Drug Administration by falling within the 75-125% potency range. Xylitol with 
5% Leu had the smallest potency with a potency of 110.60 + 15.30% while Xylitol with 10% Leu 
had the highest potency with 121.06 + 3.07%. Moreover, Xylitol with 10% LEU obtained the 
smallest %CV with 2.53% whereas Xylitol with 1% LEU obtained the highest %CV with 19.68% 
(see Table 6.4). These results indicate that Xylitol with 10% LEU had the best content uniformity 
amongst all of the formulations highlighting the significant role that L-leucine plays as an excipient. 
L-Leucine improves the inter- and intra- molecular interactions of the particles by altering the 
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physicochemical properties of the formulation, yielding a favorable uniformity profile. 
 
Table 6.4. Content Homogeneity. Content homogeneity of Commercial Xylitol, Xylitol with 0% 
LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU expressed as the percent 
coefficient of variation (%CV). 
Formulation Potency (%) % CV 
Commercial Xylitol 113.03 + 15.09 13.35 
Xylitol with 0% LEU 119.07 + 14.05 11.72 
Xylitol with 1% LEU 111.76 + 22.00 19.68 
Xylitol with 5% LEU 110.60 + 15.30 13.83 
Xylitol with 10% LEU 121.06 + 3.07 2.52 
*However, has not been taken into account for in vivo inhalation studies.  
 
6.4 Conclusion 
The results presented in this chapter have proven that xylitol crystals with different 
concentrations of L-leucine can be successfully crystalized. They also showed that L-leucine 
altered the physicochemical properties of the carriers affecting their inter- and intra-molecular 
interactions. This caused the uniformity of the carriers to improve with increasing L-leucine 
concentration. Xylitol with 5% LEU (FPF = 42.94 + 15.21) was the best DPI formulation within 
this study. This formulation had particles classified as tomahawk, which is known to show better 
aerosolized efficacy over particles with spherical morphology. The Xylitol with 5% LEU, 
however, does not compare to the 1:3 [Mannitol:Lactose] carrier from Chapter 5 whose FPF 
was 61.42 + 4.21%. 
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Chapter 7 
Effect Mannitol and Lactose crystals have on Aerosolized 
Dry Powder Inhaler Performance containing Salbutamol 
Sulphate 
 
 
7.1 Introduction 
 
In this chapter, the focus was to engineer a crystal composed of mannitol:lactose in different 
concentrations and investigate the effect it has on the overall aerosolized DPI performance of 
salbutamol sulphate. Crystal engineering is viewed as a form of supramolecular synthesis, often 
referred to as the chemistry beyond the molecule, and contributes to the continued development 
of pharmaceuticals and functional materials.316-318   For instance, Roy et. al engineered a crystal 
in such a way as to provide supramolecular hybrids where they were synthesized by a 
hydrothermal route under different pH using a hydrolyzable naphthalene diimide ligand.319  
 
Moreover, crystal engineering offers an opportunity to optimize physicochemical properties, such 
as solubility, stability, hydration, and melting point, mechanical properties, such as flowability and 
compressibility, pharmacokinetic properties, bioavailability, and permeability.320-323 Because 
amorphous powders have a higher surface free energy over crystalline material, it makes 
crystalline material a more favorable choice for drug formulation.324 
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Conventional DPI methods include milling, spray drying, and freeze drying9 whereas those 
associated to crystal formation include slurry solutions325-327, ultrasonic crystallization328, 
evaporation329, or supercritical fluids330; supercritical fluids being the chosen method here. During 
the process, supersaturation is generated by adding a second liquid to a solution of the crystals 
to be crystallized, which is miscible with the solvent and in which the crystals are insoluble or 
sparingly soluble.331 
 
DPIs as a dosage form consist of a powder formulation designed to deliver an API to the 
respiratory tract. Formulations are filled into hard-gelatin capsules that are subsequently pierced 
by the inhaler devise directly before its application.332 Recent studies have shown mannitol’s and 
lactose’s aerosolization performance in a DPI formulation showing mannitol’s more favorable 
performance over that of lactose; fine particle fraction (FPF) of 52.96 + 5.21% [Chapter 4] and 
47.11 + 9.94% [Chapter 3], respectively. Another study showed the aerosolization performance 
of spray dried mannitol and lactose combined in different ratios where the FPF was found to be 
61.42 + 4.21% [Chapter 5]. Additionally, xylitol crystals have also been used as a carrier in a DPI 
formulation where the resulting FPF was 42.94 + 15.21% [Chapter 6]. 
  
Mannitol and lactose are popular carriers to be used in DPI formulation. In many cases, 
researchers have made attempts to engineer these carriers individually. The author of this thesis 
believes that crystallization of these two carriers with different ratios simultaneously might create 
a carrier with optimum properties suitable for DPI formulations as a carrier.  With this in mind, the 
aim of this study was to engineer a crystal using different mannitol-lactose ratios and observe the 
impact it had on aersolization performance and the efficacy of the physicochemical properties of 
the DPI formulation for the delivery of salbutamol sulphate. 
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7.2 Materials and Methodology  
§ 7.2.1- § 7.2.14 
Refer to Chapter 2 sections 2.2 and 2.4-2.16. 
 
7.3 Results and Discussion  
§7.3.1 Particle size analysis 
 
Dispersion of inhaled particles is dependent on the aerodynamic stress and particle aggregate 
strength associated to the particulates. In addition, other interdependent factors such as  particle 
morphology, size, density are also at play.333-337 Figure 7.1 presents the particle size distribution 
(PSD) diagrams of the engineered carriers  (1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 
[Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) when using the Rodos and 
Cuvette systems of analysis. Figure 7.1A focusses on the Rodos system which shows the carriers’ 
true particle size, and Figure 7.1B focusses on the Cuvette system which shows the carrier’s size 
in a liquid. Comparing these two figures, it can be concluded that some degree of agglomeration 
occurred between the particles in the wet system. This occurrence has to do with the fact that for 
mixtures containing fine and coarse particles, fine particles tend to charge negatively, whereas 
large particles tend to charge positively regardless of whether the net-charge is positive or 
negative;338-341 in other words, it has to do with electrostatic charge. This accounts for the 
discrepancies in size between the two systems. In addition, the wet system might have not 
generated enough force to de-aggregate the particles, whereas in dry system a pressure of 3 bars 
wa sufficient enough to de-aggregate the particles to their original size.  
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Figure 7.1. Particle Size Distribution. Particle Size Distribution (PSD) diagrams of carriers (1:1 
[Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose]) when using the (A) Rodos dry system and when using the (B) Cuvette wet 
system. 
(A) 
(B) 
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Taking a closer look at the particle size for each system, Table 7.1 provides the volume mean 
diameter (VMD) and the particle span for the carriers. Carriers experienced differences in their 
VMDs ranging from 11.45 ± 1.57μm for the 3:1 (Mannitol:Lactose) carrier to 25.20 ± 0.38μm for 
the 1:2 (Mannitol:Lactose) carrier and 67.82 ± 3.76μm for the 1:3 (Mannitol:Lactose) carrier to 
88.21 ± 1.28μm for the 2:1 (Mannitol:Lactose) carrier, in the Rodos and Cuvette systems 
respectively. It becomes important to mention that large particles have been shown to manifest 
higher surface roughness225, 342, 343, more likely to exhibit surface impurities344, greater shape 
irregularities (i.e. cracks and dislocations)345, decreased disorder in crystal lattice225, 342, 346, and 
lower moisture uptake347, when compared to smaller particles. Moreover, particle span also 
showed differences between the two systems with particles falling between 2.85 ± 0.07 for the 
1:2 (Mannitol:Lactose) carrier to 11.87 ± 0.22 for the 3:1 (Mannitol:Lactose) carrier to 2.28 ± 0.03 
for the 3:1 (Mannitol:Lactose) carrier to 7.22 ± 0.48 for the 1:3 (Mannitol:Lactose) carrier in the 
Rodos and Cuvette systems, respectively. Furthermore, the Rodos system experienced a particle 
diameter range of 1.51 ± 0.79μm (D10%) to 42.95 ± 10.17μm (D90%) where the particle diameter 
range for the Cuvette system fell between 7.14 ± 4.42μm (D10%) and 180.01 ± 33.46μm (D90%). 
 
It becomes important to note that electrostatic forces become more significant and may even 
dominate over other particulate forces, including van der Waals forces, when the particle size is 
decreased in low environmental humidities; therefore, powder charge is inversely related to 
particle mean diameter.128, 294, 295  In addition, it has been suggested that the energy required to 
transfer an electron between two insulating solid particles is highly dependent on particle size.348, 
349 It has been reported that the amount of net-charge accumulated on mannitol increases with 
the fine particle fraction of small mannitol while it has also been shown that the net-charge of 
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lactose increases with decreasing particle size.350-354 Moreover, during the mixing of a cohesive 
powder, it is the coarser particles which act like a nuclei where they are subsequently coated with 
a thin layer of fine particles which could be  the case in our study (see Figure 7.1 and Table 7.1).355 
In the event that fine particles are in excess, it becomes true that one of the finer particulates will 
act as the nuclei thereby facilitating the catalysis of agglomeration.  
 
Table 7.1. Particle Analysis. Particle Analysis of 1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose], 
1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose] showing the volume 
mean diameter (VMD) and span when using the Rodos dry system and the Cuvette wet system. 
 
Carrier VMD (μm)        Dry System   
VMD (μm)        
Wet System   
Span               
Dry System  
Span               
Wet System  
1:1 (Mannitol:Lactose) 21.72 + 0.80 70.76 + 1.14 4.00 + 0.10 2.76 + 0.04 
1:2 (Mannitol:Lactose) 25.20 + 0.38 79.76 + 4.25 2.85 + 0.07 5.01 + 0.50 
1:3 (Mannitol:Lactose) 15.72 + 0.42 67.82 + 3.76 4.15 + 0.18 7.22 + 0.48 
2:1 (Mannitol:Lactose) 13.32 + 0.76 88.21 + 1.28 4.84 + 0.23 3.77 + 0.02 
3:1 (Mannitol:Lactose) 11.45 + 1.57 80.21 + 1.54 11.87 + 0.22 2.28 + 0.03 
 
 
Figure 7.2 presents the electron micrograms of all the carriers where it was determined that the 
1:1 [Mannitol:Lactose] carrier and the  3:1 [Mannitol:Lactose] carrier exhibited needle-like crystal 
structures whereas the 1:2 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 2:1 [Mannitol:Lactose] 
carriers exhibited rhombic crystal structures. These results indicate that the 1:1 [Mannitol:Lactose] 
carrier and the  3:1 [Mannitol:Lactose] carrier would perform better than the 1:2 
[Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 2:1 [Mannitol:Lactose] carriers due to the results 
found by Kaialy et. al 313 where it was argued that needle-like crystal structures aerosolize more 
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effectively over rhombic and spherical crystal structures. In addition, it is important to nderstand 
that most pharmaceutical solid particles are diverged from the spherical shape and that a 
particle’s shape has a significant effect on that particle’s net charge.356 357 
Figure 7.2. Scanning Electron Microscopy. SEM micrograms of (A) 1:1 [Mannitol:Lactose], (B) 
1:2 [Mannitol:Lactose], (C) 1:3 [Mannitol:Lactose], (D) 2:1 [Mannitol:Lactose], and (E) 3:1 
[Mannitol:Lactose] carrier. 
 
(A) 1:1 [Mannitol:Lactose] (B) 1:2 [Mannitol:Lactose] 
(C) 1:3 [Mannitol:Lactose] (D) 2:1 [Mannitol:Lactose] 
(E) 3:1 [Mannitol:Lactose] 
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§ 7.3.2 Solid-state Characterization of Engineered Carriers 
 
Polymorphism provides the ability of a particle to exist in more than one isomer; about one-third 
of all drugs exhibit some form of polymorphism.231 Polymorphism is an obstacle in the 
pharmaceutical industry because different polymorphs display different physical properties 
making it important to isolate different polymorphs in a batch.331 Crystal formation has been shown 
to improve physicochemical properties (i.e. solubility, dissolution, and stability) as well as the 
mechanical properties and bioavailability of the crystal.358-360 With this in mind, Figure 7.3 presents 
the chromatographs of the engineered crystal carriers (1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) 
indicating the location of any thermal event taking place; whereas Table 7.2 summarizes the 
enthalpy of the reaction (ΔHrxn) for each individual carrier’s thermal event with the corresponding 
temperature, in °C, where such event took place. 
 
Moreover, a particle’s surface area is considered a measure of surface geometry whereas surface 
free energy represents the amount of energy needed to separate particles from surfaces.361 In 
general, particles that exhibit smaller size distributions and more surface irregularities have higher 
surface areas362 whereas powders with higher specific surface areas tend to show higher moisture 
uptake347 and higher surface free energies363. Consequently, particle surface roughness affects 
the overall charge-transfer because it affects the inter-particulate and particle-surface contact 
areas.364 Looking at the results obtained from SEM and particle size analysis, it was determined 
that the above is true for this study. 
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Figure 7.3. Differential Scanning Calorimetry. DSC thermal peaks of 1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]; 
where an exothermic peak points up and an endothermic peak points down. 
 
Data presented in Table 7.2 authenticates the illustrated data presented in Figure 7.3 where it 
shows lactose having an endothermic event at 145.16 ± 0.00°C, which corresponds to the 
evaporation of water, and another endothermic event at both 216.56 ± 0.11°C and 231.41 ± 
0.94°C, which are indicative of ⍺-lactose and β-lactose, respectively. Moisture uptake is directly 
related to relative humidity (an external factor) as well as the chemical (i.e. hydrophilicity and 
hydrophobicity) and physical (i.e. powder specific surface area and particle anomeric 
composition) properties.347 In the context of aerosolization performance, it has been suggested 
Ch
an
ge
 in
 E
nt
ha
lp
y 
175 
 
that in an optimal relative humidity there is a balance between electrostatic and capillary forces 
leading to minimal cohesive forces and, thus, an improved DPI dispersion behavior.365   
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Table 7.2. DSC Thermal Traces. DSC thermal traces of Commercial Lactose, Commercial Mannitol, 1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose], 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose] indicating the enthalpy (ΔHrxn), in J/g, 
along with the Temperature (°C) of where such event took place. 
Formulation Temperature (°C) ∆Hrxn (J/g) Temperature (°C) ∆Hrxn (J/g) Temperature (°C) ∆Hrxn (J/g) Temperature (°C) ∆Hrxn (J/g) 
Commercial Lactose 145.16 + 0.00 102.52 + 3.96 — — 216.56 + 0.11 85.17 + 1.29 231.41 + 0.94 39.72 + 2.63 
Commercial Mannitol — — 168.91 + 0.66 186.64 + 19.55 — — — — 
1:1 (Mannitol:Lactose) 
130.46 + 0.12 49.48 + 9.32 163.29 + 0.16 73.77 + 17.04 204.66 + 0.25 14.02 + 4.35 228.20 + 0.06 22.49 + 6.39 
1:2 (Mannitol:Lactose) 
131.13 + 0.71 77.79 + 21.67 163.42 + 0.29 29.70 + 7.86 219.60 + 0.69 40.62 + 11.64 232.65 + 0.12 11.04 + 1.89 
1:3 (Mannitol:Lactose) 
127.66  + 0.19 82.07 + 13.15 162.61 + 0.11 33.68 + 4.17 217.07 + 0.40 39.36 + 5.42 230.36 + 0.06 11.18 + 1.58 
2:1 (Mannitol:Lactose) 
128.33 + 0.60 13.42 + 2.14 164.37 + 0.00 171.51 + 7.67 — — 228.84 + 1.31 11.65 + 0.77 
3:1 (Mannitol:Lactose) 
129.99 + 0.58 19.83 + 4.95 163.96 + 0.00 142.98 + 2.54 — — 229.12 + 0.42 11.38 + 1.97 
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Furthermore, because of the absence of any thermal event taking place at 177°C, it was 
concluded that none of the carriers were in the amorphous state as this is the corresponding place 
it is found in.237 On the other hand, mannitol experienced one endothermic event at 168.91 + 
0.66°C which corresponds to the melting of mannitol.237, 283 Determining mannitol’s polymorphic 
state, however, required further analysis (i.e. the implementation of PXRD) given that DSC, alone, 
cannot distinguish mannitol’s polymorphs. 
 
Nevertheless, 1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose], and 1:3 [Mannitol:Lactose] where 
characterized as having both ⍺- and β-lactose polymorphs along with the exhibition of the 
mannitol thermal event and 2:1 [Mannitol:Lactose] and 3:1 [Mannitol:Lactose] were characterized 
as having the mannitol thermal event along with being composed of only the β-lactose polymorph, 
as the ⍺-lactose polymorph peak was found to be missing (see Figure 7.3 and Table 7.2). 
 
Figure 7.4 depicts the powder X-ray diffraction (PXRD) patterns for all of the engineered carriers 
providing insight into their crystalline state as well as differentiating between their polymorphic 
forms. It is known that lactose has two polymorphs (⍺- and β-), which are distinguishable via 
thermodynamic analysis, and mannitol is known to have three possible polymorphic forms (⍺-, β-
, and Δ-), which are known to have specific diffraction patterns when using PXRD; ⍺-mannitol is 
known to have peaks at 9.57° and 13.79° on the 2θ plane, β-mannitol is known to exhibit peaks 
at 10.56° and 14.71° on the 2θ plane, and Δ-mannitol is known to possess peaks at 9.74° on the 
2θ plane. 274, 275, 334 With that said, 1:1 [Mannitol:Lactose] was composed of the ⍺- and β-mannitol, 
1:2 [Mannitol:Lactose] was composed of all three mannitol polymorphs (⍺-, β-, and Δ-), 1:3 
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[Mannitol:Lactose] was composed of ⍺- and Δ-mannitol, 2:1 [Mannitol:Lactose] was composed of 
⍺- and β-mannitol, and 3:1 [Mannitol:Lactose] was composed of ⍺- and β-mannitol. In addition, 
the peaks demonstrated sharp diffraction angles with no halo background, therefore they were 
classified as crystalline. 
Figure 7.4. X-Ray Diffraction. Powder X-Ray diffraction patterns of the 1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose] 
carriers. 
 
To further assess and characterize the engineered carriers, FT-IR spectra can be seen in Figure 
7.5 where ⍺-Lactose exhibits a distinct peak at 920 cm-1 and β-lactose at 950 cm-1 whereas 
Lactose Mannitol 
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α-mannitol exhibits a distinct peak at 1195 cm-1, β-mannitol at 929 cm-1, 959 cm-1, and 1209 cm-
1, and Δ-mannitol at 967 cm-1.227, 237, 296 FT-IR spectra confirmed the classifications already 
mentioned (see Figure 7.4) for the carriers; furthermore, Table 7.3 summarizes the results of the 
different polymorphic forms for each carrier contained. 
Figure 7.5. FT-IR. FT-IR spectra of commercial mannitol, commercial lactose, and the 1:1 
[Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 
[Mannitol:Lactose], and 3:1 [Mannitol:Lactose] carriers. 
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Table 7.3. Summary of Polymorphic Form. Summary of the different polymorphic forms each 
carrier contains. 
Carrier ⍺-lactose β-lactose ⍺-manntol β-mannitol Δ-mannitol 
1:1 (Mannitol:Lactose) ✓ ✓ ✓ ✓ — 
1:2 (Mannitol:Lactose) ✓ ✓ ✓ ✓ ✓ 
1:3 (Mannitol:Lactose) ✓ ✓ ✓ — ✓ 
2:1 (Mannitol:Lactose) — ✓ ✓ ✓ — 
3:1 (Mannitol:Lactose) — ✓ ✓ ✓ — 
 
 
§ 7.3.3 Powder Flow Characterization 
 
Bulk density (Db), tap density (Dt), Carr’s Index (CI), and angle of repose (!) for each of the carriers 
is listed in Table 7.4. Comparing the different carriers, the 1:3 (Mannitol:Lactose) and 3:1 
(Mannitol:Lactose) carrier had the lowest Db (0.28 ± 0.00 g/cm3) and the 1:1 (Mannitol:Lactose) 
carrier had the highest Db (0.36 ± 0.00 g/cm3) whereas, for Dt, the 3:1 (Mannitol:Lactose) carrier 
had the lowest (0.29 ± 0.01 g/cm3) and the 1:1 (Mannitol:Lactose) carrier had the highest (0.49 ± 
0.02 g/cm3). Such results are attributed the solid state characteristics already discussed in the 
previous section.  Regarding the CI and angle of repose, the 2:1 (Mannitol:Lactose) and 3:1 
(Mannitol:Lactose) carriers showed the best flow characteristics, which is needed to achieve 
satisfactory DPI formulation metering, fluidization, and dispersion.366  
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Table 7.4. Powder Flow Characteristics. Bulk density (Db), tap density (Dt), Carr’s Index (CI), and 
angle of repose (!) for each of the carriers: 1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 
[Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]. 
Carrier Db (g/cm3) Dt (g/cm3) CI (%) 
Angle of 
repose (°) 
1:1 (Mannitol:Lactose) 0.36 ± 0.00 0.49 ± 0.02 48.67 ± 5.77 46.21 ± 0.00 
1:2 (Mannitol:Lactose) 0.32 ± 0.00 0.43 ± 0.01 33.33 ± 4.04 29.13 ± 0.00 
1:3 (Mannitol:Lactose) 0.28 ± 0.02 0.38 ± 0.00 41.00 ± 8.66 35.83 ± 0.00 
2:1 (Mannitol:Lactose) 0.30 ± 0.01 0.32 ± 0.01 6.33 ± 3.51 29.13 ± 0.00 
3:1 (Mannitol:Lactose) 0.28 ± 0.00 0.29 ± 0.01 5.00 ± 1.73 30.14 ± 0.00 
 
 
§ 7.3.4 In vitro analysis of DPI formulations  
§§ 7.3.4.1 Salbutamol sulphate assessment 
 
Aerosolization performance of all of the formulations is summarized in Figure 7.6 where the 
amount of salbutamol sulphate deposited into each of the stages of the Multi-Stage Liquid 
Impinger (MSLI) is shown [capsules (C), inhaler (I), mouthpiece (M), induction port (IP), Stage 1, 
Stage 2, Stage 3, Stage 4, and Stage 5]. As can be seen in the figure, 1:2 (Mannitol:Lactose) 
obtained the lowest amount of salbutamol sulphate in the capsules with 2.03 + 1.02 μg while 3:1 
(Mannitol:Lactose) obtained the highest amount with 7.69 + 7.23 μg. When it came to the inhaler 
device, however, 3:1 (Mannitol:Lactose) exhibited the highest amount with 28.54 + 6.71μg and 
1:3 (Mannitol:Lactose) with the least amount with 3.95 + 1.50 μg. 
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In addition, the 1:2 (Mannitol:Lactose) carrier obtained the lowest amount of salbutamol sulphate 
(SS), in both, the mouthpiece (M) and induction port (IP) with 10.58 ± 6.42μg and 16.92 ± 6.30μg, 
respectively. In contrast, the 2:1 (Mannitol:Lactose) carrier obtained the highest amount of SS, in 
both, the M and IP with 18.05 + 9.83μg and 35.42 + 13.83μg, respectively. When it came to stages 
1-5, the following occurred: the highest amount of SS for Stage 1 went to the 3:1 
(Mannitol:Lactose) carrier with 116.79 + 18.30μg, for Stage 2 the 1:3 (Mannitol:Lactose) carrier 
obtained the highest amount with 109.55 + 18.62μg, for Stage 3 the 2:1 (Mannitol:Lactose) carrier 
obtained the highest amount with 233.62 + 54.94μg, for Stage 4 and Stage 5 the 1:3 
(Mannitol:Lactose) carrier obtained the highest amount with 200.22 + 41.53μg and 80.52 + 
22.39μg, respectively. Therefore, it was determined that the 1:3 (Mannitol:Lactose) carrier was 
better at delivering salbutamol sulphate to the lower regions of the lung suggesting a high fine 
particle fraction (FPF) from this carrier. 
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Figure 7.6. Aerosolization Profile. Aerosolization performance of each engineered formulation 
(1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], 
and 3:1 [Mannitol:Lactose]) highlighting the amount of SS recovered (percent recovered) for each 
and comparing them side-by-side. 
 
Table 7.5 presents the recovered dose (RD), emitted dose (ED), percent recovery, percent 
emission, percent impact loss, mass median aerodynamic diameter (MMAD), geometric standard 
deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF), drug loss (DL), dispersibility 
(DS), and effective inhalation index (EI) for salbutamol sulphate obtained from each of the 
different engineered formulations (1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose], 1:3 
[Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]). With that being said, the 
1:1 [Mannitol:Lactose] carrier accounted for having the lowest RD with 474.28 + 194.53 μg while 
the 3:1 [Mannitol:Lactose] carrier obtained the lowest ED, percent recovery, and percent emission 
with 407.26 + 190.92 μg, 93.70 + 40.56 %, 89,53 + 3.26% respectively; the 2:1 [Mannitol:Lactose] 
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carrier, however, received the highest RD, ED, and percent recovery with 637.30 + 149.78 μg, 
603.51 + 129.20 μg, and 132.49 + 31.14% respectively.  
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Table 7.5. Aerosolization Parameters. Recovered Dose (RD), Emitted Dose (ED), Percent Recovery, Percent Emission, Percent 
Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Dose (FPD), Fine 
Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) of salbutamol sulphate obtained from 
each of the different engineered formulations (1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 
[Mannitol:Lactose], and 3:1 [Mannitol:Lactose]). 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss 
(%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) 
DL 
(%) 
DS 
(%) EI 
1:1 (Mannitol:Lactose) 474.28 + 194.53 
439.55+ 
188.18 
98.60 + 
40.44 
92.30 + 
2.58 
30.23 + 
16.13 
3.22 + 
0.31 
2.01+ 
0.03 
263.61+ 
147.77 
52.34+ 
15.08 
8.59+ 
2.80 
56.74+ 
16.79 
12.02+ 
0.63 
1:2 (Mannitol:Lactose) 475.48 + 134.09 
451.24+ 
117.27 
98.85 + 
27.88 
95.31 + 
2.62 
29.30 + 
7.29 
3.60 + 
0.13 
1.97+ 
0.02 
238.91 
+ 89.82 
49.13+ 
5.94 
5.02+ 
2.69 
51.64+ 
7.53 
12.02+ 
0.14 
2:1 (Mannitol:Lactose) 637.30 + 149.78 
603.51+ 
129.20 
132.49 + 
31.14 
94.98 + 
1.82 
21.33 + 
2.38 
3.47 + 
0.04 
1.99+ 
0.01 
360.50 
+ 88.20 
56.49+ 
1.54 
5.89+ 
1.63 
59.50+ 
2.30 
12.31+ 
0.08 
1:3 (Mannitol:Lactose) 566.51 + 100.14 
545.53+ 
93.29 
117.78 + 
20.82 
96.36 + 
0.59 
7.82 + 
1.09 
2.64 + 
0.19 
2.37+ 
0.04 
391.00 
+ 89.41 
68.69+ 
4.65 
4.08+ 
0.57 
71.29+ 
4.95 
12.85+ 
0.18 
3:1 (Mannitol:Lactose) 450.70 + 195.11 
407.26+ 
190.92 
93.70 + 
40.56 
89.53 + 
3.26 
37.39 + 
13.75 
3.38 + 
0.10 
2.0+ 
0.02 
200.05+ 
138.32 
41.18+ 
11.17 
12.82+ 
5.14 
45.76+ 
10.75 
11.42+ 
0.61 
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In addition, the 1:3 [Mannitol:Lactose] carrier obtained the highest percent emission and lowest 
impact loss with 96.36 + 0.59% and 7.82 + 1.09% meaning that this carrier was the most effective 
at introducing the most API into the system while also preventing its loss during the process; the 
3:1 [Mannitol:Lactose] carrier obtained the highest impact loss with 37.39 + 13.75% thereby 
having poor physicochemical properties as the salbutamol sulphate couldn’t detach itself from the 
carrier. 
 
With respect to MMAD and GSD, the 1:2 [Mannitol:Lactose] carrier obtained the highest MMAD 
with 3.60 + 0.13 μm while the 1:3 [Mannitol:Lactose] carrier obtained the lowest with 2.64 + 
0.19μm; the highest GSD was attributed to the 1:3 [Mannitol:Lactose] carrier with 2.37 + 0.04 
while the lowest GSD was attributed to the 1:2 [Mannitol:Lactose] carrier with 1.97 + 0.02.  A 
linear correlation (r2 = 0.87) between EI and GSD was established between all of the carriers. 
Therefore, given these correlations and those between performance efficacy, particle size (i.e. 
lower MMAD), and FPF, it was concluded that the 1:3 [Mannitol:Lactose] carrier was the most 
effective at its delivery of salbutamol sulphate. 
 
Furthermore, the highest FPD received was from the 1:3 [Mannitol:Lactose] carrier with 391.00 + 
89.41μg while the lowest was attained by the 3:1 [Mannitol:Lactose] carrier with 200.05 + 
138.32μg. The 1:3 [Mannitol:Lactose] carrier proved to obtain the highest FPF from all of the 
engineered carriers with a FPF of 68.69 + 4.65% with the second highest being the 2:1 
[Mannitol:Lactose] carrier with a FPF of 56.49 + 1.54%. These results justify the results already 
discussed in Figure 7.6 where the 1:3 [Mannitol:Lactose] carrier deposited the most salbutamol 
sulphate in Stages 4 and 5. A linear correlation (r2 = 0.98) between FPF and effective inhalation 
index (EI) was established supporting the notion of the carrier’s aerosolized efficacy. With regard 
to the drug loss, the 1:3 [Mannitol:Lactose] carrier had the lowest percentage with 4.08 + 0.57% 
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while the highest drug loss was from the 3:1 [Mannitol:Lactose] carrier with 12.82 + 5.14%; as the 
results show, the most effective carrier from this overall study was the 1:3 [Mannitol:Lactose] 
carrier. In addition, the 1:3 [Mannitol:Lactose] carrier also obtained the highest dispersibility with 
71.29 ± 4.95% while the lowest was from the 3:1 [Mannitol:Lactose] carrier with 45.76 + 10.75%; 
a linear correlation (r2 = 0.95) was established between EI and the dispersibility of the carriers. 
Lastly, as was expected, the 1:3 [Mannitol:Lactose] carrier obtained the highest EI with 12.85 + 
0.18 whereas the 3:1 [Mannitol:Lactose] carrier obtained the lowest with 11.42 + 0.61.  
 
In summary, taking all of the results that have been presented into account, the carrier that 
showed the best aerosolized performance profile was the 1:3 [Mannitol:Lactose] carrier; a carrier 
containing optimal physical, chemical, and mechanical properties. 
 
§§ 7.3.4.2 Homogeneity Assessment 
 
Because the manufacturing process is considered to be an important specification looked at for 
regulatory bodies, it comes to no surprise that the blending of API with its carrier provides a critical 
checkpoint in determining blend homogeneity for a quality product. Therefore, all of the 
formulations underwent a homogeneity assessment to determine their uniformity and to determine 
whether they abided to the tightly regulated specifications from the US FDA and the European 
counterpart. Figure 7.7 presents the homogeneity profiles for all of the formulations within this 
study showcasing their percent potency; all of the engineered carriers adhered and passed the 
potency specification, which is set to the range of 75-125%. Table 7.6 shows the percent content 
homogeneity, which is expressed as the percent coefficient of variation (%CV) for each of the 
carriers. The 3:1 (Mannitol:Lactose) carrier obtained the smallest %CV with 1.60% whereas the 
2:1 (Mannitol:Lactose) carrier received the highest %CV with 12.51% (see Table 7.6) indicting 
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that the 3:1 (Mannitol:Lactose) carrier had the best content uniformity amongst all the formulations 
and the 2:1 (Mannitol:Lactose) carrier had the worst.  
 
 
Figure 7.7. Potency. Percent potency of each engineered formulation (1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) 
with respect to salbutamol sulphate. 
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Table 7.6. Content Homogeneity. Content homogeneity of 1:1 [Mannitol:Lactose], 1:2 
[Mannitol:Lactose]. 1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose] 
expressed as the percent coefficient of variation (%CV). 
Formulation % CV 
1:1 (Mannitol:Lactose) 7.39 
1:2 (Mannitol:Lactose) 6.27 
2:1 (Mannitol:Lactose) 12.51 
1:3 (Mannitol:Lactose) 5.88 
3:1 (Mannitol:Lactose) 1.60 
*However, has not been taken into account for in vivo inhalation studies.  
 
7.4 Conclusion 
 
The results presented in this chapter have proven that mannitol:lactose crystals with different 
weight per weight ratios can be successfully crystalized. They have also shown a positive 
correlation between particle size and concentration of mannitol with regard to the dry system; 
when the concentration of mannitol increases the particle size decreases. The opposite holds true 
for the wet system, however; when the concentration of mannitol increases, the particle size of 
the carriers also increases. The results have also shown that the 1:3 (Mannitol:Lactose) carrier 
[FPF= 68.69 + 4.65%] was the most effective at delivering salbutamol sulphate to the deep 
regions of the lung. This formulation had crystals classified as rhombic in structure and out-
performed the 1:3 [Mannitol:Lactose] carrier from Chapter 5 whose FPF was 61.42 + 4.21%. 
 
 
190 
 
 
Chapter 8 
Aerosolization performance of crystallized Mannitol-
Salbutamol Sulphate with different ratios  
 
 
8.1 Introduction 
 
In this chapter, the focus was to engineer a crystal composed of salbutamol:mannitol in different 
concentrations and investigate the effect it had on the overall aerosolized DPI performance of 
salbutamol sulphate. As already discussed in Chapter 7, pulmonary drug delivery has transformed 
from being a platform for local pulmonary disease treatment to being a means of systematic drug 
delivery. Particle properties are critical as they affect inhalation efficacy, pulmonary deposition, 
drug delivery, and overall performance. Moreover, crystal engineering provides an opportunity to 
optimize particles at the morphological, physicochemical, and molecular levels.367 
 
With that said, the aim of this study was to engineer a crystal using different salbutamol-mannitol 
ratios and observe the impact it had on aersolization performance and the efficacy of the 
physicochemical properties of the DPI formulation for the delivery of salbutamol sulphate. 
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8.2 Materials and Methodology  
§ 8.2.1- § 8.2.14 
Refer to Chapter 2 sections 2.2, 2.4-2.11, and 2.13-2.17. 
 
8.3 Results and Discussion  
§ 8.3.1 Particle size analysis 
 
The salbutamol-mannitol crystals were originally above the approved 1-5 µm range (see Table 
8.1), therefore they were all subjected to air jet milling to decrease their particle size. Figure 8.1 
presents the particle size distribution (PSD) diagram of the engineered air jet milled carriers in 
this study (1:1 [Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]) when using the Rodos system of analysis. 
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Figure 8.1. Particle Size Distribution. Particle Size Distribution (PSD) diagram of engineered air 
jet milled carriers (1:1 [Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 
[Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]) when using the 
Rodos dry system. 
 
Taking a closer look at the particle size, Table 8.1 provides the volume mean diameter (VMD) 
before and after air jet milling and the particle span for the engineered air jet milled carriers. 
Carriers experienced differences in their original VMDs ranging between 9.79 μm for the 4:1 
[Salbutamol:Mannitol] carrier to 26.52 μm for the 1:1 [Salbutamol:Mannitol] carrier. After being 
subjected to air jet milling, the carrier’s VMDs ranged between 1.74 + 0.12 μm for the 2:1 
[Salbutamol:Mannitol] carrier to 4.94 + 2.09 μm for the 1:1 [Salbutamol:Mannitol] carrier. These 
results indicate that there was a successful reduction in particle size coming from the carriers. 
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Moreover, the particle span of the air jet milled carriers fell between 2.21 + 0.09 for the 1:2 
[Salbutamol:Mannitol] carrier to 3.55 + 0.68 µm for the 1:1 [Salbutamol:Mannitol] carrier. 
Furthermore, the Rodos system experienced a particle diameter range of 0.66 ± 0.05μm (D10%) 
to 5.11 ± 2.86μm (D90%). 
 
Table 8.1. Particle Analysis. Particle Analysis of the 1:1 [Salbutamol:Mannitol], 1:2 
[Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol] carriers showing the original and air jet milled volume mean diameter 
(VMD) and span of the air jet milled carriers. 
 
Carrier VMD (μm)        Original   
VMD (μm)        
Air Jet Milled   
Span of               
Air Jet Milled 
1:1 [Salbutamol:Mannitol] 26.52 4.94 + 2.09 3.55 + 0.68 
1:2 [Salbutamol:Mannitol] 19.14 1.85 + 0.13 2.21 + 0.09 
1:4 [Salbutamol:Mannitol] 16.53 2.29 + 0.61 2.81 + 0.60 
2:1 [Salbutamol:Mannitol] 16.39 1.74 + 0.12 2.26 + 0.14 
4:1 [Salbutamol:Mannitol] 9.79 3.29 + 2.77 2.47 + 0.32 
 
 
Figure 8.2 presents the electron micrograms of all the carriers after air jet milling where it was 
determined that all of the engineered carriers (1:1 [Salbutamol:Mannitol], 1:2 
[Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol]) were rhombic in their crystal structure. 
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Figure 8.2. Scanning Electron Microscopy. SEM micrograms of (A) 1:1 [Salbutamol:Mannitol], 
(B) 1:2 [Salbutamol:Mannitol], (C) 1:4 [Salbutamol:Mannitol], (D) 2:1 [Salbutamol:Mannitol], and 
(E) 4:1 [Salbutamol:Mannitol] carrier. 
 
 
 
(A) 1:1  [Salbutamol:Mannitol] (B) 1:2 [Salbutamol:Mannitol] 
(C) 1:4 [Salbutamol:Mannitol] (D) 2:1 [Salbutamol:Mannitol] 
(E) 4:1 [Salbutamol:Mannitol] 
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§ 8.3.2 Solid-state Characterization of Engineered Carriers 
 
Figure 8.3 presents the DSC traces  of the engineered crystal carriers (1:1 [Salbutamol:Mannitol], 
1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol]) indicating the location of any thermal event taking place; whereas Table 
8.2 summarizes the enthalpy (ΔH) for each individual carrier’s thermal event with the 
corresponding temperature, in °C,  where such event took place. 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Differential Scanning Calorimetry. DSC thermal peaks of 1:1 [Salbutamol:Mannitol], 
1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol]; where an exothermic peak points up and an endothermic peak points 
down. 
 
Data presented in Table 8.2 authenticates the illustrated data presented in Figure 8.3 where it 
shows all of the carriers, with the exemption of commercial salbutamol, having an endothermic 
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event at 166.02 ± 2.10°C which corresponds to the melting of mannitol. It also shows that all of 
the carriers, with the exemption of commercial mannitol, having an endothermic event at 229.79 
± 17.94°C, which corresponds to the melting of salbutamol sulphate. The carriers (1:1 
[Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]) exhibited a dramatic shift (p < 0.05) in their 
salbutamol endothermic temperature going from 196.31 ± 0.71°C to 236.49 ± 8.12°C. The 
mannitol endothermic shift, however, was not as significant going from 169.27 ± 0.30°C to 165.37 
± 1.53°C (p > 0.05). 
 
Table 8.2. DSC Thermal Traces. DSC thermal traces of Commercial Mannitol, Commercial 
Salbutamol, 1:1 [Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol] indicating the enthalpy (ΔH), in J/g, along 
with the Temperature (°C) of where such event took place. 
Formulation Temperature (°C) ∆H (J/g) Temperature (°C) ∆H (J/g) 
Commercial Mannitol 169.27 ± 0.30 193.34 ± 16.39 — — 
Commercial Salbutamol — — 196.31 ± 0.71 141.97 ± 36.15 
1:1 [salb.:mannitol] 167.31 ± 0.14 120.03 ± 11.53 244.54 ± 1.91 124.06 ± 19.35 
1:2 [salb.:mannitol] 166.16 ± 0.62 98.61 ± 30.60 241.82 ± 2.83 58.57 ± 13.12 
1:4 [salb.:mannitol] 165.70 ± 0.48 71.30 ± 31.13 240.02 ± 1.24 86.13 ± 11.55 
2:1 [salb.:mannitol] 164.19 ± 0.21 45.47 ± 5.14 225.28 ± 0.23 44.21 ± 3.78 
4:1 [salb.:mannitol] 163.51 ± 0.07 36.59 ± 14.56 230.77 ± 7.06 36.01 ± 8.06 
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Figure 8.4 depicts the powder X-ray diffraction (PXRD) patterns for all of the engineered carriers 
providing insight into their crystalline state as well as differentiating between their polymorphic 
form. Mannitol is known to have three possible polymorphic forms (⍺-, β-, and Δ-), which are 
known to have specific diffraction patterns when using PXRD. ⍺-mannitol is known to have peaks 
at 9.57° and 13.79° on the 2θ plane, β-mannitol is known to exhibit peaks at 10.56° and 14.71° 
on the 2θ plane, and Δ-mannitol is known to possess peaks at 9.74° on the 2θ plane.274, 275 With 
that said, the 1:1 [Salbutamol:Mannitol] carrier was composed of ⍺- and β-mannitol, the 1:2 
[Salbutamol:Mannitol] carrier was composed of all three mannitol polymorphs (⍺-, β-, and Δ-), the 
1:4 [Salbutamol:Mannitol] carrier was composed of ⍺- and β-mannitol, the 2:1 
[Salbutamol:Mannitol] carrier was composed of β- and Δ-mannitol, and the 4:1 
[Salbutamol:Mannitol] carrier was composed of ⍺- and β-mannitol. In addition, the peaks 
demonstrated sharp diffraction angles with no halo background, therefore they were classified as 
crystalline.  
 
To further assess and characterize the engineered carriers, FT-IR spectra can be seen in Figure 
8.5 where α-mannitol exhibits a distinct peak at 1195 cm-1, β-mannitol at 929 cm-1, 959 cm-1, and 
1209 cm-1, and Δ-mannitol at 967 cm-1.237, 296 FT-IR spectra confirmed the classifications already 
mentioned (see Figure 8.4) for the carriers; furthermore, Table 8.3 summarizes the results of the 
different polymorphic forms each carrier contained. The broadening in the 3,000-3,500 cm-1 region 
is due to the increase in mannitol concentration. 
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Figure 8.4. X-Ray Diffraction. Powder X-Ray diffraction patterns of the 1:1 
[Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol] carriers. 
 
Figure 8.5. FT-IR. FT-IR spectra of commercial mannitol, commercial salbutamol, and the 1:1 
[Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol] carriers. 
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Table 8.3. Summary of Polymorphic Form. Summary of the different polymorphic forms each 
carrier contains. 
Carrier ⍺-manntol β-mannitol Δ-mannitol 
1:1 (Salbutamol:Mannitol) ✓ ✓ — 
1:2 (Salbutamol:Mannitol) ✓ ✓ ✓ 
1:4 (Salbutamol:Mannitol) ✓ ✓ — 
2:1 (Salbutamol:Mannitol) — ✓ ✓ 
4:1 (Salbutamol:Mannitol) ✓ ✓ — 
 
 
§ 8.3.3 In vitro analysis of DPI formulations  
§§ 8.3.3.1 Salbutamol Sulphate Assessment 
 
Aerosolization performance of all of the engineered formulations is summarized in Figure 8.6 
where the amount of salbutamol sulphate deposited into each of the stages of the Multi-Stage 
Liquid Impinger (MSLI) is shown [capsules (C), inhaler (I), mouthpiece (M), induction port (IP), 
Stage 1, Stage 2, Stage 3, Stage 4, and Stage 5]. As can be seen in the figure, the 1:1 
[Salbutamol:Mannitol] carrier obtained the lowest amount of salbutamol sulphate in the capsules 
with 2.12 + 0.11 μg while the 4:1 [Salbutamol:Mannitol] carrier obtained the highest amount with 
5.80 + 0.72 μg. When it came to the inhaler device, however, the 2:1 [Salbutamol:Mannitol] carrier 
obtained the highest amount of salbutamol sulphate with 18.89 + 3.23 μg while the lowest went 
to the 1:1 [Salbutamol:Mannitol] carrier with 6.36 + 4.09 μg. 
 
Furthermore, the 1:2 [Salbutamol:Mannitol] carrier obtained the lowest amount of salbutamol 
sulphate (SS), in both, the mouthpiece (M) and induction port (IP) with 6.92 ± 2.56 μg and 20.03 
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± 8.23 μg, respectively. In contrast, the 2:1 [Salbutamol:Mannitol] carrier obtained the highest 
amount of SS for the mouthpiece with 13.58 ± 1.46 μg while the 1:4 [Salbutamol:Mannitol] carrier 
obtained the highest amount in the IP with 27.70 ± 7.61 μg. With regard to Stages 1-5, the 1:4 
[Salbutamol:Mannitol] carrier obtained the highest amount for Stage 1 (157.03 ± 19.27μg), the 
2:1 [Salbutamol:Mannitol] carrier obtained the highest amount for Stages 2-4 (82.61 ± 45.27, 
211.95 ± 49.51, and 109.23 ± 26.55μg; respectively), and the 4:1 [Salbutamol:Mannitol] carrier 
obtained the highest amount in Stage 5 (24.28 ± 9.28μg). Moreover, the 4:1 [Salbutamol:Mannitol] 
carrier obtained the lowest amount in Stage 1 (76.82 ± 20.49μg), and the 1:1 
[Salbutamol:Mannitol] carrier obtained the lowest amount in Stage 2-5 (35.08 ± 3.84, 34.02 ± 
8.30, 9.54 ± 3.33, and 2.12 ± 0.81 μg; respectively). It was, therefore, determined that the 2:1 
[Salbutamol:Mannitol] carrier was better at delivering salbutamol sulphate to the lower regions of 
the lung suggesting a high fine particle fraction (FPF) from this carrier. 
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Figure 8.6. Aerosolization Profile. Aerosolization performance of each engineered formulation 
(1:1 [Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]) highlighting the amount of SS recovered 
(percent recovered) for each and comparing them side-by-side. 
 
 
Table 8.4 presents the different parameters that were taken into account in determining the 
formulation’s aerosolization performance. The 1:1 [Salbutamol:Mannitol] carrier obtained the 
lowest RD, ED, and percent recovery with 317.30 + 34.31 μg, 303.66 + 30.33 μg, and 65.97 + 
7.13% respectively while the 2:1 [Salbutamol:Mannitol] carrier obtained the highest RD, ED, and 
percent recovery with 541.42 + 83.72 μg, 508.95 + 85.45 μg, and 112.56 + 17.41% respectively. 
 
With respect to percent emission, the 1:1 [Salbutamol:Mannitol] carrier obtained the highest 
percentage with 95.76 + 1.11% while the 4:1 [Salbutamol:Mannitol] carrier obtained the lowest 
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percentage with 93.35 + 3.85%. This suggests that the 1:1 [Salbutamol:Mannitol] carrier emitted 
the most API than any other formulation. The 1:1 [Salbutamol:Mannitol] carrier, however, did have 
the highest impact loss with 70.16 + 2.52% while the 2:1 [Salbutamol:Mannitol] carrier obtained 
the lowest with 16.41 + 2.35%. 
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Table 8.4. Aerosolization Parameters. Recovered Dose (RD), Emitted Dose (ED), Percent Recovery, Percent Emission, Percent 
Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Dose (FPD), Fine 
Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) of salbutamol sulphate obtained from 
each of the different engineered formulations (1:1 [Salbutamol:Mannitol], 1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]). 
 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss (%) 
MMAD 
(μm) GSD (μm) FPD 
FPF 
(%) DL (%) DS (%) EI 
1:1 (Salbutamol:Mannitol) 317.30 + 
34.31 
303.66 + 
30.33 
65.97 + 
7.13 
95.76 + 
1.11 
70.16 + 
2.52 
 
 
 4.09 ± 
0.11 
  
 
2.03 ±  
0.03 
46.50 + 
10.63 
14.52 
+ 1.94 
4.93 + 
0.80 
15.18 
+ 2.11 
10.50 
+ 0.08 
1:2 (Salbutamol:Mannitol) 399.70 + 
30.89 
378.12 + 
32.81 
83.10 + 
6.42 
94.55 + 
1.34 
35.34 + 
6.52 
 
 
3.04 ± 
0.16 
 
 
2.08 ±  
0.02 
198.79 + 
35.35 
49.47 
+ 5.23 
6.86 + 
0.71 
52.29 
+ 5.08 
12.00 
+ 0.26 
1:4 (Salbutamol:Mannitol) 442.96 + 
7.24 
419.72 + 
8.63 
92.09 + 
1.51 
94.76 + 
1.49 
41.72 + 
5.13 
 
 
3.22 ± 
0.19 
 
 
2.03 ±  
0.03 
191.70 + 
25.21 
43.23 
+ 5.04 
6.14 + 
1.64 
45.61 
+ 5.11 
11.75 
+ 0.25 
2:1 (Salbutamol:Mannitol) 541.42 + 
83.72 
508.95 + 
85.45 
112.56 + 
17.41 
93.86 + 
1.39 
16.41 + 
2.35 
 
 
3.33 ± 
0.17 
 
 
2.00 ±  
0.06 
338.73 + 
68.45 
62.53 
+ 6.84 
6.99 + 
1.65 
66.63 
+ 7.33 
12.50 
+ 0.28 
4:1 (Salbutamol:Mannitol) 428.86 + 
93.95 
401.47 + 
94.81 
89.16 + 
19.39 
93.35 + 
3.85 
23.96 + 
8.77 
 
 
3.04 ± 
0.22 
 
 
2.09 ±  
0.07 
249.06 + 
76.31 
57.39 
+ 4.93 
8.06 + 
4.03 
61.52 
+ 5.35 
12.28 
+ 0.28 
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With respect to MMAD and GSD, however, the 1:1 [Salbutamol:Mannitol] carrier obtained the 
highest MMAD with 4.09 ± 0.11 μm while the 1:2 [Salbutamol:Mannitol] carrier and the 4:1 
[Salbutamol:Mannitol] carrier obtained 3.04 ± 0.16 μm and 3.04 ± 0.22 μm, respectively; the 
highest GSD was attributed to the 4:1 [Salbutamol:Mannitol] carrier with 2.09 ±  0.07 while the 
lowest GSD was from the 2:1 [Salbutamol:Mannitol] carrier with 2.00 ±  0.06. A linear relationship 
(r2 = 0.73) was established between MMAD and FPF for all of the carriers.  
 
Furthermore, the highest FPD has been obtained for the 1:2 [Salbutamol:Mannitol] carrier with 
338.73 + 68.45 while the lowest was for the 1:1 [Salbutamol:Mannitol] carrier with 46.50 + 10.63. 
The 1:2 [Salbutamol:Mannitol] carrier showed the highest FPF with 62.53 + 6.84% while the 
second highest was obtained for  the 4:1 [Salbutamol:Mannitol] carrier with 57.39 + 4.93%. These 
results proved that the 1:2 [Salbutamol:Mannitol] carrier was the most effective at aerosolizing 
salbutamol sulphate and support the results presented in Figure 8.6. A linear correlation (r2 = 
0.99) between FPF and effective inhalation index (EI) was established supporting the carrier’s 
aerosolized efficacy. Regarding drug loss, however, the 4:1 [Salbutamol:Mannitol] carrier had the 
highest percentage with 8.06 + 4.03% while the 1:1 [Salbutamol:Mannitol] carrier had the lowest 
with 4.93 + 0.80%. To no surprise, the 2:1 [Salbutamol:Mannitol] carrier obtained the highest 
dispersibility and effective inhalation index (EI) with 66.63 + 7.33% and 12.50 + 0.28 respectively. 
The results showed that the lowest dispersibility and EI was obtained for the  1:1 
[Salbutamol:Mannitol] carrier; a linear relationship (r2 = 0.99) was established between EI and the 
dispersibility of the carriers.. 
  
§§ 8.3.3.2 Homogeneity Assessment  
 
The 1:1 [Salbutamol:Mannitol] carrier was the only carrier to abide by the tightly regulated 
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specifications from the US Food and Drug Administration (US FDA) and the European 
counterpart.368 All the other carriers (1:2 [Salbutamol:Mannitol], 1:4 [Salbutamol:Mannitol], 2:1 
[Salbutamol:Mannitol], and 4:1 [Salbutamol:Mannitol]) went above the 75-125% range. Figure 8.7 
presents the homogeneity profiles for all of the formulations within this study. Table 8.5 presents 
the percent content homogeneity, expressed as the percent coefficient of variation (%CV), for 
each of the carriers. The 2:1 (Salbutamol:Mannitol) carrier obtained the smallest %CV with 1.66% 
whereas the 1:2 (Salbutamol:Mannitol) carrier received the highest %CV with 7.15% (see Table 
8.5) which indicate that the 2:1 (Salbutamol:Mannitol) carrier had the best content uniformity 
amongst all the formulations and the 1:2 (Salbutamol:Mannitol) carrier had the worst. 
 
Figure 8.7. Potency. Percent potency of each engineered formulation (1:1 [Salbutamol:Mannitol], 
1:2 [Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol]) with respect to salbutamol sulphate. 
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Table 8.5. Content Homogeneity. Content homogeneity of the 1:1 [Salbutamol:Mannitol], 1:2 
[Salbutamol:Mannitol]. 1:4 [Salbutamol:Mannitol], 2:1 [Salbutamol:Mannitol], and 4:1 
[Salbutamol:Mannitol] carrier expressed as the percent coefficient of variation (%CV). 
Formulation % CV 
1:1 (Salbutamol:Mannitol) 2.30 
1:2 (Salbutamol:Mannitol) 7.15 
1:4 (Salbutamol:Mannitol) 2.16 
2:1 (Salbutamol:Mannitol) 1.66 
4:1 (Salbutamol:Mannitol) 2.86 
*However, has not been taken into account for in vivo inhalation studies.  
 
 
8.4 Conclusion 
 
The results presented in this chapter have proven that salbutamol:mannitol crystals can be 
successfully crystalized to enhanced its aerosolization performance. They have also shown that 
when the concentration of salbutamol increases the particle size of the resultant crystal 
decreases. It was also proven that salbutamol:mannitol crystals can be successfully air jet 
milled. The results have also shown that the 2:1 (Salbutamol:Mannitol) carrier [FPF = 62.53 + 
6.84%] was the most effective at delivering salbutamol sulphate to the deep regions of the lung. 
This carrier had crystals classified as rhombic in structure and was unable to out-perform the 
1:3 (Mannitol:Lactose) carrier from Chapter 7 whose FPF was 68.69 + 4.65%. 
 
 
207 
 
 
Chapter 9 
Physical Mixture Comparative Study 
 
 
9.1 Introduction 
 
In this chapter, the focus was to compare each of the individual studies (Chapters 3-8) to its 
respective physical mixture counterpart. This allowed for the opportunity to determine whether it 
is most cost-effective to engineer each carrier separately or to simply use physical mixtures of the 
commercially available product. Furthermore, this chapter continued to investigate the effect L-
leucine concentration on each physical mixture formulation had on the overall aerosolized dry 
powder inhaler (DPI) performance of salbutamol sulphate. 
 
9.2 Materials and Methodology  
§ 9.2.1- § 9.2.6 
Refer to Chapter 2 sections 2.2, 2.7, and 2.13-2.16. 
 
9.3 Results and Discussion 
§ 9.3.1 In vitro analysis of DPI formulations  
§§ 9.3.1.1 Spray Dried Lactose-Leucine 
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Evaluating each of the formulations on their aerosolization performance, with increasing L-Leucine 
concentration, with that of its spray dried counterpart was done through a physical mixture 
comparative study. Figure 9.1 presents the data collected from the study where the amount of 
salbutamol sulphate (in µg) is reported for each of the MSLI compartments [capsules (C), inhaler 
(I), mouthpiece (M), induction port (IP), Stage 1, Stage 2, Stage 3, Stage 4, and Stage 5]. 
Comparing the spray dried formulations with that of the physical mixture formulations, which 
consisted of mixing spray dried lactose monohydrate, salbutamol sulphate, and the respective L-
Leucine concentration, it became evident that all of the physical mixture formulations had similar 
aerosolization performance from one another with all of them delivering the most salbutamol 
sulphate to Stage 1 (Figure 9.1) whereas the spray dried formulations experienced more of an 
array of salbutamol sulphate delivery (see Chapter 3) with 0.5% Lleucine acquiring the most 
effective aerosolization performance amongst all of the formulations.  
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Figure 9.1. Aerosolization Profile of Spray Dried Lactose-Leucine. Aerosolization performance of 
each of the physical mixture formulations (Spray Dried Lactose Monohydrate, 0.1% L-leucine, 
0.5% L-leucine, 1% L-leucine, 5% L-leucine, and 10% L-leucine) highlighting the amount of SS 
recovered (percent recovered). 
 
Furthermore, taking a closer look at the data that is presented in Table 9.1 it becomes apparent 
that the physical mixture formulations on an overall case, with the exception of 0.5% L-leucine, 
attained higher RD, ED, percent recovery, and percent emission when compared to the spray 
dried formulations. On the other hand, the spray dried formulations had less impaction loss than 
the physical mixture formulations which explains their higher FPF, DS, and EI. That is to say, 
while the physical mixture formulations were able to deliver more salbutamol sulphate into the 
respiratory tract than the spray dried formulations, the spray dried formulations were able to 
deliver more salbutamol sulphate further into the lower respiratory tract than the physical mixture 
formulations. Therefore, it was deduced that the spray dried formulations were more effective in 
their
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aerosolization performance than the physical mixture formulations. The spray dried 0.5% L-leucine formulation was the most effective 
with an FPF of 47.11 + 9.94% (see Chapter 3). 
Table 9.1. Aerosolization Parameters of Physical Mixtures of Lactose-Leucine. Recovered Dose (RD), Emitted Dose (ED), Percent 
Recovery, Percent Emission, Percent Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation 
(GSD), Fine Particle Dose (FPD), Fine Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index 
(EI) of salbutamol sulphate obtained from each of the different physical mixture formulations (Spray Dried Lactose Monohydrate, 0.1% 
L-leucine, 0.5% L-leucine, 1% L-leucine, 5% L-leucine, and 10% L-leucine).  
Formulation RD  
(μg) 
ED  
(μg) 
Recovery 
(%) 
Emission 
(%) 
Impact 
Loss 
(%) 
MMAD 
(μm) 
GSD  
(μm) 
FPD 
(μg) 
FPF  
(%) 
DL  
(%) 
DS  
(%) 
EI 
SD Lactose 434.09 + 
40.27 
376.79 + 
19.65 
90.25 + 
8.37 
87.02 + 
3.79 
52.49 + 
2.81 
3.13 + 
0.15 
2.18 + 
0.07  
110.41 + 
4.77 
25.51 + 
1.23 
14.31 + 
4.12 
29.31 + 
0.36 
10.87 + 
0.22 
0.1% L-Leucine 400.75 + 
74.78 
371.34 + 
81.01 
83.32 + 
15.55 
92.32 + 
3.29 
50.43 + 
7.27 
3.29 + 
0.20 
2.08 + 
0.06  
126.89 + 
22.45 
31.90 + 
4.98 
10.33 + 
5.06 
34.55 + 
5.22 
11.23 + 
0.33 
0.5% L-Leucine 448.39 + 
90.97 
393.77 + 
49.03 
93.22 + 
18.91 
88.69 + 
6.66 
37.14 + 
5.19 
3.31 + 
0.09  
2.10 + 
0.02  
171.29+ 
35.23 
38.21 + 
1.79 
12.08 + 
7.00  
43.22 + 
3.41 
11.14 + 
0.38 
1% L-Leucine 446.87 + 
101.35 
419.43 + 
96.19 
92.90 + 
21.07 
93.84 + 
0.73 
40.55 + 
5.95 
3.14 + 
0.11  
2.13 + 
0.04  
190.00 + 
66.58 
41.68 + 
5.55 
7.32 + 
0.81 
44.41 + 
5.79 
11.89 + 
0.67 
5% L-Leucine 413.69 + 
59.04 
376.05 + 
71.15 
86.01 + 
12.27 
90.49 + 
4.42 
31.27 + 
4.73 
3.22 + 
0.11 
2.11 + 
0.05 
190.99 + 
54.83 
45.53 + 
6.71 
11.86 + 
2.84 
50.16 + 
5.04 
11.48 + 
0.77 
10% L-Leucine 416.86 + 
204.87 
391.55 + 
203.14 
86.67 + 
42.59 
93.07 + 
2.71 
38.46+ 
12.38 
3.27 + 
0.08  
2.07 + 
0.02 
168.36 + 
61.70 
42.38 + 
8.87 
7.84 + 
2.98 
45.71 + 
10.53 
11.51 + 
0.14 
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§§ 9.3.1.2 Spray Dried Mannitol-Leucine 
 
Figure 9.2  presents the data collected from the study where the amount of salbutamol sulphate 
(in  g) is reported for each of the MSLI compartments. Comparing the spray dried formulations 
with that of their physical mixture counterpart, which consisted of mixing spray dried mannitol, 
salbutamol sulphate, and the respective L-leucine concentration, it became evident that 0.5% L-
leucine, 5% L-leucine, and 10% L-leucine delivered the most salbutamol sulphate to Stage 1, while 
0.1% L-leucine and 1% L-leucine to Stage 3. Nevertheless, their delivered amounts were 
significantly less (p < 0.05) than that of the spray dried formulations, where 6% L-leucine (see 
Chapter 4) had the most effective aerosolization performance.  
 
   
 
   
 
Figure 9.2. Aerosolization Profile of Spray Dried Mannitol-Leucine. Aerosolization performance 
of each physical mixture formulation (Spray Dried Mannitol, 0.1% L-leucine, 0.5% L-leucine, 1 L-
leucine, 5% L-leucine, and 10% L-leucine) highlighting the amount of SS recovered (percent 
recovered) for each and comparing them side-by-side. 
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Furthermore, taking a closer look at the data that is presented in Table 9.2 it becomes apparent 
that the physical mixture formulations, on an overall case, attained lower RD, ED, and percent 
recovery when compared to the engineered spray dried formulations. In addition, the spray dried 
formulations, for the most part, also witnessed higher impact loss than the physical mixture 
formulations, but the physical mixture formulations, on an overall case, showed higher percent 
emission values than the spray dried formulations. That is to say, while the physical mixture 
formulations were able to deliver more salbutamol sulphate into the system than the spray dried 
formulations, the spray dried formulations were able to deliver more salbutamol sulphate further 
into the lower respiratory tract than the physical mixture formulations. In addition, the RD of the 
spray dried formulations surpasses that of the physical mixture formulations suggesting that 
attachment/detachment of SS from the physical mixture formulations was compromised. 
Therefore, based on such comparison, it was deduced that the spray dried formulations were 
more effective in their aerosolization performance than the physical mixture formulations. The 
spray dried 6% L-leucine formulation was the most effective with an FPF of 52.96 + 5.21% (see 
Chapter 4). 
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Table 9.2. Aerosolization Parameters of Physical Mixtures of Mannitol-Leucine. Recovered Dose (RD), Emitted Dose (ED), Percent 
Recovery, Percent Emission, Percent Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation 
(GSD), Fine Particle Dose (FPD), Fine Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) 
of salbutamol sulphate obtained from each of the different physical mixture formulations (Spray Dried Mannitol, 0.1% L-leucine, 0.5% 
L-leucine, 1% L-leucine, 5% L-leucine, and 10% L-leucine). 
 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss (%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) DL (%) DS (%) EI 
Spray Dried 
Mannitol 
431 + 
143.68 
394.56 + 
147.19 
89.74 + 
29.87 
90.34 + 
5.20 
45.59 + 
6.29 
3.06 + 
0.10 
2.10 + 
0.08 
168.20 + 
85.39 
37.06 + 
8.66 
10.54 + 
5.35 
40.75 + 
7.55 
11.28 + 
0.62 
0.1% L-Leucine 358.27 + 56.95 
323.00 + 
55.85 
74.48 + 
11.84 
90.01 + 
1.59 
29.73 + 
7.94 
2.96 + 
0.08 
2.09 + 
0.02 
190.60 + 
53.42 
52.45 + 
7.23 
12.44 + 
2.03 
58.19 + 
7.12 
11.93 + 
0.37 
0.5% L-Leucine 299.25 + 95.92 
273.32 + 
91.84 
62.21 + 
19.94 
91.07 + 
1.43 
33.21 + 
9.83 
2.83 + 
0.22 
2.14 + 
0.08 
157.59 + 
77.77 
50.91 + 
8.23 
11.81 + 
2.37 
55.83 + 
8.18 
11.91 + 
0.40 
1% L-Leucine 335.68 + 68.56 
299.12 + 
58.47 
69.79 + 
14.25 
89.22 + 
1.22 
30.12 + 
2.73 
2.95 + 
0.06 
2.06 + 
0.01 
175.69 + 
32.76 
52.48 + 
1.59 
14.19 + 
3.26 
58.81 + 
0.98 
11.90 + 
0.12 
5% L-Leucine 204.82 + 54.55 
147.97 + 
53.44 
42.58 + 
11.34 
76.29 + 
31.09 
30.10 + 
4.93 
3.05 + 
0.14 
2.05 + 
0.01 
75.82 + 
43.07 
39.97 + 
23.39 
25.91 + 
32.54 
48.53 + 
14.22 
10.54 + 
2.80 
10% L-Leucine 225.30 + 41.38 
206.25 + 
43.17 
46.84 + 
8.60 
91.26 + 
2.70 
35.04 + 
1.93 
2.93 + 
0.10 
2.06 + 
0.05 
114.56 + 
29.01 
50.49 + 
3.38 
11.97 + 
2.67 
55.30 + 
2.56 
11.90 + 
0.24 
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§§ 9.3.1.3 Spray Dried Mannitol-Lactose-Leucine 
 
Figure 9.3  presents the data collected from the study where the amount of salbutamol sulphate (in 
µg) is reported for each of the MSLI compartments. Comparing the spray dried formulations with 
that of their physical mixture counterpart, which consisted of mixing spray dried mannitol, spray 
dried lactose, salbutamol sulphate, and the respective L-leucine concentration, it became evident 
that the spray dried mannitol, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and the 3:1 
[Mannitol:Lactose] physical mixture formulations delivered the most salbutamol sulphate to Stage 
1 while the spray dried lactose delivered the most salbutamol sulphate to Stage 3. The 1:3 
[mannitol:lactose] physical mixture formulation was the most effective in its aerosolization 
performance delivering the most salbutamol to Stages 3-5 when comparing them to the rest of the 
physical mixture formulations. When comparing the physical mixture formulations to their spray 
dried counterpart, however, the spray dried 1:3 [mannitol:lactose] carrier was the most effective 
in its aerosolization performance. 
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Figure 9.3. Aerosolization Profile of Spray Dried Mannitol-Lactose-Leucine. Aerosolization 
performance of each physical mixture formulation (Spray Dried Mannitol, Spray Dried Lactose, 
1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) highlighting the 
amount of SS recovered (percent recovered) for each and comparing them side-by-side. 
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Furthermore, taking a closer look at the data that is presented in Table 9.3 it becomes apparent that the physical mixture formulations, 
on an overall case, attained similar results to the spray dried formulations. The 1:3 [mannitol:lactose] physical mixture carrier obtained 
the best aerosolization profile amongst all the physical mixture formulations, but, when compared to the spray dried formulations, the 
1:3 [mannitol:lactose] spray dried carrier obtained the best aerosolization profile amongst all the carriers with an FPF of 61.42 + 4.21% 
(see Chapter 5). 
Table 9.3. Aerosolization Parameters of Physical Mixtures of Mannitol-Lactose-Leu. Recovered Dose (RD), Emitted Dose (ED), 
Percent Recovery, Percent Emission, Percent Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard 
Deviation (GSD), Fine Particle Dose (FPD), Fine Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation 
Index (EI) of salbutamol sulphate obtained from each of the different physical mixture formulations (Spray Dried Mannitol, Spray Dried 
Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]). 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss (%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) DL (%) DS (%) EI 
Spray Dried 
Mannitol 
204.82 + 
54.55 
147.97 + 
53.44 
42.58 + 
11.34 
76.29 + 
31.09 
30.10 + 
4.93 
3.05 + 
0.14 
2.05 + 
0.01 
75.82 + 
43.07 
39.97 + 
23.39 
25.91 + 
32.54 
48.53 + 
14.22 
10.54 + 
2.80 
Spray Dried 
Lactose 
413.69 + 
59.04 
376.05 + 
71.15 
86.01 + 
12.27 
90.49 + 
4.42 
31.27 + 
4.73 
3.22 + 
0.11 
2.11 + 
0.05 
190.99 + 
54.83 
45.53 + 
6.71 
11.86 + 
2.84 
50.16 + 
5.04 
11.48 + 
0.77 
1:1 374.64 + 49.47 
350.00 + 
48.71 
77.89 + 
10.28 
93.36 + 
1.40 
36.98 + 
8.97 
3.28 + 
0.59 
2.09 + 
0.01 
183.82 + 
36.17 
49.11 + 
8.34 
8.83 + 
3.22 
52.53 + 
8.23 
11.93 + 
0.40 
1:3 386.73 + 53.24 
363.49 + 
54.58 
80.40 + 
11.07 
93.88 + 
1.42 
34.69 + 
8.80 
3.30 + 
0.58 
2.06 + 
0.06 
201.78 + 
51.52 
51.63 + 
6.43 
7.62 + 
2.13 
54.96 + 
6.33 
12.06 + 
0.31 
3:1 324.10 + 73.47 
293.03 + 
75.19 
67.38 + 
15.27 
90.03 + 
3.16 
33.94 + 
11.28 
3.04 + 
0.01 
2.04 + 
0.01 
162.59 + 
69.68 
48.88 + 
10.11 
11.94 + 
3.63 
54.25 + 
10.55 
11.78 + 
0.49 
217 
 
§§ 9.3.1.4 Xylitol-Leucine Crystals 
 
Figure 9.4 presents the data collected from the physical mixture comparative study where the 
amount of salbutamol sulphate (in μg) is reported for each of the MSLI compartments. When 
comparing the data, it became evident that the physical mixture formulations carried significantly 
more (p > 0.05) salbutamol sulphate to Stage 1 than the crystallized formulations. Furthermore, 
when it came to the inhaler (I), mouthpiece (M), and induction port (IP), the physical mixture 
formulations also exhibited more salbutamol sulphate, but in this case, more salbutamol sulphate 
suggests more API being delivered to the non-targeted area. 
 
 
  
   
 
  
Figure 9.4. Aerosolization Profile of Xylitol-Leucine Crystals. Aerosolization performance of each 
physical mixture formulation (Commercial Xylitol, Xylitol with 0% LEU, Xylitol with 1% LEU, Xylitol 
with 5% LEU, and Xylitol with 10% LEU) highlighting the amount of SS recovered (percent 
recovered) for each and comparing them side-by-side. 
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Moreover, Table 9.4 presents the data from the aerosolization of the physical mixtures; comparing 
this data, it becomes evident that the physical mixture formulations observed higher RD, ED, and 
percent recovery when compared to their crystallized counterpart. Both the crystallized and the 
physical mixture formulations experienced similar percent emission values suggesting salbutamol 
sulphate being introduced into the system at a consistent rate. When it comes to impaction loss, 
however, the physical mixture formulations experienced higher values meaning more salbutamol 
sulphate was lost as a result of poor adhesive and cohesive forces; such results also correspond 
to their bigger size as indicated by their higher MMAD values. GSD for the crystallized formations 
was higher than the physical mixture formulations, but their FPD was higher. In addition, as a 
result of their bigger size and despite their higher dosage, the physical mixture formulations 
resulted in obtaining higher FPF with commercial xylitol having the highest FPF with 44.13 + 
11.27% when compared to the crystallized formulations where xylitol with 5% LEU obtained 42.94 
+ 15.21% (see Chapter 6). While commercial xylitol obtained the highest FPF from all of the 
formulations, it failed to adhere to the potency specification, like previously mentioned. Drug loss 
was higher with the crystallized formulations along with the effective inhalation index, but lower in 
dispersibility.  
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Table 9.4. Aerosolization Parameters of Physical Mixtures of Xylitol-Leucine Crystals. Recovered Dose (RD), Emitted Dose (ED), 
Percent Recovery, Percent Emission, Percent Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard 
Deviation (GSD), Fine Particle Dose (FPD), Fine Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation 
Index (EI) of salbutamol sulphate obtained from each of the different physical mixture formulations (Commercial Xylitol, Xylitol with 0% 
LEU, Xylitol with 1% LEU, Xylitol with 5% LEU, and Xylitol with 10% LEU). 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss (%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) 
DL 
(%) 
DS 
(%) EI 
Commercial Xylitol 239.29  
+ 111.70 
221.16  
+ 106.22 
49.75 + 
23.22 
92.01 + 
1.75 
43.72 + 
12.20 
2.77 + 
0.45 
2.18 + 
0.31 
113.57 + 
82.45 
44.13 + 
11.27 
8.56 + 
2.11 
47.90 + 
11.69 
11.66 
+ 0.53 
Xylitol with 0% LEU 216.19 + 
170.69 
197.97 + 
154.33 
44.95 + 
35.49 
91.91 + 
3.46 
50.01 + 
19.40 
3.10 + 
0.10 
2.09 + 
0.06 
92.87 + 
109.59 
34.25 + 
16.98 
10.12 + 
3.94 
37.27 + 
18.73 
11.21 
+ 0.78 
Xylitol with 1% LEU 461.51 + 
55.77 
431.00 + 
53.37 
95.95 + 
11.59 
93.37 + 
1.29 
73.20 + 
7.64 
3.08 + 
0.02 
2.14 + 
0.05 
75.48 + 
39.98 
16.02 + 
7.76 
7.56 + 
1.31 
17.09 + 
8.03 
10.45 
+ 0.43 
Xylitol with 5% LEU 511.81 + 
135.10 
481.56 + 
131.94 
106.40 + 
28.09 
93.89 + 
1.18 
65.43 + 
4.82 
3.26 + 
0.04 
2.00 + 
0.02 
122.23 + 
44.08 
23.57 + 
3.98 
6.77 + 
1.52 
25.10 + 
4.15 
10.84 
+ 0.20 
Xylitol with 10% LEU 535.92 + 
73.24 
501.43 + 
66.79 
111.42 + 
15.23 
93.59 + 
1.08 
48.89 + 
5.33 
3.27 + 
0.06 
1.99 + 
0.01 
198.78 + 
34.95 
37.05 + 
3.05 
7.16 + 
1.13 
39.61 + 
3.70 
11.43 
+ 0.09 
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§§ 9.3.1.5 Mannitol-Lactose Crystals 
 
Figure 9.5  presents the data collected from the study where the amount of salbutamol sulphate (in 
µg) is reported for each of the MSLI compartments. Comparing the crystallized formulations with 
that of their physical mixture counterpart, which consisted of mixing mannitol, lactose, and 
salbutamol sulphate, it became evident that the 1:1 [mannitol:lactose], 1:2 [mannitol:lactose], and 
1:3 [mannitol:lactose] carriers delivered the most salbutamol sulphate to Stage 1. The 2:1 
[mannitol:lactose] carrier delivered the most salbutamol sulphate to Stage 3 while the 3:1 
[mannitol:lactose] carrier delivered the most salbutamol sulphate to Stage 2.  
     
Figure 9.5. Aerosolization Profile of Mannitol-Lactose Crystals. Aerosolization performance of 
each physical mixture formulation (1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose], 2:1 
[Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]) highlighting the amount 
of SS recovered (percent recovered) for each and comparing them side-by-side.   
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Furthermore, taking a closer look at the data that is presented in Table 9.5 it becomes apparent 
that the physical mixture formulations, on an overall case, attained lower RD, ED, percent 
recovery, and percent emission than the crystallized formulations. The physical mixture 
formulations, however, obtained higher impact loss but lower MMAD and GSD when compared 
to the crystallized formulations. The crystallized formulations attained higher FPD and FPF when 
compared to the physical mixture formulations, but the physical mixture formulations attained 
higher drug loss. The crystallized formulations also obtained higher dispersibility and effective 
inhalation index. As a whole, the crystallized formulations outperformed the physical mixture 
formulations in their aersolization profile. The highest FPF for the crystallized formulations was 
from the 1:3 [mannitol:lactose] carrier with 68.69 + 4.65% (see Chapter 7) whereas for the 
physical mixture formulations the 2:1 [mannitol:lactose] carrier obtained an FPF of 46.00 + 
15.03%.  
 
§§ 9.3.1.6 Mannitol-Salbutamol Crystals 
 
A physical mixture comparative study was not conducted for the mannitol:salbutamol sulphate 
crystals since it would have consisted of mixing mannitol with salbutamol sulphate, which has 
already been done in this overall study. Therefore, the values obtained from the spray dried 
mannitol-leucine carriers were used, specifically the Spray Dried Mannitol sample, and it was 
determined that it was better to crystallize the carriers than to physically mix them. The highest 
FPF from the crystallized carriers was from the 2:1 [salbutamol:mannitol] carrier with an FPF of 
62.53 + 6.84% (see Chapter 8) whereas the Spray Dried Mannitol physical mixture carrier had an 
FPF of 37.06 + 8.66%. 
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Table 9.5. Aerosolization Parameters of Physical Mixtures of Mann.-Lac. Crystals. Recovered Dose (RD), Emitted Dose (ED), Percent 
Recovery, Percent Emission, Percent Impact Loss, Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation 
(GSD), Fine Particle Dose (FPD), Fine Particle Fraction (FPF), Drug Loss (DL), Dispersibility (DS), and Effective Inhalation Index (EI) 
of salbutamol sulphate obtained from each of the different physical mixture formulations (1:1 [Mannitol:Lactose], 1:2 [Mannitol:Lactose], 
1:3 [Mannitol:Lactose], 2:1 [Mannitol:Lactose], and 3:1 [Mannitol:Lactose]). 
 
 
Formulation RD (μg) ED (μg) Recovery (%) 
Emission 
(%) 
Impact 
Loss (%) 
MMAD 
(μm) 
GSD 
(μm) FPD 
FPF 
(%) 
DL 
(%) 
DS 
(%) EI 
1:1 (Mannitol:Lactose) 277.95  + 
52.19 
257.85  + 
49.66 
57.79 + 
10.85 
92.72 + 
0.42 
48.22 + 
0.94 
3.15 + 
0.30 
2.07 + 
0.10 
102.58 + 
25.68 
36.64 + 
2.19 
8.47 + 
0.72 
39.52 + 
2.20 
11.37 
+ 0.11 
1:2 (Mannitol:Lactose) 192.03  + 
37.55 
165.10  + 
46.66 
39.92 + 
7.81 
84.96 + 
8.59 
34.03 + 
9.26 
3.21 + 
0.21 
2.05 + 
0.07 
82.17 + 
39.90 
41.14 + 
12.86 
17.54 + 
9.16 
47.73 + 
10.82 
11.20 
+ 0.96 
2:1 (Mannitol:Lactose) 317.19  + 
123.10 
285.55  + 
115.17 
65.94 + 
25.59 
89.64 + 
1.50 
35.05 + 
14.79 
3.17 + 
0.07 
2.03 + 
0.05 
157.54 + 
100.74 
46.00 + 
15.03 
12.12 + 
2.42 
51.14 + 
16.02 
11.63 
+ 0.72 
1:3 (Mannitol:Lactose) 329.80  + 
120.01 
300.45  + 
111.88 
68.57 + 
24.95 
90.94 + 
1.23 
39.42 + 
17.88 
3.05 + 
0.26 
2.09 + 
0.12 
154.65 + 
111.62 
43.27 + 
14.99 
10.90 + 
2.21 
47.51 + 
16.08 
11.57 
+ 0.66 
3:1 (Mannitol:Lactose) 244.24  + 
188.34 
204.43  + 
194.57 
50.78 + 
39.16 
73.41 + 
21.63 
38.02 + 
6.86 
3.44 + 
0.80 
2.16 + 
0.07 
60.32 + 
56.56 
21.16 + 
9.34 
31.07 + 
23.49 
27.88 + 
6.78 
9.63 + 
1.65 
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§ 9.3.2 Homogeneity Assessment 
§§ 9.3.2.1 Spray Dried Lactose-Leucine 
 
A homogeneity assessment was completed to assess the uniformity of each of the physical 
mixture formulations. Table 9.6 presents the results where it shows the percent potency and the 
coefficient of variation (%CV), which was the indicator used to assess the homogeneity of the 
formulations. SD lactose was the only formulation that passed the specification requirement  that 
is set by the US Food and Drug Administration and its European counterpart with a potency of 
91.36%; the range being 75-125%. The formulation that was the most homogeneous was the 1% 
Leu with a %CV of 5.27%. 
 
Table 9.6. Potency and Homogeneity of Physical Mixtures of Lactose-Leucine. Percent potency 
and content homogeneity of the Spray Dried Lactose-Leucine  physical mixture formulations (SD 
Lactose, 0.1% Leu, 0.5% Leu, 1% Leu, 5% Leu, and 10% Leu), expressed as the percent 
coefficient of variation (%CV). 
Formulation 
Potency 
(%) 
% CV 
SD Lactose  91.36 10.29 
0.1% Leu 49.54 10.31 
0.5% Leu 48.50 13.54 
1% Leu 44.39 5.27 
5% Leu 58.90 28.71 
10% Leu 33.32 35.31 
*However, has not been taken into account for in vivo inhalation studies.  
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§§ 9.3.2.2 Spray Dried Mannitol-Leucine 
 
Table 9.7 presents the percent potency and the coefficient of variation (%CV), which was the 
indicator used to assess the homogeneity of the formulations, for the spray dried mannitol-leucine 
physical mixture formulations. The results show that all of the physical mixture formulations 
adhered to the potency specifications with the exception of the 1% L-leucine and 5% L-leucine 
which were 54.53% and 77.56% potent, respectively. With respect to the homogeneity of the 
physical mixture formulations, the 0.1% L-leucine obtained the best content homogeneity with a 
%CV of 5.44%.  
 
Table 9.7. Potency and Homogeneity of Physical Mixtures of Mannitol-Leucine. Percent potency 
and content homogeneity of the Spray Dried Mannitol-Leucine  physical mixture formulations (SD 
Mannitol, 0.1% Leu, 0.5% Leu, 1% Leu, 5% Leu, and 10% Leu), expressed as the percent 
coefficient of variation (%CV). 
Formulation 
Potency 
(%) 
% CV 
SD Mannitol  91.95 20.90 
0.1% Leu 93.34 5.44 
0.5% Leu 98.21 25.02 
1% Leu 54.53 15.55 
5% Leu 77.56 9.82 
10% Leu 93.34 20.70 
*However, has not been taken into account for in vivo inhalation studies.  
 
§§ 9.3.2.3 Spray Dried Mannitol-Lactose-Leucine 
 
Table 9.8 presents the percent potency and the coefficient of variation (%CV), which was the 
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indicator used to assess the homogeneity of the formulations, for the spray dried mannitol-lactose-
leucine physical mixture formulations. All of the physical mixture formulations adhered to the 75-
125% potency range. Moreover, the physical mixture formulation that was the most uniform was 
the 1:3 [Mannitol:Lactose] formulation with a %CV of 3.15%. 
 
Table 9.8. Potency and Homogeneity of Physical Mixtures of Mann.-Lac.-Leucine. Percent 
potency and content homogeneity of the Spray Dried Mannitol-Lactose-Leucine physical mixture 
formulations (SD Mannitol, SD Lactose, 1:1 [Mannitol:Lactose], 1:3 [Mannitol:Lactose], and 3:1 
[Mannitol:Lactose]), expressed as the percent coefficient of variation (%CV).  
 
  
 
 
 
  
*However, has not been taken into account for in vivo inhalation studies.  
 
 
§§ 9.3.2.4 Xylitol-Leucine Crystals 
 
Table 9.9 presents the percent potency and the coefficient of variation (%CV), which was the 
indicator used to assess the homogeneity of the formulations, for the xylitol-leucine physical 
mixture formulations. The Xylitol with 1% Leu, Xylitol with 5% Leu, and the Xylitol with 10% Leu 
adhered to the 75-125% potency specification with 90.97%, 94.20%, and 94.61% (respectively) 
while the Commercial Xylitol and Xylitol with 0% Leu failed the specification with potencies of 
Formulation Potency (%) % CV 
SD Mannitol  110.07 11.90 
SD Lactose 89.71 13.23 
1:1 [Mannitol:Lactose] 115.07 8.02 
1:3 [Mannitol:Lactose] 110.01 3.15 
3:1 [Mannitol:Lactose] 84.15 8.88 
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51.55% and 73.42% (respectively). With respect to the uniformity of the physical mixture 
formulations, the Xylitol with 10% Leu was the most homogeneous amongst all of the physical 
mixture formulations with a %CV of 4.67%. 
 
Table 9.9. Potency and Homogeneity of Physical Mixtures of Xylitol-Leu. Crystals. Percent 
potency and content homogeneity of the Xylitol-Leucine physical mixture formulations 
(Commercial Xylitol, Xylitol with 0% Leu, Xylitol with 1% Leu, Xylitol with 5% Leu, and Xylitol with 
10% Leu), expressed as the percent coefficient of variation (%CV).  
 
  
 
 
 
*However, has not been taken into account for in vivo inhalation studies.  
 
§§ 9.3.2.5 Mannitol-Lactose Crystals 
 
Table 9.10 presents the percent potency and the coefficient of variation (%CV), which was the 
indicator used to assess the homogeneity of the formulations, for the Mannitol-Lactose physical 
mixture formulations. The only physical mixture formulation that did not adhere to the potency 
specification was the 1:2 (Mannitol:Lactose) formulation which had a percent potency of 69.50%. 
All the other physical mixture formulations [1:1 (Mannitol:Lactose), 1:3 (Mannitol:Lactose), 2:1 
(Mannitol:Lactose), and 3:1 (Mannitol:Lactose)] adhered to the potency specification [see Table 
Formulation Potency (%) % CV 
Commercial Xylitol 113.03 13.35 
Xylitol with 0% Leu 73.42 15.95 
Xylitol with 1% Leu 90.97 13.38 
Xylitol with 5% Leu 94.20 5.38 
Xylitol with 10% Leu 94.61 4.67 
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9.10]. With respect to their homogeneity, however, the most uniform physical mixture formulation 
was the 1:1 (Mannitol:Lactose) formulation with a %CV of 6.48%. 
 
Table 9.10. Potency and Homogeneity of Physical Mixtures of Mann.-Lac. Crystals. Percent 
potency and content homogeneity of the Mannitol-Lactose physical mixture formulations [1:1 
(Mannitol:Lactose), 1:2 (Mannitol:Lactose), 1:3 (Mannitol:Lactose), 2:1 (Mannitol:Lactose), and 
3:1 (Mannitol:Lactose)], expressed as the percent coefficient of variation (%CV).  
 
  
 
  
 
 
*However, has not been taken into account for in vivo inhalation studies.  
 
§§ 9.3.2.6 Mannitol-Salbutamol Crystals 
 
As mentioned in §§ 9.2.1.6, a physical mixture comparative study was not conducted for mannitol-
salbutamol formulation since it would have consisted of mixing mannitol with salbutamol sulphate, 
which was something that has already been done (see §§ 9.2.1.2). 
 
9.4 Conclusion  
 
The results presented in this chapter showed that it was better to use the engineered carriers than 
their respective physical mixture counterpart. More optimal aerosolization performances were 
Formulation Potency (%) % CV 
1:1 (Mannitol:Lactose) 108.00 6.48 
1:2 (Mannitol:Lactose) 69.50 19.40 
1:3 (Mannitol:Lactose) 90.88 18.73 
2:1 (Mannitol:Lactose) 95.63 28.28 
3:1 (Mannitol:Lactose) 114.85 24.60 
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attained from the engineered carriers than from the physical mixture formulations. Parameters 
like FPF were higher in the engineered carriers than the physical mixture formulations; such 
parameter is used to determine a formulation’s aerosolization performance. Moreover, based on 
the results presented in this chapter, it was determined that it was more cost-effective to engineer 
the carriers than to use the physical mixture counterpart. Looking at the physical mixture 
formulations on their own, the results presented in this chapter have shown that the addition of L-
leucine lowers the potency of the resultant formulations. The addition of L-leucine causes a 
change in the inter- and intra- molecular interactions which affects the adhesive forces of 
salbutamol sulphate thus affecting the formulation’s aerosolization performance. 
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Chapter 10 
 
General Discussion and Future Work 
 
10.1 General Discussion 
 
The previous chapters illustrated an enhanced methodological approach for the 
enhancement of aerosolized particulates. The goal was to engineer a carrier with optimal 
aerosolization properties such that an increase in the FPF was observed. It was also 
important to engineer the carriers following the US Food and Drug Administration’s 
guidelines, which also follow the US Pharmacopeia, in the event that any of the carriers 
become used for manufacturing purposes; these guidelines also follow the European 
pharmacopeia.222, 223, 235, 368 
 
Chapter 3 looked at spray dried lactose-leucine carriers to determine their aerosolized 
efficiency concluding that the optimal FPF that was reached was 47.11± 9.94% from the 
0.5% L-leucine carrier. It was also determined that the addition of L-leucine improved the 
stability of amorphous spray dried lactose while also providing a lubrication effect.21 
Moreover, the results obtained from the physical mixture comparative study (see Chapter 
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9) showed that it is more efficient and effective to engineer the carriers than to mix spray 
dried lactose, L-leucine, and salbutamol sulphate. 
 
Chapter 4 looked at spray dried mannitol-leucine carriers and it was concluded that the 
optimal FPF that was reached was from the 6% L-Leucine with a FPF of 52.96 + 5.21%. 
The results also confirmed that mannitol can serve as a suitable alternative carrier over 
lactose in DPI formulations and could be suitable for lactose intolerant patients suffering 
from asthma, COPD, or other lung diseases which can be treated via DPI formulations.14 
224 258 The physical mixture comparative study showed that it is more effective to engineer 
the carriers than to mix spray dried mannitol, L-leucine, and salbutamol sulphate 
(Albuterol sulphate). Finally, the results also supported the findings from Chapter 3 where 
it showed L-leucine’s lubrication effect. 
 
Chapter 5 looked at spray dried mannitol-lactose-leucine carriers and it was concluded 
that the optimal FPF that was reached was from the 1:3 [Mannitol:Lactose] carrier with a 
FPF of 61.42 + 4.21%. Comparing this to the physical mixture comparative study, it was 
concluded that it is more efficient to engineer the carriers than to mix spray dried lactose, 
sprayed dried mannitol, L-leucine, and salbutamol sulphate. The use of 5% L-leucine (w/w) 
modified the physicochemical properties of the spray dried particles along with their 
morphology. The results also showcase the lubrication effect that L-leucine provides to 
the carriers upon aerosolization. 
 
In chapter 6, the type of carrier was changed from lactose and mannitol to xylitol to see if 
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a more suitable carrier can be developed for DPI formulations with a high FPF. Therefore, 
in chapter 6 xylitol-leucine crystals as carriers were developed and it was concluded that 
the optimal FPF that was reached was from the Xylitol with 5% LEU with a FPF of 42.94 
+ 15.21%; this was because the Commercial Xylitol (FPF = 44.13 + 11.27) failed the 
uniformity assessment and, as a result, could not be used or implemented. Xylitol with 
5% LEU had particles classified as tomahawk, which is known to show better aerosolized 
efficacy over particles with a spherical morphology. The results also showed that L-leucine 
altered the physicochemical properties of the carriers which affected their inter- and intra-
molecular interactions. Comparing these formulations to the formulations in the physical 
mixture comparative study, it was concluded that it was more efficient to engineer the 
carriers than to simply mix xylitol, L-leucine, and salbutamol sulphate together.  
 
In Chapter 7 the idea was to develop binary mixtures of some of there main carriers 
including lactose and mannitol to enhance the aerosolization performance of drugs from 
DPI formulations. The results concluded that the optimal FPF that was observed was from 
the 1:3 [Mannitol:Lactose] carrier with a FPF of 68.69 + 4.65%. This formulation had 
crystals classified as rhombic in structure and out-performed the 1:3 [Mannitol:Lactose] 
carrier from Chapter 5 whose FPF was 61.42 + 4.21%. The results also showed an 
inverse relationship between particle size and concentration of mannitol with regards to 
the dry system; when the concentration of mannitol increased the particle size decreased. 
In addition, there was a positive correlation between the concentration of mannitol and 
the particle size with respect to the wet system; when the concentration of mannitol 
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increased, the particle size of the carriers also increased. Comparing these results to the 
physical mixture comparative study (see Chapter 9), it was determined that it was more 
efficient and cost-effective to engineer the carriers rather than simply mixing mannitol, 
lactose, and salbutamol sulphate. 
 
In other chapters, generally, salbutamol sulphate was physically added to the engineered   
carrier particles, whereas in Chapter 8 the idea was to develop an engineered carrier-API 
via a crystallization technology. The results proved that the optimal FPF that was 
observed was from the 2:1 [Salbutamol:Mannitol] carrier with a FPF of 62.53 + 6.84%. 
This carrier had crystals that were classified as rhombic in structure. There was also an 
inverse relationship between the concentration of salbutamol and the particle size of the 
resultant crystals; when the concentration of salbutamol increased, the crystal size 
decreased. These carriers were also successfully air jet milled. Comparing these results 
to the physical mixture comparative study (see Chapter 9), it was concluded that it was 
more effective to engineer the carriers than to simply mix mannitol and salbutamol 
sulphate.  
 
All in all, these results have shown that it is more efficient and cost-effective to engineer 
carriers for pulmonary delivery than to use commercially available products. They have 
also shown the impact that L-leucine, as an excipient, has on the overall aerosolization 
performance of any given carrier. This effect was shown via the lubrication effect that L-
leucine provides when it is used as an excipient.21 Using L-leucine also alters the physical 
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chemical properties of the resultant carrier in such a way as to allow for an increase in 
the aerosolization performance, measured via the carrier’s FPF, to be seen.342 L-Leucine 
also alters the carrier’s morphology, creating more of an irregular shape, causing a 
change in the carrier’s aerosolization profile.345 Furthermore, the results also provide, and 
support, the notion that an irregular crystal has a better aerosolization performance than 
a more spherical shape crystal;356 this was seen in a number of carriers that were used 
throughout this overall study. The results also show that the methodology that has been 
presented has the capability of altering the polymorphic form of the resultant carrier 
wether that be via spray drying or crystallization. 
 
Moreover, commercially available DPI have emitted doses of approximately between 50% 
and 80% and FPFs between 20% and 40%, but this overall study showed that FPFs can 
reach almost 70%.369, 370 Table 10.1 presents all of the carriers that were used throughout 
this overall study highlighting their FPF and %CV, which was used as an indicator for 
content homogeneity. As the table shows, the 1:3 [mannitol:lactose] crystal carrier was 
the most effective in reaching the highest FPF among all of the carriers. Throughout this 
overall study, one of the goals was to attain a high FPF and a low %CV. The carrier that 
was the most homogeneous (lowest %CV) was the spray dried 1:3 (mannitol:lactose) 
carrier with a %CV of 0.76%. On an overall case, however, the bet carrier and, thus, 
formulation was the 1:3 [mannitol:lactose] crystal carrier. 
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Table 10.1. Summary of all Formulations. Summary of all carriers used within this Thesis 
highlighting FPF and content homogeneity expressed as the percent coefficient of variation 
(%CV). 
Formulation FPF (%) % CV 
Spray Dried Lactose 25.51 ±  1.23 10.29 
SD Lactose w/ 0.1%L-Leucine 34.99 ±  8.89 7.15 
SD Lactose w/ 0.5% L-Leucine 47.11 ±  9.94 5.48 
SD Lactose w/ 1% L-Leucine 44.33 ±  6.53 17.92 
SD Lactose w/ 5% L-Leucine 43.08 ±  7.38 13.23 
SD Lactose w/ 10% L-Leucine 44.50 ± 17.40 8.65 
Spray Dried Mannitol 37.06 + 8.66 20.90 
SD Mannitol w/ 0.06% L-Leucine 37.54 + 2.46 3.88 
SD Mannitol w/ 0.3% L-Leucine 38.86 + 8.54 14.08 
SD Mannitol w/ 0.6% L-Leucine 48.45 + 9.44 11.94 
SD Mannitol w/ 3% L-Leucine 47.19 + 13.76 11.90 
SD Mannitol w/ 6% L-Leucine 52.96 + 5.21 13.38 
SD 1:1 (Mannitol:Lactose) 42.58 + 18.43 13.22 
SD 1:3 (Mannitol:Lactose) 61.42 + 4.21 23.47 
SD 3:1 (Mannitol:Lactose) 42.85 + 9.36 0.76 
Commercial Xylitol 44.13 + 11.27 13.35 
Xylitol with 0% LEU 34.25 + 16.98 11.72 
Xylitol with 1% LEU 25.84 + 11.05 19.68 
Xylitol with 5% LEU 42.94 + 15.21 13.83 
Xylitol with 10% LEU 35.61 + 12.58 2.52 
1:1 (Mannitol:Lactose) 52.34 + 15.08 7.39 
1:2 (Mannitol:Lactose) 49.13 + 5.94 6.27 
2:1 (Mannitol:Lactose) 56.49 + 1.54 12.51 
1:3 (Mannitol:Lactose) 68.69 + 4.65 5.88 
3:1 (Mannitol:Lactose) 41.18 + 11.17 1.60 
1:1 (Salbutamol:Mannitol) 14.52 + 1.94 2.30 
1:2 (Salbutamol:Mannitol) 49.47 + 5.23 7.15 
1:4 (Salbutamol:Mannitol) 43.23 + 5.04 2.16 
2:1 (Salbutamol:Mannitol) 62.53 + 6.84 1.66 
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4:1 (Salbutamol:Mannitol) 57.39 + 4.93 2.86 
 
 
10.2 Future Work 
 
The research that has been presented in these chapters offer a major contribution to the 
field of chemistry and pharmaceutical sciences. They provide an insight into how to 
engineer carriers and tailor them for the usage via the pulmonary tract. Nevertheless, 
there are other methods and techniques that can be used which have not been discussed 
and/or implemented within this overall study. 
 
One of those includes co-crystals; co-crystals represent a useful way of altering chemical 
properties at the atomic level, by choosing a suitable co-former that will form a specific 
non-covalent bond, to yield an engineered supramolecular architecture. Co-crystals are 
formulations of increasing interest to the pharmaceutical industry given their potential of 
improving the solubility and dissolution behavior, while also improving the physical 
stability of the active pharmaceutical ingredient compared to their pure state.  
 
Co-crystals are defined as crystalline single phase materials composed of two or more 
molecular and/or ionic compounds generally in a stoichiometric ratio which are neither 
solvents nor salts. Co-crystals offer an opportunity to optimize physicochemical 
properties, such as solubility, stability, hydration, and melting point, mechanical 
properties, such as flowability and compressibility, pharmacokinetic properties, 
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bioavailability, and permeability. Because amorphous powders have a higher surface free 
energy over crystalline material, it makes crystalline material a more favorable choice for 
drug formulation. In addition, it has been shown that co-crystals also alter the bulk and 
surface properties of the active pharmaceutical ingredient (API) of interest. 
 
Another technique that can be explored further and become implemented within this 
overall study is spray freeze drying. Spray freeze drying is a particle engineering 
technology that has been investigated in the production of inhalable powder formulations. 
It is a process that produces lyophilized powders with a spherical morphology and one 
that combines the advantages of both freeze-drying and spray-drying as the drying 
process is extremely mild and most powders are flowable without further processing. 
 
Subsequently, the frozen solvents produce porous particles which affect the carrier’s 
behavior and, consequently, affect their aerosolization performance. In addition, this 
technique also provides a mechanism to control the size of the particles that are 
produced. A parameter that has been shown, in this overall study, to have critical 
importance.  
 
Furthermore, another technique that can be used to further this overall study’s findings is 
that of 3D printing. Fused deposition modeling (FDM) is a type of extrusion 3D printing 
technology where a polymer filament is heated and extruded through a nozzle to create 
an object. These objects can have ultra-fine particles which are usually less than 100 nm 
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in size; these ultra-fine particles can be used, if engineered to agglomerate, as carriers 
or as is if made from the API of interest. The ultra-fine particles are released at rates of 
billions of particles per minute during operation. Moreover, these 3D printers are 
increasingly popular because of their low cost, low weight of filaments, processing 
flexibility, and ease of use. 
 
Operating these printers is done with poly-lactic acid (PLA) which is derived from 
renewable sources like corn. PLA is popular because of its mechanical properties, 
biodegradability, and low cost. Something to consider, however, is whether or not they 
are safe to use for inhalation purposes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
238 
 
References 
 
1. Ali Nokhodchi and Gary P. Martin. Pulmonary Drug Delivery- Advances and Challenges. Wiley. 2015. 
ISBN:9781118799543.  
2. Byron PR, Pathon JS. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7:49–75.  
3. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and 
prospects. Critical Reviews in Therapeutic Dug Carrier Systems. 2002; 19 (4-5); 425-98.  
4. Massaro GD, Massaro D.Formulation of pulmonary alveoli and gas exchange surface area: 
quantitative and regulation. Annual Review of Physiology. 1996; 58: 73-92. 
5. Byron PR, Patton JS. Drug delivery via the respiratory tract. Journal of Aerosol Medicine. 1994; 7 (1): 
49-75 
6. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nature 
Reviews Drug Discovery. 2007; 6 (1): 67-74 
7. Byron PR, Hindle M, Lange CF, et. al. In vivo-in vitro correlations: predicting pulmonary drug deposition 
from pharmaceutical aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010; 23 
(Suppl. 2): S59-69. 
8. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle 
performance. J Pharm Sci. 2012;101:1107.  
9. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug 
delivery. Pharm Res. 2007;24: 411–37.  
10. De Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. Air classifier technology (ACT) in dry 
powder inhalation: part 1. Introduction of a novel force distribution concept (FDC) explaining the 
performance of a basic air classifier on adhesive mixtures. Int J Pharm. 2003;260:187–200.  
11. De Boer AH, Chan HK, Price R. A critical view on lactose-based drug formulation and devise studies 
for dry powder inhalation: which are relevant and what interactions to expect? Adv Drug Del Rev. 
2012;64:257–74.  
12. Thalberg K, Berg E, Fransson M. Modeling dispersion of dry pow- ders for inhalation: the concepts of 
total fines, cohesive energy and interaction parameters. Int J Pharm. 2012;427:224–33.  
13. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Resp 
Med. 2002;96:293–304.  
14. Smyth HDC, Hickey AJ. Carriers in dry powder delivery: implications for inhalation system design. 
American Journal of Drug Delivery. 2005. 3 (2):117-32. 
15. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest. 1985; 88 (Suppl. 2): 
152S-60S. 
16. Martonen TB. Mathematical model for the selective deposition of inhaled pharmaceuticals. Journal of 
Pharmaceutical Sciences. 1993; 82 (12): 1191-9. 
17. C Darquenne. Particle Deposition in the Lung. 2006 Elsevier Ltd. All rights reserved.   
18. Heyder J. Alveolar deposition of inhaled particles in humans. American Industrial Hygiene Association 
Journal. 1982; 43 (11): 864-6. 
19. Heyder J. Particle transport onto human airway surfaces. European Journal of Respiratory Diseases 
Supplement. 1982; 119: 29-50. 
20. Schulz H, Brand P, and Heyder J. Particle deposition in the respiratory tract. In: Gehr P, ans Heyder 
J, eds, Particle-Lung Interactions. Marcel Dekker, Inc. New York. 2000. 
21. Yeh HC, Schum GM. Models of human lung airways and their appliction to inhaled particle deposition. 
Bulletin of Mathematical Biology. 1980;42 (3): 461-80. 
22. Kim CS, Hu SC. Regional deposition of inhaled particles in human lungs: comparison between men 
and women. Journal of Applied Physiology (1985). 1998; 84 (6): 1834-44. 
23. Lippman M, Yeates DB, Albert RE. Deposition, retention, and clearance of inhaled particles. British 
Journal of Industrial Medicine. 1980; 37 (4): 337-62. 
24. Lourenco RV, Cotromanes E. Clinical aerosols II. Therapeutic aerosols. Archives of International 
Medicine. 1982; 142 (13): 2299-308. 
239 
 
25.  Lavorini F, Magnan A, Dubus JC, et. al. Effect of incorrect use of dry powder inhalers on 
management of patients with asthma and COPD. Respiratory Medicine. 2008; 102 (4): 593-604. 
26. Villax P, McDermott IG, Brunce M. Single Inhaler. US8109267 B2, 2012. 
27. De Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Comparative in vitro performance evaluation of 
the Novopulmon 200 Novolizer and Budesonide-ratiopharm Jethaler: two novel budesonide dry powder 
inhalers. Die Pharmaie. 2004; 59 (9); 692-99.  
28. Al-Showair, RAM, Tarsin WY, Assi KH, et. al. Can all patients with COPD use the correct inhalation 
flow with all inhalers and does training help? Respiratory Medicine. 2007; 101 (1); 2395-401.  
29. S. R. Percy, Improvement in drying and concentrating liquid substances by atomizing, US Patent 
US125406, 1872.  
30. Vehring, R., 2008. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25, 999–1022.  
31. C. Kemp, in: E. Tsotsas, A.S. Mujumdar (Eds.), Fundamentals of energy analysis of dryers, Modern 
Drying Technology: Energy Savings, vol. 4, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 
2011, pp. 1–45. 
32. A.S. Mujumdar, Handbook of Industrial Drying, fourth ed. CRC Press, Florida, 2014. 33. D.M. Parikh, 
Handbook of Pharmaceutical Granulation Technology, third ed. CRC Press, New York, 2009.  
34. Singh, Abhisek and Van den Mooter, Guy. Spray drying formulation of amorphous solid dispersions. 
Advanced Drug Delivery Reviews. 100; 27-50. 2016. 
35. Curatolo W, Nightingale J, Herbig S. Utility of hydroxypropyl- methylcellulose acetate succinate 
(HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res. 
2009;26:1419–31.  
36. Gao P. Amorphous pharmaceutical solids: characterization, stabilization, and development of 
marketable formulations of poorly soluble drugs with improved oral absorption. Mol Pharm. 2008;5:903–4.  
37. Ré, M.-I., 2006. Formulating drug delivery systems by spray drying. Dry. Technol. 24, 433–446.  
38. Chiou, W.L., Rielman, S., 1971. Pharmaceutical application of solid dispersion system. J. Pharm. Sci. 
60, 1281–1302.  
39. Amrit Paudel, Zelalem Ayenew Worku, Joke Meeus, Sandra Guns, Guy Van den Mooter. 
Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and 
process considerations. International Journal of Pharmaceutics 453 (2013) 253–284. 
40. J.W. Lubach, D. Xu, B.E. Segmuller, E.J. Munson, Investigation of the effects of phar- maceutical 
processing upon solid-state NMR relaxation times and implications to solid-state formulation stability, J. 
Pharm. Sci. 96 (2007) 777–787. 
41. M. Sugimoto, T. Okagaki, S. Narisawa, Y. Koida, K. Nakajima, Improvement of disso- lution 
characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-
soluble polymer, Int. J. Pharm. 160 (1998) 11–19.  
42. R. Dontireddy, A.M. Crean, A comparative study of spray-dried and freeze-dried 
hydrocortisone/polyvinyl pyrrolidone solid dispersions, Drug Dev. Ind. Pharm. 37 (2011) 1141–1149. 
43. S. Guns, A. Dereymaker, P. Kayaert, V. Mathot, J.A. Martens, G. Van den Mooter, Comparison 
between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of 
ethylene glycol and vinylalcohol, Pharm. Res. 28 (2011) 673–682.  
44. O. Mahmah, R. Tabbakh, A. Kelly, A. Paradkar, A comparative study of the effect of spray drying and 
hot‐melt extrusion on the properties of amorphous solid dispersions containing felodipine, J. Pharm. 
Pharmacol. 66 (2014) 275–284. 
45. A.M. Agrawal, M.S. Dudhedia, A.D. Patel, M.S. Raikes, Characterization and perfor- mance 
assessment of solid dispersions prepared by hot melt extrusion and spray drying process, Int. J. Pharm. 
457 (2013) 71–81. 
46. Maltesen MJ, et al. Quality by design—spray-drying of insulin intended for inhalation. Eur J Pharm 
Biopharm. 2008;70:828–38.  
47. Prinn K, et al. Statistical modeling of protein spray-drying at the lab scale. AAPS PharmSciTech. 
2002;3(1):E4.  
48. Oakley DE. Spray dryer modeling in theory and practice. Dry Technol. 2004;22:1371–402.  
49. E. Dobry, D.M. Settell, J.M. Baumann, Spray drying and scale-up, Pharmaceutical Sciences 
Encyclopedia, John Wiley & Sons, Inc. 2015, pp. 1–26.  
240 
 
50. F. Gaspar, J. Vicente, F. Neves, J.-R. Authelin, Spray drying: scale-up and  
manufacturing, in: N. Shah, H. Sandhu, D.S. Choi, H. Chokshi, A.W. Malick (Eds.), Amorphous Solid 
Dispersions, Springer, New York 2014, pp. 261–302.  
51. K. Masters, Spray Drying Handbook, fifth ed. Longman Scientific & Technical, New York, 1991. 
52. Nonelectrolytes, in: P.J. Sinko (Ed.), Martin's Physical Pharmacy and Pharmaceuti- cal Sciences, fifth 
ed.Lippincott Williams & Wilkins, New Delhi 2006, pp. 119–141.  
53. K. Rizi, R.J. Green, M. Donaldson, A.C. Williams, Production of pH‐responsive micro- particles by 
spray drying: investigation of experimental parameter effects on mor- phological and release properties, 
J. Pharm. Sci. 100 (2011) 566–579.  
54. H. Al‐Obaidi, S. Brocchini, G. Buckton, Anomalous properties of spray dried solid dispersions, J. 
Pharm. Sci. 98 (2009) 4724–4737.  
55. M. Farid, A new approach to modelling of single droplet drying, Chem. Eng. Sci. 58 (2003) 2985–
2993.  
56. E.H.J. Kim, X. Dong Chen, D. Pearce, On the mechanisms of surface formation and the surface 
compositions of industrial milk powders, Drying Technol. 21 (2003) 265–278.  
57. M. Mezhericher, A. Levy, I. Borde, Spray drying modelling based on advanced drop- let drying 
kinetics, Chem. Eng. Process. 49 (2010) 1205–1213.  
58. D. Chiou, T. Langrish, R. Braham, The effect of temperature on the crystallinity of lactose powders 
produced by spray drying, J. Food Eng. 86 (2008) 288–293.  
59. R. Aftel, A.K. Gupta, C. Cook, C. Presser, Gas property effects on droplet atomization and 
combustion in an air-assist atomizer, Symposium (International) on Combus- tion, Elsevier 1996, pp. 
1645–1651.  
60. S. Özbilen, Influence of atomising gas on particle characteristics of Al, Al–1 wt-% Li, Mg, and Sn 
powders, Powder Metall. 43 (2000) 173–180.  
61. T. Kudra, M. Poirier, Gaseous carbon dioxide as the heat and mass transfer medium in drying, Drying 
Technol. 25 (2007) 327–334.  
62. M.I.U. Islam, T.A.G. Langrish, The effect of different atomizing gases and drying media on the 
crystallization behavior of spray-dried powders, Drying Technol. 28 (2010) 1035–1043.  
63. D.W. Green, Perry's Chemical Engineers' Handbook, eighth ed. McGraw-hill, New York, 2008. 
64. Lane, W. R. A microburrette for producing small liquid drops of known size. Journal of Scientific 
Instruments. 24. 98-101; 1949. 
65. Liu, W., Chen, X. D., and Selomulya, C. On the spray drying of uniform microparticles. Particuology. 
22. 1-12; 2015. 
66. Anders, K., Roth,N., and Frohn, A. Operation characteristics of vibrating-orifice generators: The 
coherence length. Particle and Particle Systems Characterization. 9. 40-43; 1992.  
67. J.T. Edward, Molecular volumes and the Stokes–Einstein equation, J. Chem. Educ. 47 (1970) 261.  
68. R. Vehring, W.R. Foss, D. Lechuga-Ballesteros, Particle formation in spray drying, J. Aerosol Sci. 38 
(2007) 728–746.  
69. S. Wang, T. Langrish, A review of process simulations and the use of additives in spray drying, Food 
Res. Int. 42 (2009) 13–25.  
70. Healy, A.M., McDonald, B.F., Tajber, L., Corrigan, O.I., 2008. Characterisation of excipient-free 
nanoporous microparticles (NPMPs) of bendroflumethiazide. Eur. J. Pharm. Biopharm. 69, 1182–1186.  
71. Papelis, C., Um, W., Russel, C.E., Chapman, J.B., 2003. Measuring the specific surface area of 
natural and manmade glasses: effects of formation process, morphology, and particle size. Colloids Surf. 
A: Physicochem. Eng. Aspects 215, 221–239.  
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